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310 A U T H O R I N D E X
Like last year, it is a renewed privilege for me to introduce the proceedings of
our annual scientific and social forum, the National Congress of the Italian
Society for the Study of Headaches, Headaches: acquisitions and controver-
sies, this year in its XXth edition.
The chosen topics cover many fields, the developments of which need to
be reviewed critically, confronted with original results from the numerous dif-
ferent interdisciplinary research groups of our large and scientifically very
productive society.
The main issues, from the genetics of primary headaches to the socioeco-
nomic aspects; from the considerations regarding the ICHD-II criteria to the
problem of cortical excitability; from headache as an emergency condition in
childhood and adolescence to psychopathological factors, will be dealt with.
On the frontline of therapy, the intriguing problem/resource of the placebo will
also be discussed, along with the strategies in using triptans and the new per-
spectives of preventative therapies. The difficulties of managing the chronic
patient and the often related problem of drug misuse/abuse will also be specif-
ically addressed.
Along with invited lectures and round tables, a workshop and pros and cons
sessions have been organised to expand the modalities of congressional
debate. Two scientific sessions have been planned in cooperation with the
Italian Society of Internal Medicine and with the Italian Association of
Ambulatorial and Territorial Neurologists, underlying the multidisciplinary
nature of our society and our commitment with other societies in order to pro-
vide more integrated answers to patients’ needs.
This year’s contributions emphasise the continuous growth of our society.
The great increase in the number of submissions from a significantly larger
number of members prompted the Scientific Committee to organise a new ses-
sion entitled Oral communications with posters. Its aim is to give evidence
both to the oral presentation and to the wealth of data that only a poster can
offer, so that results can, firstly, be pointed out orally, in front of the plenary
audience, and secondly, discussed at length individually with those colleagues
who are specifically interested in the topic.
As you will have noticed, the Congress Proceedings are now peer-reviewed
abstracts, in keeping with the modalities adopted by other large, authoritative
societies. Furthermore, the abstracts of the Congress are no longer printed in a
supplement, but within The Journal of Headache and Pain, which since last
January has become the official journal of the European Headache Federation
(EHF) – a significant gesture of esteem towards our society by the EHF and a
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recognition of the quality of The Journal of Headache and Pain. Being hosted
in a regular issue of the journal gives the congresses of the European national
societies – in this case ours – a vast international audience, fostering mutual
knowledge and cooperation.
The location of the Congress in Rome, after the previous one in
Padua/Venice, continues a choice that connects science and culture. Along
with an excellent scientific programme, participants will be able to enjoy the
artistic and historical atmosphere that only the “Città Eterna” can offer. On this
occasion, I wish to thank, also on behalf of our society, all those who have
helped to organise this XXth SISC Congress and contributed to the preparation
of the proceedings: my Co-President of the Congress, Professor Girolamo Di
Trapani; the Scientific Committee and Secretariat; the Local Organizing
Committee; the entire Executive Committee of the Italian Society for the
Study of Headaches; and our generous Sponsors. And last, but not least, all of
you, who continuously work with your patients and in your labs to promote
new developments to relieve the burden of headache.
A warm, friendly welcome to Rome, with wishes of a very fruitful, scien-
tifically and socially rewarding congress.
Giorgio Zanchin
President
Italian Society for the Study of Headaches
ORAL PRESENTATIONS
Published online: 11 August 2006
KEY LECTURES
GENETICS OF TENSION-TYPE HEADACHE
1,2,3,4M.B. Russell
1Head and Neck Research Group and 2Faculty Division Akershus
University Hospital, Nordbyhagen, Norway; 3Department of Research
and Development and 4Department of Neurology, Akershus University
Hospital, Norway; e-mail: m.b.russell@medisin.uio.no
Objective To analyze the importance of genetic and environmental
factors in tension-type headache.
Subjects and methods Review of literature.
Results A family study of chronic tension-type headache suggested
that genetic factors are important due to a 3-fold significantly increased
risk of chronic tension-type headache among first degree relatives
compared to the general population. A twin study suggested that ten-
sion-type headache is caused by 81% non-shared environmental effects
and of 19% additive genetic effects. Another twin study suggests that
no and frequent episodic tension-type headache is partly inherited due
to a significant higher concordance rate among monozygotic than dizy-
gotic twin pairs, while infrequent episodic tension-type headache is
caused by environmental factors. Data for chronic tension-type
headache were inconclusive.
Discussion The first twin study was based on twin pairs with co-occur-
rence of tension-type headache and migraine. This probably biased the
result, since migraine increases the risk and frequency of tension-type
headache. The family study of chronic tension-type headache was a
clinic population and some of the probands had co-occurrence of
migraine and tension-type headache, which may have caused overesti-
mation of the family risk.
Conclusions Genetic factors are likely to play a role in no and frequent
episodic tension-type headache. Infrequent episodic tension-type
headache is caused primarily by environmental factors. Chronic ten-
sion-type headache may be inherited but the data are too limited to
allow firm conclusions.
THE ROLE OF PLACEBO IN HEADACHE RESEARCH
H-C. Diener
Department of Neurology, University Duisburg-Essen, Essen, Germany, 
e-mail: h.diener@uni-essen.de
For a long time it has been known that almost any treatment or proce-
dure used in headache patients will lead to an improvement. This is
true for the treatment of headache attacks and the prevention of
headache. The concept of controlled randomised trials revealed that
placebos have a profound effect in headache patients. The consequence
was that most modern trials in the treatment of headache use placebo
groups. The responder rate to placebo depends on the endpoint and is
around 20%–30% for improvement of headache in trials treating acute
headache events and around 30% in prevention trials. Originally, it was
assumed that the placebo effect would decrease over time. Long-term
studies with topiramate or botulinum toxin, however, showed that the
effect of placebo lasts over 6 or 9 months. Subcutaneous placebo is
more effective than oral placebo. In the U.S.A. and in Southern Europe
the placebo response is higher than in Northern Europe. Children and
adolescents have a much higher placebo response than adults.
Expectation will play a major role, when the randomisation ratio
between placebo and verum is known. The quality of a trial has no
influence on the placebo responder rate. Placebos can lead to side
effects. In trials treating anxiety, placebo resulted in headache in 20%
of the patients. Information about possible weight gain in a migraine
prevention trial resulted in profound increase in body weight in the
placebo run-in phase. Placebo might have a similar mode of action as
“real” drugs. PET and functional MRI studies indicate that placebo will
activate similar brain structures as opioids.
ICHD-2 AND ITS REVISION
J. Olesen
Department of Neurology, University of Copenhagen, Glostrup Hospital,
Copenhagen, Denmark; e-mail: jeol@glostruphosp.kbhamt.dk
ICHD-2 features many improvements over the first edition of The
International Headache Classification. Perhaps the single most impor-
tant change is the introduction of the entity medication-overuse
headache (MOH). The strengthening of the causal relations under sec-
ondary headaches, the changes regarding migraine with aura and the
introduction of a number of new entities are also important.
Subsequently, the introduction of chronic migraine was criticised
because it was extremely demanding and very few patients would fit
into these criteria. In order to include a reasonable number of patients
with frequent migraine and headache on 15 days or more per month,
new appendix criteria for chronic migraine were published. Also the
criteria for MOH were changed. It is now a default rule that, if patients
have a medication-overuse and a primary headache they must receive
the diagnosis of medication-overuse headache.
A last major remaining problem is the Classification of secondary
headaches, where improvement or disappearance of headache is
requested after removal of the causative disorder. This means that
patients cannot actually receive the diagnosis while they still have the
headache.
This latter problem and other problems will be dealt with subsequent-
ly by the Classification Committee and revised appendix criteria will
be printed in Cephalalgia. It is the hope that these appendix criteria will
subsequently be tested and that results will justify the changes so that
they can be included in a future revised version of the ICHD-2.
MIGRAINE HEADACHES: FROM MODELS TO MECHANISM
M.A. Moskowitz
Massachusetts General Hospital, Harvard Medical School, Boston,
Massachusetts, USA; e-mail: moskowitz@helix.mgh.harvard.edu
Experimental and clinical findings established a firm scientific foun-
dation for the notion that cortical spreading depression (CSD) under-
lies migraine visual aura and perhaps other migraine auras. Recent
reports found that CSD activates trigeminal afferents innervating the
meninges, and that this activation travels to the brainstem to trigger
parasympathetic efferents promoting vasodilation within the dura
mater. This provides strong evidence that neurovascular changes
within the dura mater develop as a consequence of CSD in experi-
mental animals. When acute abortive anti-migraine drugs were
administered in this paradigm, the drugs suppressed evidence of
CSD-induced trigeminovascular activation. Hence, intrinsic activity
within the forebrain causes sustained vasodilation of meningeal
blood vessels via parasympathetic reflex activation. We also found
that CSD causes activation of a class of enzymes called “matrix met-
alloproteinases” (MMPs) in brain. These enzymes are activated with-
in vessels early after CSD (contiguous depolarization of neurons and
glia) and remain so for nearly 48 hours. MMPs are constituents of an
inflammatory cascade within the brain triggered by the generation of
reactive oxygen species (e.g. nitric oxide (NO)) and provide indirect
evidence for upregulation of a pro-inflammatory state in brain and its
connective tissue coverings. Evidence from Reuter and colleagues
implicate meningeal inflammation as an important mechanism dri-
ving the delayed headache response to nitroglycerin. Infusion of
J Headache Pain (2006) 7:243–281
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nitroglycerin caused upregulation of the inducible isoform of NO
synthase (NOS) and NO within resident dural macrophages,
meningeal oedema, cytokine activation and evidence implicating NF-
kB, a proinflammatory transcription factor. CSD is not part of the
pathophysiology of delayed nitroglycerin headache.
In some migraine subtypes, genes controlling translocation of Ca2+,
sodium and potassium ions have been implicated in migraine patho-
physiology, perhaps altering the susceptibility to CSD. Environmental
factors may modulate individual susceptibility by lowering the CSD
threshold. Recently, mice carrying a human familial hemiplegic
migraine-1 mutation were shown to express an abnormally low CSD
threshold, and this phenotype was associated with enhanced neuro-
transmitter release.
More recent experimental data provide evidence that widely-pre-
scribed migraine prophylactic drugs (topiramate, valproate, propra-
nolol and amitriptyline, and methysergide) suppress CSD in experi-
mental animals when administered chronically. These drugs dose-
dependently suppress CSD frequency by 40%–80% and increase
cathodal stimulation threshold. Acute treatment was ineffective. This
previously unknown coherent action provides a potential common
physiological target for the most widely used prophylactic com-
pounds in migraine. It also opens up the possibility to develop more
effective migraine prophylactic drugs to target specific cellular and
molecular mechanisms underlying CSD or a physiological event in
human brain closely related to it. Together these experimental data
support the conclusion that CSD is an important underlying event in
migraine pathophysiology.
NEUROGENIC INFLAMMATION: FURTHER THERAPEUTIC
PERSPECTIVES
1,2P. Geppetti, 2P. Nicoletti, 1J.G. Capone, 2E. Del Bene
1Headache Centre, Department of Neuroscience, University
Hospital S. Anna, Ferrara, Italy; 2Clinical Pharmacology Unit and
Headache Centre, University of Florence, Florence, Italy; e-mail:
pierangelo.geppetti@unifi.it
Abnormal activation of neuropeptide-containing neurons of the trigem-
inal ganglia may initiate and/or maintain the pathophysiological
processes that eventually result in migraine headache and associated
phenomena [1]. A subpopulation of polymodal A-δ and C primary sen-
sory neurons of dorsal root ganglia (DRG) and trigeminal ganglia is
characterized by the ability to synthesize and release diverse neu-
ropeptides, including calcitonin gene-related peptide (CGRP) and
tachykinins, substance P (SP) and neurokinin A (NKA). CGRP, SP and
NKA released from the peripheral endings of primary sensory neurons
cause a series of proinflammatory responses at the vascular and
extravascular levels collectively referred to as “neurogenic inflamma-
tion”. If SP/NKA via activation of NK1 receptors increase the extrava-
sation of plasma protein in meningeal postcapillary venules, CGRP via
activation of specific receptors on vascular smooth muscle dilates
intra- and extracranial arteries. Capsaicin has the unique ability to
excite (and at high doses desensitize) an ion channel (TRPV1)
expressed in sensory neurons, thus producing burning pain and releas-
ing sensory neuropeptides. Triptans are specific antimigraine drugs,
acting on serotonin 5-HT1B/1D receptors, which, among other actions,
by this mechanism inhibit sensory neuropeptide release from peripher-
al and central endings of trigeminal neurons. It is possible that a major
component of the efficacy of triptans in migraine is due to inhibition of
neurogenic inflammatory responses. However, the role of plasma pro-
tein extravasation mediated by NK1 receptor activation by SP/NKA in
migraine has been questioned by the negative results obtained in more
than one clinical trial with selective NK1 receptor antagonists. In con-
trast, the high affinity nonpeptide antagonist for the human CGRP
receptor, BIBN4096BS, has been found effective in reducing both the
headache and the associated phenomena of the migraine attack without
affecting cardiovascular baseline parameters [2]. Neurogenic vasodi-
latation promoted by CGRP released from perivascular endings of
trigeminal sensory neurons significantly contributes to the migraine
mechanism. Inhibition of CGRP release by triptans or blockade of the
CGRP receptor are different strategies that successfully target a similar
pathogenic mechanism.
References
1. Moskowitz MA, Buzzi MG (1991) Neuroeffector functions of sen-
sory fibres: implications for headache mechanisms and drug
actions. J Neurol 238[Suppl 1]:S18–S22
2. Olesen J, Diener HC, Husstedt IW et al (2004) Calcitonin gene-
related peptide receptor antagonist BIBN 4096 BS for the acute
treatment of migraine. N Engl J Med 350:1104–1110
GENETICS OF PRIMARY HEADACHES
NEURONAL CALCIUM CHANNELS AND MIGRAINE
1D. Pietrobon, 1M. Shapovalova, 1A. Tottene, 2L. Gherardini, 
3R.R. Frants, 4M.D. Ferrari, 3,4A.M.J.M. van den Maagdenberg, 
2T. Pizzorusso
1Department of Biomedical Sciences, University of Padua and Institute
of Neuroscience CNR, Padua, Italy; 2Institute of Neuroscience CNR,
Pisa, Italy; 3Departments of Human Genetics and 4Neurology, Leiden
University Medical Centre, Leiden, The Netherlands; e-mail:
daniela.pietrobon@unipd.it
Mutations in CACNA1A, the gene encoding the pore-forming subunit
of CaV2.1 (P/Q-type) calcium channels, cause a group of dominantly
inherited human neurological disorders, including familial hemiplegic
migraine type-1 (FHM-1), a rare autosomal dominant subtype of
migraine with aura. P/Q-type calcium channels are expressed in all
brain structures that have been implicated in the pathogenesis of
migraine and play a prominent role in controlling neurotransmitter
release. Functional studies into FHM-1 may provide unique insight
into the molecular and cellular mechanisms of migraine. We have
investigated the functional consequences of eight FHM-1 mutations by
expressing recombinant human CaV2.1 channel subunits in HEK293
cells and in cerebellar granule cells from cacna1a-/- mice lacking
CaV2.1 channels. A consistent effect of FHM-1 mutations was to
increase Ca2+ influx through single human CaV2.1 channels in a broad
voltage range, as a consequence of an increased channel open proba-
bility mainly due to a shift to lower voltages of channel activation [1].
Recently, the generation of knockin (KI) mice carrying the R192Q [2]
and S218L FHM-1 mutations allowed us to analyze for the first time
mutant CaV2.1 channels expressed at their endogenous level in neu-
rons, and evaluate the consequences of FHM-1 mutations on neuro-
transmission and cortical spreading depression (CSD, the phenomenon
underlying migraine aura). Compared to wild-type mice, KI mice
showed: 1) an increased P/Q-type Ca2+ current density in cerebellar
granule cells in primary culture and dissociated cortical pyramidal cells
in a broad voltage range and similar current densities at higher volt-
ages; 2) an increased susceptibility to CSD as revealed by a lower
threshold for induction and a higher velocity of CSD propagation in
vivo. S218L KI mice also showed a higher incidence of recurrent
waves of CSD after stimulation. Moreover, facilitation of CSD propa-
gation was strikingly larger in S218L than in R192Q KI mice, in cor-
relation with the more severe clinical phenotype of the S218L muta-
tion. The gain-of-function effects on both P/Q-type Ca2+ current and
CSD were about twice as large in homozygous as compared to het-
erozygous mice, revealing an allele-dose effect consistent with domi-
nance of the mutation in FHM-1. Our data show an important role of
CaV2.1 channels in the initiation and spread of CSD, and point to cor-
tical hyperexcitability as the basis for increased susceptibility to CSD
in migraine. The FHM-1 KI mice are promising animal models to
study migraine mechanisms and treatments.
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1. Tottene A, Fellin T, Pagnutti S et al (2002) Familial hemiplegic
migraine mutations increase Ca2+ influx through single human
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GENETIC MUTATIONS AND POLYMORPHISMS IN MIGRAINE
A. Ambrosini
Headache Clinic, INM Neuromed, IRCCS, Pozzilli, Isernia, Italy; 
e-mail: anna.ambrosini@neuromed.it
Migraine is an ictal neurological disorder, which frequently runs in
families. It is supposed to be a complex genetic disorder, where addi-
tive genetic effects and environmental factors are interrelated. Genetic
load can be seen as determining a critical migraine threshold that is
modulated by external as well as internal factors and, if reached, leads
to an attack.
At present, the only known monogenic subtype of migraine is familial
hemiplegic migraine (FHM), a rare autosomal dominant subtype of
migraine with aura. FHM patients have attacks of migraine associated
with hemiparesis to a variable degree. The first FHM (FHM1) gene
identified was CACNA1A on chromosome 19p13. This gene codes for
the pore-forming subunit of voltage-dependent P/Q-type calcium chan-
nels. Only three years ago the second FHM (FHM2) gene was identi-
fied. FHM2 mutations have been found on the ATP1A2 gene on chro-
mosome 1q23, which codes for the main subunit of the Na,K- ATPase.
Both these genes have been supposed to play a role also in common
forms of migraine, especially with aura, but results are still controver-
sial. A mutation on the ATP1A2 gene has been described in a pedigree
with basilar-type migraine, which is a form of migraine with aura clin-
ically linked to FHM, although more common. Very recently, a third
FHM gene (FHM3) has been identified on chromosome 2q24. It is the
SCN1A, coding for the voltage-gated sodium channel. At present, only
one mutation on this gene has been associated with FHM.
Although no mutations have been identified in common forms of
migraine, some linkage studies revealed many migraine susceptibility
loci. Significant linkages to chromosomes 1q23, 15q11-q13, 11q24,
6p12-p21, 4q24 and 19p13 were described in migraine with aura, and
to chromosomes 5q21, 4q21, 14q21-q22, 1q31, Xq24-q28 and Xp22 in
both types of migraine.
The prevalence of various gene polymorphisms may be higher in
migraineurs than in controls. This was reported for dopamine D2 and
D4 receptors, angiotensin converting enzyme, serotonin transporter,
dopamine β hydroxylase, endothelin type A receptor, insulin receptor,
methylenetetrahydrofolate reductase, estrogen receptor 1 and tumor
necrosis factor β genes. The role played by these various polymor-
phisms remains to be determined; some of them may not be specific to
migraine, but they could increase susceptibility to the disorder and
induce endophenotypic vulnerability markers.
MOLECULAR GENETICS OF CLUSTER HEADACHE: A
REVIEW
I. Rainero
Neurology II, Headache Centre, Department of Neuroscience,
University of Turin, Turin, Italy; e-mail: irainero@molinette.piemonte.it
Introduction In the past, cluster headache (CH) was not thought to be
an inherited disorder. Recent studies have suggested that genetic fac-
tors play a role in the disease [1]. Genetic epidemiological surveys
have clearly shown that first-degree relatives of CH patients are more
likely to have CH than the general population. In addition, CH has
been reported in some concordant monozygotic twin pairs. Recently,
we have reported in an Italian population a significant association
between the HCRTR2 gene and the disease. This association was con-
firmed in a German study. The purpose of this review is to describe
recent advances in the molecular genetics of CH.
Methods We searched MEDLINE (1966–2004) and reference lists of
retrieved articles. The search terms “cluster headache”, “genetics” and
“molecular genetics” were used. Only original articles published in
English were included.
Results Several studies reported lack of association between different
candidate genes and CH. Excluded genes were: CACNA1A, NOS,
HFE, Clock and elusive amine receptors (TAR 1, TAR 3, TAR 4, TAR
5, PNR, GPR58) genes. We reported a significant association between
the 1246 G>A polymorphism of the gene encoding for the hypocretin
receptor 2 (HCRTR2) and CH [2]. Patients homozygous for the G
allele, in comparison with the remaining genotypes, have a five-fold
higher risk of developing the disease. This association was confirmed
in a large sample of 226 patients with CH from Germany.
Discussion At present, the type and the number of genes involved in
cluster headache are still unclear. A significant association between the
HCRTR2 gene and the disease was found. This gene, however, is not a
major gene but rather a disease-modifying gene. These findings sug-
gest that the hypocretin/orexin system may be involved in the patho-
genesis of CH. Hypocretins influence a wide range of physiological
and behavioural processes like appetite regulation, sleep-wake cycle,
neuroendocrine and sympathetic functions. Moreover, recent findings
suggested that hypocretins modulate pain threshold and nociceptive
transmission. Additional studies are needed to elucidate the role of the
HCRTR2 gene in the pathogenesis of CH and to search for major genes
in this rare but severe headache disorder.
References
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MEDICATION-OVERUSE HEADACHE AS DEPENDENCE DIS-
ORDER: A DRD4 GENE POLYMORPHISM ANALYSIS
1,2C. Di Lorenzo, 3G. Di Lorenzo, 1C. Rengo, 4G. Sances, 4N. Ghiotto,
4E. Guaschino, 5F.M. Santorelli, 1G.S. Grieco, 3A. Siracusano,
2F. Pierelli, 4,6G. Nappi, 1,2C. Casali
1Molecular Genetics Laboratory, IRCCS Neurological Institute “C.
Mondino” Foundation, IRCCS “San Raffaele”, Rome, Italy; 2Depart-
ment of Neurology and ORL, and University Centre for Adaptive
Disorders and Headache (UCADH), University of Rome “La
Sapienza”, Polo Pontino, Latina, Italy; 3Psychiatric Clinic, Departme-
nt of Neuroscience, University of Rome “Tor Vergata”, Rome, Italy;
4Headache Unit, and University Centre for Adaptive Disorders and
Headache (UCADH), IRCCS Neurological Institute “C. Mondino”
Foundation, Pavia, Italy; 5Molecular Medicine, IRCCS “Bambino Ge-
sù”, Rome, Italy; 6Department of Neurology and Otolaryngology, Uni-
versity of Roma “La Sapienza”, Rome, Italy; e-mail: cherub@inwind.it
Introduction Medication-overuse headache (MOH) is a chronic
headache disorder developed from an episodic primary headache as a
consequence of analgesic drug overuse. Characteristically, only drug
discontinuation can substantially improve the clinical picture. MOH is
currently regarded as a bio-behavioural disorder with drug dependence.
Several genetic studies have highlighted the role of dopamine receptor
subtype (DRD4) polymorphisms in illicit drug consumption and alco-
hol dependence. Furthermore, some DRD4 polymorphisms have been
correlated with the variability of novelty seeking behaviour (NS), a
personality dimension – determined by Cloninger’s Tridimensional
Personality Questionnaire (TPQ) – associated with substance abuse
and dependence.
In our study we investigated the role of a DRD4 polymorphism in MOH.
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Materials and methods Fifty-seven unrelated MOH patients were
recruited and the diagnosis confirmed after 2 months of drug discon-
tinuation. All patients were interviewed using the Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID-I), to obtain a categor-
ical psychiatric diagnosis, and completed the TPQ. After obtaining
written informed consent from the patients, their genotype with respect
to a 120 bp “tandem duplication” in the 5’-untranslated region of the
DRD4 gene was determined. Two types of polymorphism-lengths
occurred: long (L), the commonest, and short (S), which have been cor-
related with high NS scores and substance dependence.
To find predictors of the monthly amount of drug consumption, in the
statistical analysis we considered as independent variables: years of
disease duration, type of analgesic drug, genotype, and the subscales of
TPQ in the statistical analysis.
Results Twenty-eight patients were homozygous carriers for the L
form (L/L), 26 were heterozygous (L/S) and 3 were homozygous for
the S form (S/S).
• ANOVA analysis showed that in our patients the S/S and L/S geno-
types predicted high scores of NS.
• Linear logistic regression indicated that only the persistence (P)
score (a subscale of TPQ) and the presence of allele S (S/S and S/L)
were factors predictive of the monthly amount of analgesic drug
consumption.
Discussion As with disorders characterized by substance dependence,
in MOH the S allele is related to NS. Moreover, the S allele seems to
also be a predictor of increased drug consumption so that it can be
regarded as an aggravating factor for this disease.
Conclusions In MOH patients the DRD4 polymorphism is linked to
behavioural components like NS and is correlated with the extent of
the drug overuse.
THE HEMOCHROMATOSIS (HFE) GENE INFLUENCES THE
CLINICAL FEATURES OF MIGRAINE
E. Rubino, I. Rainero, C. Rivoiro, W. Valfrè, E. Binello, E. Zampella, 
P. De Martino, S. Gentile, P. Fenoglio, L. Savi, S. Gallone, L. Pinessi
Headache Centre, Neurology II, Department of Neuroscience,
University of Turin, Turin, Italy; e-mail: elisarubino@inwind.it
Introduction Several studies suggested that iron metabolism may be
involved in the pathogenesis of migraine. Iron concentrations in the
periaqueductal gray matter of migraine patients are significantly
increased. A large population-based study showed a high migraine
prevalence in women with hemochromatosis (HH), a disease associat-
ed with progressive iron overload in several organs. The hemochro-
matosis gene (HFE) is located in 6p21.3 and encodes for a HLA class
I-like molecule involved in iron metabolism. Two principal polymor-
phisms in the HFE gene, C282Y and H63D, have been identified as the
cause of HH. Using a case-control design, we performed an association
study in a cohort of Italian migraine patients to evaluate whether a par-
ticular allele or genotype of the HFE gene would modify the occur-
rence and the clinical features of the disease.
Methods A total of 256 consecutive unrelated migraine patients (98
men, 158 women; mean age±SD=40.3±9.4 years) were involved in the
study. The diagnosis of migraine was made according to the
International Classification of Headache Disorders (ICHD-II) criteria.
Two hundred and twenty-five patients fulfilled the diagnostic criteria
for migraine without aura (MO) and 31 for migraine with aura (MA).
A group of 237 sex-, age- and geographically (Northern Italy) matched
healthy subjects (95 men, 142 women, mean age±SD=41.5±13.3
years) were used as controls. Patients and controls were genotyped for
the C282Y and H63D polymorphisms of the HFE gene.
Results Phenotype and allele frequencies of both polymorphisms
were similarly distributed in migraine patients and controls. The
patients carrying the DD genotype of the H63D polymorphism
showed a later age at onset of the disease and an increased number of
migraine attacks.
Discussion Our data suggests that the HFE gene is not a major disease
gene for migraine. However, the H63D polymorphism of the HFE gene
may be considered a modifying genetic factor in migraine.
CYP 450 POLYMORPHISM CONTRIBUTES TO THE VARI-
ABILITY OF THE RESPONSE TO PHARMACOTHERAPY IN
PRIMARY HEADACHE
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Currently available treatments for primary headaches have a limited
efficacy, due in part to the wide variation in individual responses.
Variability in individual response to headache treatment may be due to
several factors, including a patient’s compliance with treatment, sever-
ity and type of headache and intercurrent illnesses, drug interaction
with other medications taken concurrently, diet, and individual biolog-
ical characteristics such as age, nutritional status, hepatic and renal
functions. Hereditary differences may therefore be only one of the
causes of the variable effect of pharmacotherapy in primary headache.
However, genetic factors may underlie much of such variability.
Most drugs are subjected to more or less extensive metabolism. Only a
few of the cytochrome P (CYP) 450 family enzymes are responsible
for the majority of metabolic reactions involving drugs. They include
the isoforms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.
Several of the drug metabolizing enzymes are polymorphic, having
more than one variant of the gene. This polymorphism is responsible
for interindividual differences in the efficacy of drug treatment, side
effects of drugs, and drug toxicity. Genetic polymorphisms with clini-
cal implications have been described for 2D6, 2C19, 2C9, 1A2, and
3A4. Genetic polymorphism of CYP450 enzymes characterizes the
general population into three groups: poor metabolizers, extensive
metabolizers, and ultraextensive metabolizers. There are three ways to
gain information on metabolizing enzyme activities: to study the genes
that code for the enzyme, to study the level of enzyme expression in a
certain tissue, and to assess the actual enzyme activity using an enzyme
specific probe (phenotyping). Genotyping is a more simple procedure
compared to phenotyping. Phenotyping might be helpful in detecting
interethnic differences, or in studies aimed at detecting enzyme induc-
tion or inhibition. Probe substrates that may be used to assess the activ-
ity of specific cytochromes P450 in vivo are: caffeine for CYP 1A2,
dextromethorphan for CYP 2D6, and midazolam for CYP 3A4.
Polymorphism of CYP450 enzymes may or may not have a clear clin-
ical significance for the affected medications, depending on the impor-
tance of the enzyme for the overall metabolism of a medication, the
expression of the other drug metabolizing enzymes in the patient, the
therapeutic index of the drug, the presence of concurrent medications
or illnesses, and other polygenic factors that impact drug response.
PATHOGENETIC ASPECTS OF HEADACHES: FROM
THE EXPERIMENTAL MODEL TO MAN
CA-DEPENDENT EXOCYTOSIS AND CGRP RELEASE IN
MICE TRIGEMINAL GANGLION NEURONS
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Introduction Activation of trigeminal ganglion (TG) nociceptors and
consequent neurotransmitter release are centrally involved in the
development of migraine headache. Calcitonin gene-related peptide
(CGRP) is one of the most important vasoactive neurotransmitters in
migraine. Major lines of evidence are: i) CGRP is found in human
jugular venous during migraine attacks; ii) the administration of the
antimigraine agent sumatriptan relieves headache and re-establishes
normal CGRP levels; and iii) intravenous administration of CGRP
induces headache and migraine in migraineurs. Elucidation of the
release mechanism for CGRP in TG neurons may thus be critical in the
understanding of migraine pathology [1, 2]. In dorsal root ganglia
(DRG) neurons it has been recently shown that a significant compo-
nent of exocytotic release and even a greater fraction of depolarization-
induced CGRP release do not require Ca2+ influx. We then set out to
assess the Ca2+ dependence of exocytosis and of CGRP release in TG
neuron of mice. This investigation was carried out considering that a
subtype of migraine with aura, familial hemiplegic migraine type 1
(FHM1), is caused by mutations of CaV2.1 channels, abundantly
expressed in TG neurons [2].
Methods Depolarization-induced membrane capacitance changes
were measured in the whole-cell configuration of the patch-clamp
technique, by using the Neher-Lindau method. CGRP release was
assessed by immunocytofluorimetric methods.
Results With 5 mM external Ca2+, 200-ms depolarizing pulses to 0
mV evoked a Ca2+ current of -3.4±0.4 nA, and an increase in mem-
brane capacitance of 292±67 pF (n=17). Bath application of 200 µM
Cd2+ fully inhibited the Ca2+ current, but reduced the depolariza-
tion-induced capacitance change by only 24±6% (n=4). When neu-
rons were stimulated with a train of 20 depolarizing pulses, the frac-
tion of Cd2+-sensitive capacitance change increased to 45±7%
(n=4). Similar results were obtained when the inhibition of Ca2+
influx was attained by removing the external Ca2+. K+-induced
depolarization of TG neuronal cultures in 2.5 mM external Ca2+
increased CGRP release by 19.4±2.1 fold of its basal level (n=8).
When neurons were incubated in a medium containing 30 µM Ca2+,
the K+-induced CGRP release was reduced to 5.4±1.1 fold of its
basal level (n=4).
Conclusions Our data indicate that TG neurons possess both a Ca2+-
dependent and a Ca2+-independent exocytotic release, and that the
CGRP release is strongly controlled by the Ca2+-dependent component.
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CEREBROSPINAL FLUID LEVELS OF OREXIN-A AND COR-
TICOTROPIN-RELEASING FACTOR SUGGEST THEIR
INVOLVEMENT IN THE NEGATIVE MOTIVATIONAL STATE
THAT DRIVES “DRUG DEPENDENCE” IN MEDICATION-
OVERUSE HEADACHE
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Background Hypocretin-1 and -2 (Hcrt-1 and Hcrt-2), also referred to
as orexin-A and -B, are two neuropeptides, which are considered criti-
cal components for maintaining and regulating the stability of arousal
to mediate the hypothalamic response to stress. Experimental evidence
suggests that corticotrophin-releasing factor (CRF) activates the
hypocretin system, which relays orexin-A to brainstem nuclei as well
as to the extended amygdala, a structure involved in the negative moti-
vational state that drives addiction [1, 2].
No studies have been conducted until now to investigate the role of
hypocretins, in particular orexin-A, in medication-overuse
headache (MOH).
Objective The present study was aimed at investigating the levels of
orexin-A and CRF in the cerebrospinal fluid (CSF) of chronic migraine
(CM) and probable CM+probable medication-overuse headache
(PCM+PMOH) patients.
Patients and methods Twenty-five patients affected by CM and 30
patients with a prior history of migraine without aura and diagnosed as
having PCM+ PMOH were admitted to the study.
Control CSF specimens were obtained from 20 age-matched subjects
who underwent lumbar puncture for diagnostic purposes and in all of
them CSF and blood tests excluded CNS or systemic diseases.
Orexin-A and CRF were determined by radioimmunoassay methods.
Clinical variables which were related to CSF levels of orexin-A and
CRF were: number of days with headache per month; intensity of
headache measured with the visual analogue scale; duration of chronic
headache (years); daily drug intake; and Leeds Dependence
Questionnaire (LDQ) scores.
Results Significantly higher levels of orexin-A and CRF were found in
the CSF of PCM+PMOH patients and to a lesser extent in patients with
CM compared with control subjects (orexin-A=p<0.001 and p<0.02,
=p<0.002 and p<0.0003). A trend toward a significantly positive cor-
relation between CSF levels of orexin-A and CRF emerged in the
PCM+PMOH group, but did not reach the level of statistical signifi-
cance. A significantly positive correlation was also found between CSF
orexin-A values but not with CRF and daily drug intake and LDQ
scores in the latter group (r=0.53, p<0.001 and r=0.48, p<0.002,
respectively).
In both CM and PCM+PMOH patient groups there was no correlation
between number of day with headache per month, intensity of
headache and duration of chronic headache.
Discussion Results of the present study support the involvement in
the orexin-A system mediated by CRF activation, in the negative
motivational state that drives drug dependence in MOH. This is sup-
ported by the relationship between the number of drugs abused and
the scores of a self-completion 10-item instrument (LDQ) to measure
dependence upon a variety of substances. These findings suggest a
potential role for this hypocretin in driving drug seeking also in MOH
through activation of stress pathways in the brain, has been shown in
experimental models.
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PRIMARY CULTURES OF RAT TRIGEMINAL GANGLIA NEU-
RONS AS AN IN VITRO MODEL TO INVESTIGATE
MIGRAINE MECHANISMS AND THERAPIES
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We are currently developing an in vitro model based on primary cul-
tures of neonatal rat trigeminal ganglia neurons, with the aim to inves-
tigate the pathophysiological mechanisms underlying migraine, as well
as the effects of putative antimigraine agents.
Primary cultures were prepared as follows: ganglia from 6–7 day-old
rats were quickly removed and digested by collagenase and trypsin;
cells were seeded on 24-well tissue culture plates, coated with poli-D-
lysine and laminin at a density of 130–150 x 103 cells/well and incu-
bated at 37°C in a humidified atmosphere containing 5% CO2. The cul-
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ture medium was changed within 24 h from seeding. Plating medium
was enriched with 50 ng/mL of 2.5 S murine nerve growth factor.
Cytosine arabinoside 10 µM was added to arrest non-neuronal cell
growth. All experiments were performed from 3 to 6 days after dissec-
tion. In this model, we developed a radioimmunoassay (RIA) method
to measure calcitonin gene-related peptide (CGRP) released in the
incubation medium; this parameter can be taken both as an index of
neuronal function as well as a pivotal mediator of migraine pathology.
We found that CGRP was released in sizable amounts after 10–60 min-
utes experiments. Basal CGRP release was increased in a significant
manner by depolarizing solutions (i.e., incubation media containing 56
mM KCl). Release was also increased by the Na+-channel activator,
veratridine, with significant increases from 10-8 M onward. Apart from
non-specific depolarizing agents, CGRP release was also increased in
a concentration-dependent manner by the vanilloid receptor agonist
capsaicin, with an estimated EC50 of 0.3 µM.
Preliminary findings show the opioid-related peptide nociceptin, also
referred to as orphanin, reduces basal CGRP release from cultured neu-
rons. We are currently investigating the effects of nociceptin over spe-
cific (capsaicin) and non-specific (KCl and veratridine)-stimulated
CGRP release.
FOCAL GRAY MATTER DECREASE IN THE CEREBRAL PAIN
NETWORK OF MIGRAINE PATIENTS
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Introduction Migraine is considered a frequent, primary headache dis-
order due to transient abnormal brain function. According to the cur-
rent classification of the International Headache Society, structural
brain lesions are absent in primary headaches. However, recent studies
with voxel-based morphometry (VBM) demonstrated selective brain
alterations in both cluster headache (bilateral increase of gray matter in
postero-lateral hypothalamus) and chronic tension-type headache (gray
matter decrease in orbifrontal cortex, insula, and anterior cingulate cor-
tex). The purpose of this study was to investigate the presence of struc-
tural abnormalities in patients with migraine using the optimized
voxel-based morphometry method, a highly sensitive technique to
detect focal gray and white brain matter abnormalities.
Methods A group of 27 right-handed migraine patients, diagnosed
according to ICHD-II criteria, and 27 right-handed healthy controls
underwent high resolution structural magnetic resonance imaging
(MRI). Data was analyzed using MATLAB 6.5 and Statistical
Parametric Mapping 2 (SPM2). Covariance analysis was used to detect
local gray matter changes in migraine patients and between episodic
and chronic migraine. Regression analysis was performed to search for
a relationship between local gray matter changes with the clinical char-
acteristics of migraine.
Results Significant gray matter volume reduction was found in the right
superior temporal gyrus, right parietal operculum, right inferior frontal
gyrus, left angular gyrus, left inferior parietal lobule and left precentral
gyrus of migraine patients. In comparison with episodic migraine,
patients with chronic migraine showed a significant bilateral reduction
of gray matter concentration in the anterior cingulate cortex (AAC),
right angular gyrus and right inferior frontal gyrus. Finally, we found a
significant correlation between the frequency of migraine attacks and
the reduction of gray matter concentration in AAC of migraine patients.
Discussion Our study shows a significant gray matter reduction in
migraine patients of several cortical areas involved in pain processing
and a selective alteration of AAC related to frequency of migraine
attacks. Functional neuroimaging shows that several brain regions are
activated by pain, including frontal and pre-frontal cortices, operculo-
insular cortex, primary and secondary somatosensory cortices, AAC,
thalamus and regions within the parietal and temporal cortices. In addi-
tion, AAC plays a key role in the affective and attentive processing of
pain sensations. Our data supports the results of previous studies sug-
gesting that migraine may be considered a progressive brain disorder
and highlights the importance of prophylactic antimigraine therapy in
order to avoid the progression of the disease.
EVIDENCE FOR SPINAL CORD HYPERSENSITIVITY AND
ABNORMAL MODULATORY INFLUENCE OF DIFFUSE NOX-
IOUS INHIBITORY CONTROLS IN MEDICATION-OVERUSE
HEADACHE
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Background It has been postulated that chronic exposure to antimi-
graine and/or analgesic treatment may interfere with the pain control
system, leading to a central sensitization phenomenon responsible for
chronic headache.
Diffuse noxious inhibitory controls (DNICs) are part of a central pain
modulatory system that relies on spinal and supraspinal mechanisms.
It has been postulated that chronic or frequent exposure to antimi-
graine and/or analgesic treatment may lead to a downregulation of
specific receptors and may subsequently change central inhibitory
(anti-nociceptive) pathways such as DNICs, leading to central sensiti-
zation phenomena responsible for chronic headache pain. Our previ-
ous study [1] showed that the temporal summation threshold (TST) of
the nociceptive flexion reflex (RIII) represents a useful tool to evalu-
ate both the central sensitization of pain pathways and the functional
activity of DNICs.
Objective The present study investigated the TST of the RIII reflex in
medication-overuse headache (MOH) patients before and after with-
drawal therapy.
Methods Twenty-four MOH patients before and after withdrawal treat-
ment and 25 age- and sex-matched controls were evaluated. TST of the
RIII reflex and the subjective painful sensation were measured before,
during and after activation of the DNICs by the cold pressor test (CPT),
which involved immersing the hand in cold water (2–4°C). After 7–10
days of withdrawal treatment all patients were re-evaluated.
Results Significantly (p<0.01) lower RIII threshold and TST were
found in patients versus controls. In patients, the CPT induced a sig-
nificantly (p<0.01) lower TST increase with respect to controls. After
the withdrawal therapy we found an improvement of the evaluated
parameters, and a highly significant increase (p<0.01) in the TST dur-
ing CPT.
Conclusions These data confirm the hypothesis of a lack of function of
the DNICs and of a central sensitization phenomenon in MOH patients.
The improvement after withdrawal treatment suggests that medication
overexposure could interfere with inhibitory central pain mechanisms.
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Introduction Nitroglycerin activates spinal and brain nociceptive
structures via nitric oxide (NO) and plays an important role in the ini-
tiation and maintenance of pain. Chronic stress affects both pain
threshold and behaviour, and unavoidable stress paradigms such as
immobilization are used to study nociception. We have recently report-
ed that chronic stress enhances the hyperalgesia induced by nitroglyc-
erin in the rat. This may be particularly relevant to migraine, since
nitroglycerin triggers spontaneous-like attacks in humans, and an
unfavourable migraine outcome (transformation into a chronic daily
headache) is associated with chronic stress and comorbid depression.
Pregabalin is an antiepileptic and analgesic drug with significant
effects on thermal allodynia and mechanical hyperalgesia; we therefore
investigated the effect of pregabalin in this experimental model of
chronic migraine.
Materials and methods Pain perception was measured using the laten-
cy of response to a tail flick test (hot stimulus). Measures were made 1,
2 and 4 hours following nitroglycerin (10 mg/kg i.p.) in rats immobi-
lized for 7 days using dedicated plexiglass restraining cages, and treat-
ed with pregabalin at the dose of 60 mg/kg per os or with vehicle.
Results Chronic stress caused hyperalgesia, which was further
enhanced by nitroglycerin after 2 and 4 hours (p<0.05). By contrast,
chronic stress-induced pain perception decreased in pregabalin treated
animals (p<0.05); in the same group, the hyperalgesic effect of nitro-
glycerin was also found to be significantly dampened (p<0.05).
Discussion and conclusions These preliminary data suggest that
pregabalin acts as an antinociceptive drug by affecting the mecha-
nisms leading to hyperalgesia in the rat. Pregabalin may thus repre-
sent a novel therapeutic option in the management of chronic
migraine in humans.
CEREBRAL EXCITABILITY IN MIGRAINE
ROLE OF THE BRAINSTEM IN MODULATION OF CORTICAL
EXCITABILITY IN PRIMARY HEADACHE
M. de Tommaso
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Neuroimaging and neurophysiological studies have done much to clarify
the fundamental neurological basis of migraine. One of the most pivotal
investigations in the history of migraine pathophysiology reported activa-
tions from a positron-emission tomography (PET) study of acute
migraine. Brain activation was seen in the dorsal midbrain and dorsal
pons during the acute attack. Remarkably, the same midbrain area was
identified in a study of iron homeostasis in episodic and chronic migraine.
Clinical reports have identified secondary migraine after disturbances in
the brainstem, again in the same regions. From triangulation of these
observations, a candidate region for a key defect in migraine would be the
ventrolateral periaqueductal grey (PAG). The PAG is known to ordinari-
ly inhibit trigemino-vascular nociceptive input and to remarkably facili-
tate it when voltage-gated calcium channels are blocked. It is largely
involved in the modulation of pain transmission, being activated or deac-
tivated by the cortical areas subtending the attentive and emotive com-
pounds of pain. In this view, it has been shown that migraine patients are
unable to modulate pain, for a lack of inhibition of the nociceptive cortex
during distractive tasks [1]. There is controversy about the status of basal
hypo- or hyperexcitability of the migraine cortex, leading to the phenom-
enon of reduced habituation to repetitive stimuli and cognitive tasks [2].
This basic abnormality seems to affect the nociceptive cortex, other than
the cortical zones elaborating multimodal stimuli [2]. Whatever is its ori-
gin, reduced habituation results in cortical over-activity, with reduced effi-
cacy of the cortical-subcortical reciprocal connections. Changes in corti-
cal synchronization have been described in migraine as an underlying
abnormality, which may also interfere with brainstem modulation [3].
Abnormal cortical information processing, probably based on the phe-
nomenon of altered neuronal synchronization, may be a basic feature
in migraine; the brainstem, particularly the zones corresponding to the
PAG, may consequently change its ascending firing to the cortex and
its descending control on the nociceptive afferents, with a self-main-
taining circuit prone to the generation and the persistence of headache.
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CORTICAL EXCITABILITY AND HABITUATION MECHA-
NISMS IN MIGRAINE
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Controversy has arisen about the excitability status of the cerebral cor-
tex in migraineurs between attacks. Intuitively, some clinical features
of migraine such as hypersensitivity to environmental light or noise,
and the aura symptoms suggest hyperexcitability of the cerebral cor-
tices. In the physiological sense, however, hyperexcitability would
mean that the brain responds to a subliminal stimulus with an increased
amplitude. This abnormality has never been precisely demonstrated
studying cortical excitability in migraine patients.
Increased cortical excitability or decreased intracortical inhibition, as
well as hypoexcitability or normal function of inhibitory cortical
interneurons have been observed in migraine by using transcranial
magnetic stimulation (TMS), thus providing ambiguous results.
It has been hypothesized that the finding of an interictal deficit of
habituation of cortical evoked responses is probably not due to hyper-
excitability or to underactivity of intracortical inhibition, but to a
reduced preactivation excitability level of the sensory cortices, stated
by activity in thalamo-cortical loops and aminergic projections from
the upper brainstem. This low preactivation level, in conjunction with
the cortical “ceiling theory”, could indeed explain the low amplitudes
found in the first blocks of several types of evoked responses and the
lack of habituation in subsequent blocks, since it would offer a
larger range for suprathreshold cortical activation before reaching
the “ceiling”.
Interestingly, this dishabituation phenomenon is reversible, since it
normalizes just before and during an attack. It remains to be deter-
mined if activation of the dorsal rostral brainstem and of thalamo-cor-
tical projections may contribute to ictal normalization of the cortical
preactivation level.
REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN
MIGRAINE: RECENT EVIDENCE
F. Brighina, A. Palermo, G. Giglia, B. Fierro
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e-mail: filippo.brighina@virgilio.it
Transcranial Magnetic Stimulation (TMS) has been employed to study
the pathophysiology of migraine. All studies reported abnormal corti-
cal activation in migraineurs during the interictal phase; the findings
however were controversial, some authors describing hypo- and others
hyper- excitability of the migraine visual cortex.
Repetitive TMS (rTMS) is able to modulate cortical excitability, with
low frequency (≤1 Hz) decreasing while high frequency (> 1 Hz)
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increasing activation of stimulated cortices.
A few rTMS studies have been conducted in migraine. We showed that
low-frequency rTMS has paradoxical facilitatory effects on striatal and
extra-striatal cortex in migraine and interpreted this result as due to
reduced efficiency of cortical inhibitory circuits, unable to be up-regu-
lated by rTMS. According to this hypothesis, we found dysfunction of
inhibitory circuits also in the motor cortex of migraineurs. Through
paired pulse TMS we showed that migraineurs present reduced intra-
cortical inhibition at baseline. After 1 Hz stimulation, parodoxical
potentiation of intracortical facilitation (ICF) occurs, opposite to the
suppression of ICF induced by the same trains in healthy controls.
In contrast, Bohotin et al. [1] in a rTMS experiment found that the
facilitatory frequency 10 Hz favours the recovery of habituation of
visual evoked potentials that is reduced in migraine. The authors spec-
ulated that migraineurs have a reduced cortical activation that can be
reversed by facilitatory rTMS. Moreover, in the authors’ view, the rela-
tionship between reduced-activation and deficient-habituation is also
confirmed by the results of 1 Hz rTMS application in healthy subjects;
in this group, in fact, reducing activation through 1 Hz rTMS that nor-
mally exerts an inhibitory effect gives similar habituation impairment
compared with migraine.
However, the effects of rTMS greatly depend on the basal excitability
state of stimulated cortex. In fact, in a recent paper [2] we found that
during visual deprivation, a condition known to increase visual cortical
excitability, rTMS can exert opposite effects, with low frequencies
increasing while high frequencies decreasing excitability of the occip-
ital cortex. This means that rTMS should be interpreted cautiously
when investigating cortical excitability, to avoid a circular reasoning,
i.e., the same rTMS effects are conditioned by the basal excitability
state of the stimulated cortex.
rTMS if given in repeated stimulation sessions is also able to induce
persistent plastic changes of the stimulated cortex, and this is the ratio-
nale for its use in experimental treatment of various neurological and
psychiatric diseases.
Recent findings about this rTMS application seem to open interesting
therapeutic perspectives in migraine.
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VISUAL EVOKED GAMMA BAND RESPONSES IN SUB-
GROUPS OF MIGRAINE WITH AURA
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Background Visual stimuli evoke high frequency oscillations in the
gamma band range (GBOs, 20–35 Hz) generated both by pre- (early
GBOs) and post-synaptic (late GBOs) mechanisms. Recently, Sandor
et al. [1], with MR-lactate spectroscopy, observed that a pattern of
dishabituation, as previously found with evoked potentials, was present
in a subgroup of migraine patients with associated paraesthesia, pare-
sis or dysphasia as aura (MAplus), while in the subgroup with high
resting lactate, the aura seems to be limited to the visual cortex.
Taking into account that a close relationship was observed between
oscillatory response and metabolic cortical demand [2], we searched
for pathophysiological differences in the clinically distinct subgroups
of migraine with aura (MA) exploring visual evoked GBOs during the
interictal period.
Materials and methods Eighteen patients affected by migraine with
typical aura (ICHD-II code 1.2.1, 2004) were enrolled in this study: 8
with pure visual aura (MA) and 10 with visual aura associated with
paraesthesia or dysphasia (MAplus). Migraineur groups were com-
pared to 15 healthy volunteers (HV).
We extrapolated the GBOs from the broad-band visual evoked poten-
tials (VEPs), with an off-line band pass digital filter (20–35 Hz). We
analyzed peak-to-peak amplitude and habituation (the amplitude change
(%) between the 1st and 6th block of 100 sequential averaged respons-
es) of the conventional broad-band N1-P1 and of each of 6 peaks of
GBO burst evoked by the checkerboard pattern. We considered as early
GBOs the first 3 oscillatory peaks, and as late GBOs the last 3.
Results The conventional broad-band VEPs showed the well-known
pattern of dishabituation in both MA (p=0.038) and MAplus (p=0.001)
patients when compared to HV.
After digital filtration, there was a significant habituation deficit of the
later two, but not of the earlier GBO peaks in MAplus patients com-
pared to HV (respectively p=0.035 and p=0.032). In contrast, the MA
group with pure visual aura showed an increased early oscillatory peak
activity compared to HV (2nd p=0.024 and 3rd p=0.013), without
habituation deficit of the later GBO peaks.
Discussion We found different patterns of visual oscillation responses
in two subgroups of MA patients, which seem to mimic those observed
with MR-lactate spectroscopy in patients with the same diagnosis. We
hypothesized that an abnormal metabolic demand due to repetition of
visual stimulus leads to dishabituation, which exists in MAplus patients,
and to a predominant energetic metabolism dysfunction in MA patients.
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Introduction Although migraine represents the most common primary
headache in childhood, its pathophysiology is poorly understood. In
spite of the bulk of studies dealing with this problem in adults, the
pathophysiological base of paediatric migraine has been only rarely
investigated. As in adults, children with migraine show a reduced habit-
uation to repetitive sensory stimuli [1, 2]. Although this characteristic
neurophysiological phenomenon suggests an abnormal excitability of
the cerebral cortex in this disease, whether cortical excitability in
migraine is reduced or increased is still far from demonstrated.
Materials and methods We investigated cerebral cortex excitability in 15
children (mean age 11.7±1.6 years, 5 males, 10 females) affected by
migraine without aura (MO) and in 10 age-matched control subjects (CS)
(mean age 10.9±2.1 years, 6 males, 4 females). We calculated the
somatosensory evoked potential (SSEP) latency and amplitude modifica-
tions after paired electrical stimuli at 5, 20 and 40 ms interstimulus inter-
vals (ISIs), comparing it with a single stimulus condition taken as baseline.
Results In MO patients, the amplitudes of the cervical N13 and of the
cortical N20, P24 and N30 responses at 20 and 40 ms ISIs showed a
higher recovery than in CS (two-way ANOVA, p<0.05).
Discussion Since the SSEP recovery cycle depends on inhibitory
interneuron function, our findings suggest that a somatosensory system
disinhibition occurs in migraine. This is a generalized phenomenon, not
limited to the cerebral cortex, but involving also the cervical grey matter.
Conclusions The shortened SSEP recovery cycle in migraine children,
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besides showing that the somatosensory system is hyperexcitable in
this disease, might represent a useful marker to control the effect of
prophylactic pharmacological treatments.
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Introduction Comorbidity of migraine and epilepsy has long been sus-
pected, but the nature of this association is still unresolved. The preva-
lence of epilepsy in migraine patients is reported to range from 1% to
17%, with a mean of 5.9%. We evaluated the prevalence of epilepsy in
a large population of migraineurs.
Materials and methods We analysed the clinical charts of 1098 con-
secutive patients referred to our Headache Centre completely fulfilling
the ICHD-II diagnostic criteria for migraine, with specific attention to
those patients diagnosed also with epilepsy.
Results We identified 16 migraine patients affected by epileptic syn-
dromes: 5 cases with partial idiopathic epilepsy, 4 cases with partial
symptomatic epilepsy, 6 cases with generalized idiopathic epilepsy and
1 case with generalized symptomatic epilepsy. The mean age of the
patients was 36.2±9.9 years, with a large preponderance of females (13
out of 16 cases), with a ratio F:M=4.3:1. Three patients suffered from
migraine with aura; in one of them the seizures occurred only during
or immediately following migraine aura (1.5.5 Migraine-triggered
seizures according to ICHD-II, in the past referred to as “migralepsy”).
The remaining 13 subjects were affected by migraine without aura; one
of them had also brief headaches synchronous with partial seizures
(7.6.1 Hemicrania epileptica). Four patients complained of post-ictal
headaches (7.6.2 Post-seizure headache), whose features were almost
completely identical to those of their usual migraine headaches.
Discussion The prevalence of epilepsy in our population of
migraineurs was 1.5%. This finding is in contrast with the data report-
ed in previous studies, where a higher prevalence, ranging from 1% to
17%, was noted. A possible explanation for the low prevalence found
in our study is that patients with seizure disorders may be more likely
to contact specific centres for the study of epilepsy, even if they also
suffer from disabling migraine headaches. Patients with both condi-
tions could consider migraine less relevant to their health perception,
as compared to epilepsy.
Conclusions The prevalence of epilepsy in migraineurs seems to be
less prominent than reported in previous studies, even if methodologic
problems make these studies difficult to interpret. Nonetheless, the
prevalence of epilepsy in our migraine population was significantly
higher than that found in the general population, which is approxi-
mately 0.5%. Our data support the hypothesis that the comorbidity of
migraine and epilepsy may be explained by a state of neuronal hyper-
excitability that increases the risk of both disorders.
ICHD-II: RE-EVALUATION AND INSTRUMENTS OF
APPLICATION
REVISION OF THE ICHD-II CRITERIA FOR CHRONIC
MIGRAINE
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Chronic headaches continue to be the most debated aspect of the
International Classification of Headache Disorders. Following the
introduction of the concept of chronic migraine in the second edition of
the classification (ICHD-II), it has been found that the chronic
migraine criteria proposed are, in fact, fulfilled by very few patients in
clinical practice and clinical trials. To amend this situation, the
Headache Classification Committee of the International Headache
Society (IHS), which met during the International Headache Congress
in Kyoto, decided to develop criteria that more accurately reflect the
large majority of this population of patients.
The proposed version had already been distributed and through fruitful
discussion, further amendments and improvements were made. It was
decided to make the revised criteria available for future research,
inserting them in the Appendix to ICHD-II. The Headache
Classification Committee of the IHS invites the headache community
to study these new criteria and to set up clinical trials for this severely
affected population of headache patients.
The revised criteria for chronic migraine are: a) headache (migraine
and/or tension-type) present for 15 or more days per month for at least
three months; b) patients must have had five or more typical migraine
attacks; c) typical migraine attacks must have been present on at least
8 days per month for no less than three months. An important addi-
tional criterion concerns the response to triptans or ergot treatment.
However, some important problems remain unsolved, including the
threshold for considering a migraine “high frequency”. In migraine
prophylaxis clinical trials the threshold is from 2 to 6 attacks per
month, but considering that an attack can last three days, a threshold of
eighteen days per month for chronic migraine would seem to be more
appropriate. Another question regards the need for at least two months’
monitoring by diary card (as opposed to just one month). This would
allow the inclusion, for female patients, of one or two menstrual cycles
and make it possible to report different frequency of attacks or number
of days of headache in different periods of observation. Furthermore,
drug response could be extended to the NSAIDs. In addition, there is
no consensus in treatment guidelines about the threshold at which pro-
phylaxis is necessary, particularly with regard to additional clinical cir-
cumstances.
The Headache Classification Committee hopes that, with these revised
criteria for chronic migraine, the majority of patients with this disorder
seen in clinical practice can be correctly evaluated.
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The classification of “Medication-Overuse Headache” (MOH) in
chapter 8.2 of ICHD-II [1], although recently simplified to a list of
drugs producing medication-overuse headache if overused [2], is still
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ambiguous as far as combination analgesic-overuse headaches are
concerned. Subforms 8.2.5 and 8.2.6 include drugs belonging to
remarkably different classes, which can hinder and bias the compar-
ative assessment of the clinical studies about medication-overuse
headache. The same group of patients can include both patients tak-
ing combinations containing simple analgesics and caffeine and those
taking combinations containing opioids and butalbital; but simple
analgesics, even if associated to caffeine, do not have the same CNS
effects as barbiturates and opioids. These central effects could influ-
ence the outcome of medication-overuse headache treatment differ-
ently from NSAIDs. We think that the classification of chapter 8.2
should be changed in order to be effectively used both in the clinical
setting and in research. The classifying criteria should be the phar-
macological class and the presence or absence of a dependence-pro-
ducing property of the overused drugs. The same classification is also
used by WHO ICD-10NA codes and aetiological ICD-10 code for
secondary headache disorders and would simplify code transferabili-
ty among classifications.
The major changes that we propose are: (i) classifying the drugs
inducing MOH into two groups: drugs with psychotropic effects that
produce tolerance, dependence, repetition of intake and, sometimes,
abstinence symptoms after withdrawal; drugs related to non-depen-
dence-producing substances; (ii) including in the first group also the
combinations of analgesics and drugs with psychotropic effects,
since we consider the latter as the most important component to
maintain overuse.
The classification that we propose could contribute to a more precise
assessment of the various drug classes in conditioning the evolution of
primary headache syndromes, the outcome of withdrawal treatments
and the short and long-term relapse rate. Finally, we believe that it
would be useful, for clinical and research purposes, to know the
dosages of overused drugs and the duration of overuse, in order to cor-
rectly assess the outcomes of medication-overuse headache treat-
ments. In fact, the outcomes of the same medication-overuse headache
treatment could be different, e.g., in a patient who has been taking 600
mg ibuprofen by mouth every other day for 4 months and in a patient
who has been taking a combination containing 50 mg butalbital and/or
30 mg codeine on three days per week for two years.
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Introduction On the basis of our previous study [1], which highlights
the specificity of osmophobia for migraine, in comparison to tension-
type headache and other primary headaches, we started a clinical study
to investigate the presence of this symptom in secondary headaches
and to evaluate its relevance in the differential diagnosis between pri-
mary and secondary headaches.
Materials and methods The clinical study was conducted on a series
of consecutive patients from the Neurological Clinic, the Operative
Unit of Neurosurgery and the Neurotraumatological Clinic of the
University of Padua, bearing pathological conditions potentially able
to cause headache. Through a semistructured questionnaire we select-
ed all patients suffering from secondary headache; the presence of a
primary form of headache was also investigated (ICHD-II, 2004). A
part of the questionnaire concerned the possible presence of osmopho-
bia in the course of headache attack both in primary and secondary
headaches. All the patients who presented alterations of their state of
consciousness, who for any reason could not give reliable answers or
who presented anatomic and/or functional alterations of olfactory func-
tion, were excluded.
Results We recruited 395 patients of whom 44 were excluded (accord-
ing to the criteria previously reported). In the remaining 351, sec-
ondary headaches were referred in 36%; more specifically, of these,
39% had headache attributed to head and/or neck trauma (16/41), 34%
to cranial or cervical vascular disorders (41/123), 36% to non-vascular
intracranial disorders (65/179), and 25% had other secondary
headaches (2/8). Among the group of patients who did not report sec-
ondary headache, 10% only had a preexisting primary headache;
whereas, in the group with secondary headaches, 27% had a preexist-
ing primary headache. Among these, only two migraineurs had osmo-
phobia that was in connection with attacks of preexisting migraine
without aura and not with secondary headache. None of the patients
affected only by secondary headache reported osmophobia before or
during the attacks.
Conclusions The presence of osmophobia is a relevant marker in
favour of the diagnosis of migraine [1]. This study, which needs further
confirmation with a larger survey, highlights how osmophobia presents
a high specificity in the differential diagnosis between migraine vs ten-
sion-type headache and other primary headaches, even between
migraine and the secondary headaches we considered.
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Migraine is very frequently observed by general practitioners (GPs).
Its clinical characteristics, which must fulfil the International
Classification of Headache Disorders – 2nd edition (ICHD-II) crite-
ria, along with a normal physical and neurological examination, are
essential for the diagnosis; further investigations are usually request-
ed only to exclude a possible secondary origin. GPs are largely the
first medical figure that the migraine sufferers speak to; because of
the workload of GPs, the traditional approach to the patient could be
too time demanding.
We developed a computerized programme for use by GPs; the aim
of the software is to give a simple, informative and timesaving sup-
port to GPs for the diagnosis of the principal forms of primary
headaches (migraine, tension-type headache, cluster headache). It
highlights the red flags of a possible secondary headache, and it
lists, step by step and at the end of the process, the clinical features
of the patient’s headache which, previously inserted by the physi-
cian, led to the selection of a particular diagnosis, allowing a critical
re-evaluation of the suggested diagnosis. With respect to a previous
edition, we implemented the programme with the acute therapy
options. In the case of a migraine diagnosis, the programme gives
suggestions regarding the most appropriate choices, according to the
category of drugs, to the comorbidity, and to the efficacy and toler-
ability of previous/actual drugs reported by the patient.
It is also possible to create a clinical sheet containing all the informa-
tion regarding the first observation and the follow-up visits.
In conclusion, this software aims to represent a moment of education-
al growth, suggesting a practical clinical-therapeutic flowchart for
migraine diagnosis, in accordance with ICHD-II criteria.
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Introduction Prior research shows that around 10% of women and 5%
of men reported headache at the age of 70. However, the primary
headaches (PHs) in the elderly are still poorly studied. To date, no stud-
ies that have used the International Classification of Headaches, 2nd
edn (ICHD-2) to classify PHs in the elderly over 70 years old have
been reported in the literature. This study had the objectives to classi-
fy the PHs in a USA and Italian elderly population (≥ 70 years old)
according to the ICHD-2.
Methods Our cohort consisted of 426 elderly subjects without demen-
tia (53% female, age range 70 to 94, mean=78.6 years). To assess the
prevalence of PHs in this population we used a standardized question-
naire to prospectively survey participants of the Einstein Aging Study
(EAS) and of the Rummo Aging Study (RAS). The EAS and RAS are
a multidisciplinary project that follows a representative sample of
seniors focusing on the description of cognitive pathways in the elder-
ly. The questionnaire assessed current headache diagnoses (prior year),
as well as prior headache diagnoses, according to the ICHD-2. All sub-
jects participating in the EAS and RAS underwent neurologic exami-
nation, and most had neuroimaging. Consistently, we could confident-
ly exclude secondary headache disorders.
Results One-year prevalence was 7.6% for migraine (migraine without
aura 1.6%; migraine with aura 1.7%; probable migraine without aura
2.1%; probable migraine with aura 2.2%), 6.1% for episodic tension-
type headache (ETTH) and 1.4% for chronic migraine. For those with-
out headache in the past year a history of CDH was present in 3.1% of
patients, a history of migraine in 4.7% and a history of ETTH in 6.9%
of the sample. A remission of headache before age 50 was present in
50% while before age 65 in 81.2%. Around 15% of our sample had
recurrent PHs in the past year, and 7.6% met ICHD-2 criteria for
migraine. Most fulfilled a probable diagnosis rather than the full criteria.
Conclusions While 4.8% of patients had more than 15 days of
headache per month at some point in their life, just 1.1% had it now.
Headache remission prior to age 65 is common.
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The actual application, by a computerized structured record, of the cur-
rent International Headache Society (IHS) diagnostic criteria in clini-
cal practice has been investigated in adults, while data in children are
lacking. We tested the computerized record, based on ICHD-II criteria,
by entering and analyzing data reported on the case sheets of 800 chil-
dren (range 6–18 years) attending our paediatric headache centre.
Concordance between the clinical and computerized diagnoses was
found in 70% of the cases examined. There was an absolute agreement
of diagnosis (100%) in the subjects with chronic migraine (CM) and
migraine with aura (MA) and almost complete in those with migraine
without aura (MO) (99.1%). In episodic tension-type headache, con-
cordance was reached in 50% of the cases and only in 9% with proba-
ble migraine. In the remaining types of headache, the computerized
record showed, other than the diagnosis provided by the clinician, fur-
ther probable alternatives.
In the types of headache with a large amount of information and typical
accompanying symptoms, concordance was 100% and there were no
diagnostic problems. In contrast, when we have headache types with
intermediate characteristics and/or lack of accompanying symptoms, the
software elaborates different diagnoses according to ICHD-II criteria.
The computerized structured record could be, in selected cases, an
improvement for the specialist to orient the diagnosis. The clinician
must make the diagnosis and consider the clinical and family history,
the presence of trigger factors, and the psychological aspects in a holis-
tic vision of the patient. Further studies are needed to improve the soft-
ware in order to increase the diagnostic concordance.
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Migraine and tension-type headache represent the most common forms
of primary headaches. In the absence of biological markers, the diag-
nosis of these forms of headache depends entirely on the information
obtained from clinical interviews as well as from physical examination.
Headache diaries make it possible to record prospectively the charac-
teristics of every attack, and this may reduce the recall bias and
increase accuracy in the description.
The advent of the International Classification of Headache in 1988, with
its recent revision (2004), has greatly contributed to the definition of
precise criteria for the diagnosis of migraine and tension-type headache
across the world. Nonetheless, support is needed to facilitate the adop-
tion of these criteria, especially in the non-specialized clinical settings.
We have recently developed a basic version of a diagnostic headache
diary for migraine and tension-type headache. Our objective was to
devise a tool for assisting the diagnosis of these two types of headache
in headache centres, as well as in non-specialized practice. The diary
had to satisfy two important requisites: 1) simplicity, and 2) complete-
ness for ICHD-II based diagnosis.
A pilot study was performed in order to test the diary in the Headache
Centres of Pavia and Copenhagen. The data obtained were presented and
discussed in a Consensus meeting held in Valencia during the last
European Headache Federation Congress (April 2006). The findings
obtained showed that the use of the diary is suitable for naive (de novo)
patients and provides complete information for diagnosis in a very high
percentage of subjects. Comparison of the diagnoses based on history and
physical examination (gold standard) with those obtained from the diary
showed a satisfactory degree of concordance. Furthermore, the use of the
basic headache diary allowed a more detailed diagnostic definition.
A second version of the diary, aimed at a more precise detection of aura
symptoms, is under preparation and will be tested in several European
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countries in the near future. Hopefully, this process will lead to the
availability of a validated tool – common but at the same time country-
specific – for the proper and homogeneous diagnosis of migraine and
tension-type headache across Europe.
Future steps include: 1) the preparation of an electronic version with a
software-assisted diagnostic process; and 2) the elaboration of targeted
diaries (i.e., for menstrual related attacks, for cluster headache, for chil-
dren, etc.).
CLINICAL ASPECTS OF HEADACHES I
SYNCOPE IN MIGRAINE
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Introduction Migraine is an episodic, multifactorial neurovascular
disorder characterized by recurrent attacks of disabling headache and
autonomic nervous system (ANS) dysfunction. Syncope is a paroxys-
mal symptom consisting of a brief, self-limiting transient loss of con-
sciousness due to global cerebral hypoperfusion. Several reports sug-
gest that there is comorbidity between the two conditions.
Case report We describe the case of a 53-year-old woman suffering from
migraine without aura since the age of 20. The attacks were constantly
characterized by severe intensity and remarkable autonomic distur-
bances, in particular, nausea, vomiting and photophobia. In association
with the most disabling attacks, usually once a year, she suffered from
typical syncopes, which never occurred outside the migraine attacks. The
patient was otherwise healthy and did not need any pharmacologic treat-
ment, other than the symptomatic drugs for migraine. After age 40, the
syncopes occurred more frequently, on average 2–3 times a year, with the
intensity and frequency of migraine remaining unchanged. The patient
consequently underwent a cardiac electrophysiologic study that was nor-
mal. At the age of 51 she had an extremely severe migraine attack with
prominent autonomic disturbances; she developed multiple brief syn-
copes and was thus referred to the Emergency Department. Immediately
after her admission, she had a protracted loss of consciousness, and the
ECG-monitoring showed a complete sinus arrest lasting 20 seconds and
resolved by the precordial thump procedure. After sinus rhythm was
restored, further brief episodes of sinus arrest were documented. It was
therefore established, considering the previous history of frequent and
recurring syncopes, to implant a permanent pacemaker. The cardiologic
tests were normal, in particular, possible coronary heart disease was ruled
out by performing a treadmill test and a myocardial scintiscan. The tilt
table testing was positive for induced syncope. After her discharge, she
was regularly followed-up for 2 years and no further syncope recurred,
despite the persistency of severe migraine attacks.
Discussion A higher lifetime prevalence of syncope among
migraineurs was reported in some studies and an autonomic dysregu-
lation was suggested to be involved in the pathophysiologic mecha-
nisms of migraine. A dysfunctional or unstable ANS might render an
individual more susceptible to migraine by reacting to triggers at a
lower threshold.
Conclusions Migraineurs with disabling attacks seem to be more
prone to ANS dysfunction. To our knowledge, we report the first
patient suffering from strictly and exclusively migraine-associated syn-
copes who required the implant of a permanent pacemaker.
ALTERATIONS IN GLUCOSE-INSULIN METABOLISM IN
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Introduction Migraine is characterized by a complex biochemical
dysfunction attributed to a disorder of the trigeminal and hypothalam-
ic pathways. Impairment of glucose metabolism has been reported in
migraine, but data are scarce and inconsistent [1].
Objective The main aim was to verify if migraineurs present alter-
ations in glucose and insulin metabolism.
Patients and methods The study population included three groups of
subjects: 1. Migraineurs (M) consecutively seen at the headache centre
of our hospital; 2. Patients affected by headache other than migraine
(O), consecutively seen at our headache centre; 3. Healthy volunteers
(HV), recruited among colleagues, nurses and technicians from our
hospital. All the recruited people underwent a general blood test and a
standard oral glucose tolerance test after a 12-hour fasting period, mea-
suring levels of glucose and insulin.
Results In a 6-month period we recruited 84 migraineurs (73 women,
11 men), 25 patients with non-migraine headache (20 women, 5 men),
and 26 healthy controls (24 women, 2 men). Both headache groups
presented blood glucose levels (mg/dL) higher than the healthy control
group (fasting: M 96, O 98, HV 83, p=0.000; at 30 minutes: M 142, O
143, HV 114, p=0.001; at 60 minutes: M 122, O 117, HV 95, p=0.008;
at 120 minutes: M 102, O 93, HV 93, p=0.139). Compared to the other
groups, migraineurs presented significantly higher insulin levels at any
time of the test, both fasting and after glucose loading (fasting: M 10,
O 7, HV 6, p=0.001; at 30 minutes: M 86, O 47, HV 48, p=0.000; at
60 minutes: M 79, O 43, HV 35, p=0.000; at 120 minutes: M 51, O 28,
HV 29, p=0.001).
Conclusions High blood glucose levels can be recorded in headache
patients, but do not seem to be specific to migraineurs. High insulin
levels are recorded in migraineurs, and these data seem to be specific
to this group of patients [2]. These findings are in keeping with recent
reports on the effects of insulin on brain functions and lend support to
the possible involvement of insulin in the pathogenesis of migraine.
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CLINICAL PICTURE OF CLUSTER HEADACHE IS NOT
RELATED TO SEVERITY OF PATENT FORAMEN OVALE
N. Morelli, M. Maluccio, S. Gallerini, G. Orlandi, S. Gori, L. Murri
Department of Neurosciences, Institute of Neurology, University of
Pisa, Pisa, Italy; e-mail: n.morelli@inwind.it
Introduction Patent foramen ovale (PFO) recently has been implicat-
ed in several diseases such as cryptogenic stroke, Obstructive Sleep
Apnea Syndrome (OSAS) and migraine with aura. The nature of the
relationship between PFO and migraine has not been completely
understood. Although migraine and cluster headache (CH) are separate
entities, pathophysiology and treatment partially overlap between
them; also, in CH some studies have documented that the prevalence
of PFO is higher than in the general population [1]. No correlation has
been found between the clinical picture of migraine and severity of
PFO [2] and no data are available for CH.
Material and methods We studied 18 patients (15 males and 3
females) with episodic CH, according to ICHD-II criteria (2004), who
resulted positive for the presence of PFO to evaluate a correlation
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between the entity of PFO and clinical picture (duration, daytime recur-
rence of attacks and the age of onset of disease) of CH. PFO was
assessed with transcranial Doppler contrast (detection of right-to-left
shunt) and confirmed by transesophageal echocardiography. Clinical
parameters were evaluated by means of the clinical chart of the patients.
Results and discussion The patients with CH had a mean age of 36±6
years and male/female ratio of 15/3. Eleven patients showed low-grade
PFO, 2 medium-grade PFO and 5 high-grade PFO. The age of onset of
CH was 35±6 years, duration of attacks was 96±16 minutes and the
daily recurrence was 1.8±0.6. The correlation was analyzed with
matrix of correlation (R2). No relationship was found between clinical
parameters and PFO entity – at least as evaluated by means of
microbubble detection – suggesting that the extent of PFO does not
affect the clinical parameters of headache. From a speculative point of
view these data may support the hypothesis that a particular genetic
substrate may determine the persistence of PFO and the presence of
CH in absence of a clear pathogenic link.
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MYOFASCIAL TRIGGER POINTS IN MIGRAINE PATIENTS
E. Tafuri, L. Di Ianni, A. Savini, A. Fabrizio, G. Sidonio, R. Lerza, 
G. Affaitati, A. Mezzetti, M.A. Giamberardino
Headache Centre, “G. D’Annunzio” University of Chieti, Chieti, Italy;
e-mail: emmanueletafuri@hotmail.com
Introduction Previous studies have shown that migraine patients often
present myofascial trigger points (TrPs) in the cervical muscles whose
target areas coincide with the site of migraine pain and that TrP treat-
ment (repeated injections) over two months significantly improves
migraine symptoms during the same period.
Objective The aim of the present study was to evaluate, in this type
of patients, the long-term effects of TrP treatment, and in particular,
to assess if TrP extinction results in stable, beneficial effects on
migraine symptoms.
Methods Thirty-five patients (30 women, 5 men, aged 23–47 years),
affected with frontal and/or temporal migraine and TrPs in the stern-
ocleidomastoid, splenius cervicis or semispinalis cervicis muscles (tar-
gets located in the same sites as the migraine attacks) were examined.
All underwent measurement of electrical pain thresholds in skin, sub-
cutis and muscle at TrP and target level at baseline, and after 60, 120
and 180 days. TrP infiltration with local anesthetic was performed on
days 1, 3, 10, 30 and 60. Number and maximal intensity (VAS scale)
of migraine attacks were recorded for 60 days before and 180 days
after the start of treatment. All patients were free from any other pain
medication during the study.
Results At baseline, pain thresholds of all three tissues at TrP and tar-
get level were significantly lower than those recorded in 20 healthy
controls of comparable age, testifying to the state of hyperalgesia
(p<0.001). After 60 days of treatment:– all thresholds were significant-
ly increased in both TrP and target (ANOVA: p<0.002); number and
intensity of migraine attacks decreased significantly compared to pre-
treatment (p<0.001). The threshold increase correlated significantly
with the reduction of migraine pain (p<0.01). At 120 and 180 days, all
thresholds did not change significantly with respect to day 60. Number
and intensity of migraine attacks relative to the periods: days 60–120
and days 120–180 did not differ significantly from those of the period
days 0–60 of treatment.
Conclusions Extinction of myofascial TrPs, whose targets coincide with
the site of migraine pain, has beneficial effects on migraine symptoms,
which go far beyond the treatment period. This procedure is therefore
recommended as an integral part of migraine treatment in these cases.
STATIC AND DYNAMIC POSTURE OF HEAD AND NECK IN
MIGRAINE PATIENTS
M. De Marinis, A. Petrelli, L. Borrello, M. Mingoia, N. Accornero
Department of Neurological Sciences, University of Rome “La
Sapienza”, Rome, Italy; e-mail: m.de.marinis@mclink.it
Background Migraine attacks may be accompanied by tension
headache-like symptoms, such as neck and shoulder pain with muscle
contraction. Headache due to cervical dystonia has been recently
recognised by the new IHS classification of headache disorders.
Objective The aim of this study was to assess the head-neck static pos-
ture and the range of head-neck motion in migraine patients without
any disorders of the cervical spine or soft tissues of the neck.
Methods We studied the head-neck static posture and the range of
head-neck motion in 70 headache-free migraine patients and 70 con-
trols. Static posture was assessed with a photographic method.
Dynamic posture was assessed with a specific computerized device
that evaluated the following head-neck movements: right/left rotation,
flexion/extension and right/left sidebending (while the patients were in
the sitting position). The results were expressed as angles (in degrees).
Results Head-neck static posture was normal in migraine patients and
controls. In motion testing, head rotation was decreased on one side
and extension was less marked than flexion in migraine patients.
Statistically significant differences between right versus left-side head
rotation (p<0.001) and head flexion versus extension (p<0.01) were
found in migraine patients, but not in controls.
Conclusions The results of this study suggest that, although the head-
neck static posture was normal, head-neck motility may be abnormal in
migraine patients. Muscle tenderness and contraction, as a possible
consequence of pain, may be responsible for these abnormalities.
Alternatively, more complex central mechanisms, such as sensitisation,
may be evoked in the interpretation of our results.
HEADACHE IN THE EMERGENCY DEPARTMENT: CLINICAL
AND DIAGNOSTIC ASPECTS IN A ONE-YEAR RETROSPEC-
TIVE ANALYSIS
1P. Meineri, 1F. Mondino, 2L. Dutto, 1E. Grasso, 2U. Sturlese
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Introduction Headache is one of the most frequent complaints in the
population referring to an emergency department (ED): in previous
studies it accounted for 1%–4% of all presenting symptoms. In Italian
studies this percentage varied from 0.6% to 1.2%. Moreover,
headache represents one of the most frequent reasons for neurologi-
cal consultation (NC).
Methods By means of a computerized database, we retrospectively
examined all clinical records of patients presenting to our ED during
2005, complaining of headache as the only or prevalent symptom.
Results A total of 69 441 patients were admitted to the ED during 2005.
Among these, 1 009 (1.45%) complained of headache; 390 were males,
619 were females; mean age was 39.5 years (41.4 years for males, 37.6
years for females). In this period 2 437 NC were done in the ED (3.51% of
all consultations) and 40.8% of them were requested because of headache.
Two hundred and fifty-one (24.8%) headaches were diagnosed as pri-
mary headaches (PH) (belonging to the first 4 groups of the IHS clas-
sification) and 439 (43.5%) as secondary headaches (SH). Four hun-
dred and thirty-two (42.8%) patients were coded as “headache not oth-
erwise specified” (NOS) (code 784.0 of the International Classification
of Diseases system (ICD)). As regards to diagnosis, 1 037 consults
were requested; 418 (40.3%) were NC, followed by 50 (4.8%) neuro-
surgical, and 31 (3.0%) neuropaediatric visits. CT scan was performed
in 341 patients (82.6%) requested mostly by the ED physician.
Moreover, 5 perfusional SPECT (in migraine with aura), 3 lumbar
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punctures and 2 MRI were carried out. Four hundred and eighty-four
(47.9%) patients received post-discharge advice. Among these, 191
(39.4%) were referred to our headache centre, but only 48 (25.1%)
attended it.
Discussion Our epidemiologic data are similar to those from interna-
tional studies, but show a higher prevalence of headache, when com-
pared to other Italian studies. This is probably because we considered
all headaches, including traumatic and paediatric headaches.
The proportion between primary and secondary headaches (1/1.75) dif-
fers from that of other studies that show an equal prevalence for PH
and SH or a higher prevalence of PH. We have indeed many NOS
headaches, which could really be PH. In our opinion, PH are not easi-
ly diagnosed in an ED for many factors: 1) the IHS classification is too
rigid to be used in this context; 2) the ICD system, to which ED physi-
cians have to refer in the discharge form, is very limited and most
headaches do not have a corresponding code; 3) the ED environment
does not facilitate a differential diagnosis among headaches.
HANDEDNESS AND UNILATERAL HEADACHE IN MIGRAINE
1G.B. La Pegna, 2V. Saporito, 3C. Morreale, 4A. D’Agati
1Unità Operativa Complessa “Neurodegenerative Diseases”, A.S.L. 2,
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Introduction In april 2002, Lipscombe and Prior [1] published the
results of a research inherent to “a possible relationship between hand-
edness and unilateral headache in migraine”.
The aim of the study was: “It seems surprising that if pain is related to
vasodilation of the meningeal arteries that one side should be more
painful than the other. Why should it be that vessels on one side dilate
in preference to the other? One thought we had was the possibility that
this could be linked to handedness”.
The authors concluded that “The distribution of (patients) handedness
was in accord with the expected 10:1 right-to-left-handedness. The
identification of a unilateral location for two-thirds of the patients was
interesting, though the variability of sides for a third of this subgroup
(i.e., localized always to one side or the other but not predominantly
one side) was higher than expected [1].
One-third of migraine patients who localized their headache did so to
the left and one-third to the right. There was no correlation whatsoev-
er with handedness” [1].
Objective The aim of the present study was to verify, through a wider
patient sample size (502 v. 126, [1]), the relationship between handed-
ness and unilateral headache in migraine.
Methods We administered a questionnaire, similar to the one used by
Lipscombe and Prior, to migraine patients who presented to our Centre
during a 6-month period and compared the results with a group of non-
migraineurs, observed in the same period.
Results Of 2 395 neurologic non-migraine patients, 2 272 (94.86%)
were right-handed and 123 (5.14%) left-handed, mean age: 60.25
years; F 1515, M 880. Of 502 migraine patients, 91.24% (458) were
right-handed and 8.76%, (44) left-handed (more than expected), mean
age: 35.19 years; F 394, M 108.
We found bilateral pain in 18.73% (94/502) of migraine patients and
unilateral pain in 81.27% (408/502) (more than two-thirds of the
patients of Lipscombe and Prior’s study). Of these, 82.10% (376/458)
right-handed and 72.73% (32/44) left-handed patients reported unilat-
eral pain. Thus, the right-handed patients reported more often unilater-
al pain. Of all patients (502), 61.16% (307) identified recurrent
headache occurring on the same side (right side or left side), but in the
unilateral headache patient group (408) this recurrent headache occur-
ing on the same side was referred by 75.24% (59.90%: right; 20.34%:
left) and only 24.76% (101) referred pain changing sides.
Surprisingly, in the right-handed patients (74.76%) (209) with recur-
rent pain on the same side, it was referred to the right side, and only
25.36% (71) referred pain to the left side. In contrast, 55.56% (15/27)
of the left-handed patients identified headache on the right side, and
44.44% (12/27) referred headache to the left side.
Discussion It is possible that unilateral right-handed headache suf-
ferers might experience pain in their hand dominant hemisphere.
Lipscombe and Prior’s hypothesis of “a possible relationship
between handedness and unilateral headache in migraine” [1] is con-
firmed, at least in right-handed patients, because our right-handed
patients localized pain predominantly on one side; thus, a relation-
ship between right-handedness and the dominant unilateral side of
headache may be possible.
Why is the phenomenon predominant in right-handed patients and less
so in left-handed patients? This is not a contradiction because unilater-
al headache sufferers might experience pain in their hand dominant
hemisphere, while the left-handed patients, considering the possible
variability of cortical centres [2] (for instance, speech centre), could
report the pain in likewise varying manners.
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CLINICAL ASPECTS OF HEADACHES II
CHRONIC GASTRIC INFECTION BY HELICOBACTER
PYLORI AND GASTROINTESTINAL SYMPTOMS DURING
MIGRAINE ATTACKS
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Introduction In recent years Helicobacter pylori (H. pylori) infection
has been supposed to play a role even in many extra-gastrointestinal
illnesses [1], migraine among these [2].
Several mechanisms could link chronic H. pylori infection and vascu-
lar diseases including a low-grade acute phase response, free radical
formation and immune-mediated mechanisms. However, the precise
mechanism by which chronic H. pylori infection mediates these vas-
cular effects remains unclear. Previous studies on seropositivity for H.
pylori in migraine patients showed contradictory results.
Objective The purpose of this study was to investigate whether chron-
ic gastric infection by H. pylori is in some way linked to the presence
of gastrointestinal symptoms during migraine attacks.
Materials and methods A group of 104 patients (78 women and 26
men, age range 21–59 years, mean age±SD 39.70±12.41 years) attend-
ing the Headache Centre of the University of Turin, suffering from
migraine without aura according to the International Headache Society
criteria (ICHD-II), were studied.
H. pylori gastric infection was diagnosed by means of both the 13C-
urea breath test and the presence against H. pylori in serum. In accor-
dance with previous published research guidelines, only patients with
positive results for both tests were defined as infected by H. pylori.
The patients were divided into three groups, according to the pres-
ence of nausea (group A: 37 patients), both nausea and vomiting
(group B: 54 patients) or the absence of both (group C: 13 patients)
during the attacks.
Results In group A, 13 patients (35.1%) were positive and 24 (64.9%)
negative to the infection; in group B, 20 (37%) were positive and 34
(63%) were negative to the infection; finally, in group C, 2 (15.4%)
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were positive and 11 (84.6%) were negative to the infection (p=ns).
Discussion and conclusions On the basis of these data the presence of
chronic gastric H. pylori infection does not seem to be related to gas-
trointestinal features during attacks, even though patients with gas-
trointestinal symptoms have a higher percentage infection than those
without (36.3% vs 15.4%).
This observation could suggest the opportunity to ascertain the pres-
ence of infection particularly in this group of patients.
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HEADACHE PICTURES DURING THE COURSE OF CERE-
BRAL VENOUS THROMBOSIS
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Aim Description and classification of headache symptoms during the
course of Cerebral Venous Thrombosis (CVT) in the acute-subacute
phase (group A) and among headache patients with angiographic
abnormalities suggesting previous CVT (group B).
Methods Headache classified according to ICHD-II; neurological
deficits and outcome by National Institutes of Health Stroke Scale
(NIHSS) and modified Rankin Scale (mRS); seizures, intracranial
hypertension, subacute encephalopathy and other syndromes by stan-
dard descriptive criteria. Neuroimaging: MRI and/or CT intracranial
angiography and digital subtraction angiography (DSA). Clinical and
neuroimaging follow-up: mean 19 months.
Patients Consecutive cases of acute CVT: n=40 (group A), 32 F (80%),
mean age at onset 37.4 years; main risk factors: thrombophilic condi-
tions in 28 patients (70%), oral contraceptives in 19 subjects (47.5%),
overweight (BMI≥30) in 30%. Site of thrombosis: transverse sinuses
(70%), superior sagittal (60%) and others (cortical veins/jugular/oth-
ers) isolated or in combination (55%). Clinical pictures (acute-posta-
cute phases): headache as presenting symptom in 25/40 (62.5%), dur-
ing the entire course, 85%, isolated – as the only symptom – in 5/40
(12.5%); sensorimotor deficits 37.5%; seizures 30%; intracranial
hypertension with or without papilledema 17.5%; other neurological
syndromes 50%. Most frequent complications during follow-up:
epilepsy (42%) and headaches (33%); neuroimaging evidence of par-
tial or complete recanalization occurred in over 85% at different time
intervals from the acute event.
A smaller group of headache patients – n=17 (group B) with disabling
symptoms (either episodic or more or less continuous), poor response
to treatments, with neuroimaging signs suggesting a previous/remote
CVT: 12 F, 5 M, 39.2 years at observation and with concomitant neu-
rological focal abnormalities (clinical/EEG, CT/MR) in 36%.
Results Headache (any new/sudden-onset) is confirmed as being the
most frequent symptom during the acute phase of CVT (present in 85%
of cases) and also the most frequent and significant inaugural symp-
tom. Headaches attributed to CVT are more frequently characterized
by hyperacute disabling symptoms mimicking primary thunderclap
headache and headache during the course of CSF hypotension or sub-
arachnoid haemorrhage – as underscored by ICHD-II. Less frequently,
migraine-like attacks, cervicogenic headache and other headaches with
less specific characteristics may be observed.
Migraine-like headaches and clinical pictures fitting the criteria for
one of the complications of migraine are more often observed during
the long-term follow-up of CVT as well as among those headache
patients showing chronically recurring disabling symptoms coupled
with evidence of possible-probable previous/remote CVT. Also for
these cases, even in the absence of a close temporal relationship to
the thrombotic event, the inclusion in the 6.6 diagnostic subgroup
should be considered.
OSMOPHOBIA IN JUVENILE PATIENTS SUFFERING FROM
MIGRAINE AND TENSION-TYPE HEADACHE
1E. Corletto, 1P.A. Battistella, 1L. Dal Zotto, 1A. Resos, 1E. Tripoli, 
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Introduction The differential diagnosis between migraine (M) and
tension-type headaches (TTH) is based on ICHD-II criteria (2004)
including photophobia, phonophobia, nausea and vomiting as signifi-
cantly associated symptoms. Osmophobia (O), i.e., altered odor per-
ception, is reported in point D of the Appendix of this classification as
a possible accompanying symptom of migraine without aura (MO);
recently O has been found to be specific for the diagnosis of adult
migraine [1]. In a pilot study we found that O was frequent in juvenile
M, but it seems less specific than in adults [2].
Materials and methods Two hundred and seventy-five consecutive
patients, referred to our Centre in 2005, were affected by M or TTH,
according to ICHD-II criteria. Mean age was 11.4±3.0 (6–17 years),
158 females (57.5%) and 117 males (42.5%). One hundred and
sixty–seven (60.8%) suffered from M (144 (52.4%) MO and 23 (8.4%)
migraine with aura (MA)), and the remaining 108 (39.2%) from TTH
(88 (32%) frequent TTH and 20 (7.2%) chronic TTH).
Results The prevalence of O during attacks in the study population
was 18.5%, higher in M patients (25.1%) compared to those with
TTH (8.3%). In particular, O was found in 27.1% of MO, 13% of
MA, 8% of episodic TTH and 10% of chronic TTH. There was no
correlation between O and age or gender. O was usually described as
a very early onset symptom (mean age at the onset of O: 8.1± 3.3
years and of headache: 8.1±2.7 years). The offending odors were per-
fumes (63%), food-related smells (53%) and tobacco smoke (30%).
The olfactory stimulus triggered the attack in 37.3% of osmophobic
patients (26.2% with M).
In the differential diagnosis between MO and episodic TTH, O was a
poorly sensitive symptom (27.1%) but rather specific (91.7%), and
its specificity was greater than photophobia (61.4%) and phonopho-
bia (45.5%). Regarding the positive predictive value, O had a greater
value (82.3%) when compared to photophobia (74.1%) or phonopho-
bia (65.5%), occupying third place after nausea (95.3%) and vomit-
ing (100%).
Discussion In this sample of patients with juvenile primary headache,
during M attacks, O was present in a smaller proportion (25.1%) than
in adults reported in the literature (24.7–47.7%), and was observed less
frequently in TTH. However, O represents a more specific factor for
the diagnosis of migraine than photophobia and phonophobia.
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HEADACHE IN CHILDREN YOUNGER THAN 6 YEARS OF AGE
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Children’s Headache Centre, Paediatric Neurology Clinic, Anna
Meyer Paediatric Hospital, Florence, Italy; e-mail: c.scalas@meyer.it
Aim In order to study the clinical features of headache in pre-school-
age children, we retrospectively reviewed records regarding subjects
younger than 6 years observed in the Headache Centre of the Anna
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Meyer Paediatric Hospital of Florence.
Methods We included in the study children who were evaluated dur-
ing a period of five years (from 2001 to 2005), and were under 6 years
of age at first observation. All the patients underwent a clinical evalu-
ation/history and, if necessary, laboratory tests, radiological and other
instrumental investigations. The headaches were classified according
to the second edition of the International Classification of Headache
Disorders (ICHD-II, 2004).
Results Of a total of 2 935 patients examined in the study period, 115
children (3.9%) were younger than 6 years, with a male/female distri-
bution=68/47 (59.1% vs. 40.9%); mean age was 4.5 years, age range
from 1.10–5.11 years. One hundred subjects (87%) had a positive fam-
ily history for headache.
Thirty patients performed imaging tests: in 5 cases neuroimaging
abnormalities were identified and led to the diagnosis: Arnold Chiari
type 1 malformation in 1 case, sinusitis in 3 cases, and low CSF pres-
sure in ventriculoperitoneal shunt in 1 case.
According to ICHD-II, 2004, we found 96 children at first observa-
tion with primary headaches (83.5%): 11 cases with migraine with-
out aura (MO) (9.6%), 1 case with migraine with aura (MA)
(0.86%), 2 cases with cyclical vomiting (1.7%), 6 cases with benign
paroxysmal vertigo of childhood (5.2%), 69 cases with probable
migraine (60%), 3 cases with infrequent tension-type headache
(2.6%), 3 cases with probable tension-type headache (2.6%). Sixteen
subjects had secondary headache (13.9%) (particularly systemic
viral or bacterial infections and sinusitis); three children reported a
mixed pattern.
A follow-up evaluation was possible in 57/115 cases (49.6%), 34
males (59.6%) and 23 females (40.4%); mean age of 4.5 years.
Eighteen children (31.5%) were in “remission” and 39 patients
(68.5%) showed recurrent symptoms: 12 cases with MO (21%), 1
case with cyclical vomiting (1.8%), 1 case with MO and cyclical
vomiting (1.8%), 2 cases with benign paroxysmal vertigo of child-
hood (3.5%), 21 cases with probable migraine (36.8%), 2 cases with
infrequent tension-type headache (13.5%). At follow-up only prima-
ry headaches were present.
Conclusions Our study shows male gender prevalence in pre-school
age (male/female=1.44/1). Primary headaches were more frequent than
secondary and post-traumatic headache; chronic daily headache and
idiopathic stabbing headache were absent. Further follow-up studies
are necessary to improve knowledge, treatment and outcome of
headache in children younger than 6 years of age.
THUNDERCLAP HEADACHE CAUSED BY MINIMALLY
INVASIVE MEDICAL PROCEDURES: DESCRIPTION OF TWO
CASES
F. Devetag Chalaupka, G. Caneve, G. Zaiotti
Department of Neurology and Neurophysiology, S. Maria del Prato
Hospital, Feltre, Belluno, Italy; e-mail: fdeveta@libero.it
Thunderclap headache, defined by IHS classification as a severe head
pain of sudden onset, may raise the question of whether a subarachnoid
hemorrhage has occurred.
We report two very unusual cases of thunderclap headache complicat-
ing minimally invasive medical procedures.
In the first case, headache developed as the consequence of a pneumo-
cephalus caused by an inadvertent intrathecal puncture during oxygen-
ozone therapy for lumbar disk herniation.
The headache of the second case was due to intracranial hypotension,
caused by the persistence of the needle used for epidural anesthesia,
which then penetrated into the subarachnoid space.
TREATMENT OF NONTRAUMATIC HEADACHE IN THE
EMERGENCY DEPARTMENT
G. Relja, A. Granato, Z. Bisin, G. Nider, M. Zorzon, W. Zalukar, 
G. Pizzolato
Department of Clinical Medicine and Neurology, Headache Centre,
University of Trieste, Trieste, Italy; e-mail: antonio_granato@
hotmail.com
Introduction Nontraumatic headache (NTH) is a common complaint
in the Emergency Department (ED), accounting for 0.6%–4.5% of all
visits. Guidelines for therapy of headache in the ED setting are lacking.
Objective The aim of the study was to analyse the therapies employed
in patients presenting to the ED with a chief complaint of headache in
order to provide therapeutic guidelines to ED physicians and improve
the cost-to-benefit management of such patients.
Patients and methods A retrospective analysis of the records of all
patients presenting in a six-month period (January 1, 2004 to June 30,
2004) with nontraumatic headache (NTH) to the ED of the University
Hospital of Trieste was performed. Demographic and clinical informa-
tion, therapies administered, and time spent in the ED were obtained.
Data were analysed using the Statistical Package for the Social
Sciences (SPSS 12.0).
Results We screened 300 NTH patients (0.8% of all ED visits), 61% F
and 39% M with a mean age of 45 [SD 19] years. Diagnosis at discharge
was secondary headache (41.3%), primary headache (24.3%), and
headache “not otherwise specified” (NOS) (34.4%). One hundred and
seventy patients (56.6%) were treated with mono- (86 patients, 50.6%)
or poli-therapy (84 patients, 49.4%): 56.7% with NSAIDs, 13.4% with
benzodiazepines, 10.7% with antiemetics, 6.2% with antihypertensives,
1.5% with triptans, and 11.5% with other drugs. Forty out of 50 patients
with migraine received pharmacologic treatment, 90% with NSAIDs
and 10% with triptans. The mean time spent in the ED was 225 [SD
285] minutes, with no differences between primary, secondary and NOS
headaches (p=NS). The length of stay in the ED was similar in patients
with primary headache treated with mono- (119 [SD 121] minutes) or
poli-therapy (114 [SD 60] minutes) (p=NS). A significant difference in
the length of stay in the ED between migraineurs who were adminis-
tered triptans (112 minutes [SD 25]) and migraineurs treated with
NSAIDs (265 minutes [SD 282], p=0.02) was found.
Conclusions Most used drugs were NSAIDs, first of all ketorolac and
indomethacin. Patients with primary headache had the same outcome
in terms of time spent in the ED when treated with mono- or poli-ther-
apy. Only 10% of migraineurs received triptans, despite the recom-
mendation to use triptans as first-line drugs for moderate and severe
migraine attacks. The administration of triptans in patients with
migraine significantly reduced the length of stay in the ED. Patients in
whom triptans were used did not need other drugs. Therapeutic guide-
lines to ED physicians are needed to improve the cost-to-benefit man-
agement of such patients.
CHRONIC HEADACHES: NEW ACQUISITIONS
THE ROLE OF SENSITIZATION MECHANISMS IN CHRONIC
HEADACHES
G. Sandrini
University Centre for Adaptive Disorders and Headache, IRCCS “C.
Mondino” Institute of Neurology Foundation, University of Pavia,
Pavia, Italy; e-mail: gsandrin@unipv.it
The mechanism underlying the development of migraine attack as well
as why episodic migraine becomes chronic over time in some patients, is
still debated. It has been shown that sensitization of trigeminal peripher-
al nociceptors as well as the subsequent central sensitization of second
and third order neurons play a critical role in migraine attack and cephal-
ic and extracephalic cutaneous allodynia. In migraine it can be hypothe-
sized that central sensitization is strictly dependent on incoming impuls-
es from the meninges in the early phase of the attack, and later maintains
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itself in the absence of such sensory inputs. This view is supported by
evidence that early triptan treatment blocks the migraine attack and cuta-
neous allodynia in allodynic patients. It is reasonable that an activity-
independent central sensitization can develop in patients with frequent
attacks and long-lasting disease, leading to a chronic form of headache.
This hypothesis could explain the high extracephalic sensitivity to
electrical stimuli in chronic migraine with overuse of symptomatic
drugs, to thermal and mechanical stimuli, observed in patients with
migraine attacks and transformed migraine as well as the close associ-
ation between chronic migraine and other chronic painful syndromes
such as fibromyalgia, in which both a widespread central sensitization
and a defective functioning of the supraspinal antinociceptive system,
has been hypothesized.
Functional imaging studies in chronic headaches emphasized the
involvement of modulatory nociceptive and antinociceptive brainstem
and cortical structures. Such structures may contribute to the patholog-
ical changes in the physiological properties of trigeminal neurons and
could explain the subsequent sensitization of the nociceptive pathways
at several levels of the central nervous system during migraine attack.
In this view, both an activity-dependent (sensitization of peripheral
nociceptors) and an activity-independent (probably driven by a perma-
nent dysfunction of descending modulatory pathways) central sensiti-
zation, may account not only for the transformation of episodic to
chronic pain condition but also for a widespread abnormal nociceptive
processing along the cephalic and extracephalic pain pathways, induc-
ing a spreading process of central sensitization.
CURRENT VIEWS ON A NEW OPTION IN THE LONG-TERM
PREVENTION OF CHRONIC DAILY HEADACHE
G. Coloprisco, P.G. Santi, S. de Filippis, I. Farinelli, P. Martelletti
Department of Medical Sciences, Regional Referral Headache Centre,
2nd School of Medicine, Sant’Andrea Hospital, University of Rome “La
Sapienza”, Rome, Italy; e-mail: paolo.martelletti@uniroma1.it
The treatment of Chronic Daily Headache (CDH) is still inadequate.
Effective, well-tolerated prevention represents the last goal for a com-
plete rehabilitation of CDH patients. Medication-overuse headache
(MOH) often overlaps CDH, causing the re-prophylaxis phase schedule
after detoxification to be inadequate and providing only short-term
relief. We presently reviewed studies concerning the efficacy of
Botulinum Toxin Type A (BoNT-A) as preventative treatment for CDH.
The 2004 IHS classification of CDH includes all chronic headaches last-
ing more than 15 days per month, for a period longer than 90 days. The
clinical forms mentioned in this term are the following: Chronic
Tension-Type Headache (CTTH), Chronic Migraine (CM), Transformed
Migraine (TM), Hemicrania Continua (HC), and New Daily-Persistent
Headache (NDPH). This large group of chronic headaches needs to be
definitively recognized in the next revision of the IHS Classification.
The therapeutic armamentarium of CDH is based on old drugs, antide-
pressants (tricyclics) and NSAIDs. There is an evident paucity of evi-
dence-based medicine current treatments used in the prevention of CDH.
Both topiramate and BoNT-A seem to represent – in terms of efficacy –
the most convincing options in the operational therapeutic scenario of
CDH. Nevertheless, the presence of adverse events (AEs) should always
be considered in the therapeutic choice of these chronic disorders.
A retrospective analysis of both open and double-blind studies on the
efficacy of BoNT-A in CDH, with or without MOH, showed conflict-
ing results. Some authors explained these results with a selection of
CDH patients with and without MOH in the trials. BoNT-A prevention
mechanisms for CDH are not completely known, and are probably not
just based on acetylcholine inhibition of the neuromuscular junction.
BoNT-A may have a distinct antinociceptive mechanism or inhibit cal-
citonin gene-related peptide release, substance P and other neuropep-
tides at the trigeminal level, as suggested by studies in animal models.
Further larger studies are needed to confirm the efficacy of BoNT-A
and therefore to provide a new effective, safe and widely accepted ther-
apeutic option for CDH.
THE CHRONIC PATIENT AND DRUG ABUSE
MEDICATION-OVERUSE HEADACHE: FROM THEORY TO
PRACTICE
1G. Sances, 1N. Ghiotto, 1G. Sandrini, 1,2G. Nappi
1Headache Unit and University Centre for Adaptive Disorders and
Headache (UCADH), IRCCS “C. Mondino” Institute of Neurology
Foundation, Pavia, Italy; 2Department of Clinical Neurology and
ORL, University of Rome “La Sapienza”, Rome, Italy; e-mail:
grazia.sances@mondino.it
Medication-overuse headache (MOH) is a secondary headache coded
in section 8.2 of the revised International Classification of Headache
Disorders (ICHD-II) [1]; the diagnostic criteria for MOH defines the
substance overused (ergotamines, triptans, analgesics, opioids, combi-
nations), the duration of overuse (at least 3 months), and the days of
intake per month. According to ICHD-II, the diagnosis of MOH can be
assigned when, within two months of discontinuation of the overused
medication, the following conditions are met: reversion of headache
from a chronic to episodic pattern (<15 headache days/month) and dis-
continuation of overuse (<10–15 days/month).
MOH is a considerable health problem, reported by up to 10% of
European Specialty Headache Clinics. The clear pathogenesis of MOH
is unknown. Is the overuse a causative, aggravating or facilitating fac-
tor? Does the overuse depend on the drug type, the duration of expo-
sure, or the habits of the patient? There is general agreement that the
only treatment for MOH is withdrawal of the overused drug, but there
are no guidelines or consensus recommendations on the management
of this condition. There are some indications on withdrawal as outpa-
tients or in-patients but very few prospective studies have investigated
the course and outcome of MOH after withdrawal.
The main problem in the management of MOH is relapse into overuse
after withdrawal. The management of these patients must therefore
include, in addition to detoxification and drug therapies, an integrated
programme of care covering the needs of the patient and family mem-
bers, lifestyle indications, non-pharmacological therapy, interaction
between patients (support groups), and planning for discharge.
In our Headache Centre a course of care (CARE) has been developed
for the management of MOH patients [2]. In this prospective study
inpatient detoxification was followed by scheduled visits for two years
after discharge. Each subject underwent a baseline standard interview
and a Structured Clinical Interview for DSM-IV Axis I Disorders
(SCID-I). After discharge the subjects returned for five scheduled vis-
its (three in the first and two in the second year). We also conducted
telephone follow-ups between visits. The management of these patients
needs more than pharmacological treatment and must include non-
pharmacological modalities and patient education. CARE is a model
for the management of a chronic condition and it allows monitoring of
the course of MOH with regard to relapses and predictors of outcome.
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COMPARISON BETWEEN PATIENTS WITH TRANSFORMED
MIGRAINE AND MEDICATION OVERUSE AND PATIENTS
WITH EPISODIC MIGRAINE AND OCCASIONAL MEDICA-
TION USE
A. Ferrari, S. Leone, C.P.R. Coccia, D. Pinetti, A. Bertolini, 
E. Sternieri
Headache Centre, Division of Toxicology and Clinical Pharma-
cology, University Centre for Adaptive Disorders and Headache
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Frequent use of symptomatic medication is considered one of the
major factors able to transform an episodic headache into a chronic
one. Migraine sufferers are most at risk of slipping into this complica-
tion. Our aim was to compare sociodemographic data, family history,
physiological and medical history, health services utilized, drugs
taken/prescribed and outcome of two groups of subjects: 1) trans-
formed migraine patients with medication overuse, and 2) episodic
migraine patients with only occasional analgesic use.
Methods We studied: – 150 patients, suffering from transformed
migraine and probable medication-overuse headache (TM group), con-
secutively admitted during 2005 to the in-patient ward of the Headache
Centre of the University Hospital of Modena and Reggio Emilia, Italy,
to undergo withdrawal from their overused medications; – 100 patients
suffering from episodic migraine, only occasionally using analgesics
(EM group), consecutively referred to the outpatient wards of the
Headache Centre during November and December 2005.
Results TM patients began to suffer from migraine earlier than EM
patients. Drug and/or alcohol abuse was significantly higher among
first-degree relatives of TM (19%) than of EM (6%) patients. The most
frequent comorbid disorders were psychiatric (67%) and gastrointesti-
nal diseases (43%) in TM patients, and allergies (31%) in EM patients.
Seventy percent of TM patients and 42% of EM patients were taking
daily at least another drug, besides those for headache treatment. TM
patients were above all taking sedative-hypnotics (30%). Instead, EM
patients were above all taking antiulcer agents (15%). Most overused
medications in the TM group were triptans (43%); the EM group used
primarily just NSAIDs (56%). After withdrawal of the overused med-
ication, a prophylactic headache treatment was prescribed to each TM
patient, antidepressants being the most prescribed drugs (59%).
Prophylactic headache treatment was also prescribed to 86 of 100 EM
patients, flunarizine being the most prescribed drug (58%). At 3
months follow-up, prophylactic treatments reduced at least by 50% the
frequency of headache in around 75% of patients of both groups; how-
ever, headache remained significantly more frequent in TM than in EM
patients: only a minority (15%) of TM patients reverted to a headache
frequency comparable to that of EM patients.
Conclusions Most transformed migraine patients overusing medica-
tions had characteristics substantially different from those of episodic
migraine patients. Transformed migraine, even after withdrawal from
medication overuse, could not be completely reverted by current pro-
phylactic treatments; therefore, a large number of patients with trans-
formed migraine remain at risk of relapse.
MEDICATION-OVERUSE HEADACHE: CLINICAL ASPECTS
AND PATHOPHYSIOLOGICAL IMPLICATIONS
L.M. Cupini
Headache Centre and Cerebrovascular Diseases, Neurology Unit, S.
Eugenio Hospital, Rome, Italy; e-mail: lecupini@tin.it
Medication-overuse headache (MOH) is a health problem widely rec-
ognized in the last few decades. Epidemiological data suggest that at
least 1% of the general population have MOH. This pathological con-
dition is associated with considerable long-term morbidity and disabil-
ity. The substances associated with the overuse have dramatically
changed over the past years. All symptomatic drugs, such as triptans,
analgesics, ergots and opioids, along with the common combination
substances currently on the pharmacological market are capable of
inducing MOH. The delay between the beginning of symptomatic drug
overuse and daily headache is shortest for triptans, longer for ergot
alkaloids and longest for analgesics.
A linear relationship between analgesic use and headache frequency
has been found. The disorder affects either adolescents or adults of var-
ious ages. MOH has been frequently associated with psychiatry comor-
bidity, behaviours of substance dependence, low socioeconomic status,
metabolic and neuro-hormonal changes. The pathophysiology of MOH
remains unclear. Among the suggested pathophysiological mechanisms
underlying MOH are mechanisms of central sensitization as well as
compulsive reward-seeking behaviour [1]. Medication-overuse
headache has been recently found associated with reversible metabol-
ic changes in some pain processing structures and with persistent
orbitofrontal hypofunction even after withdrawal of analgesics [2].
Interestingly, this latter finding is known to occur in drug dependence
and suggests similar pathophysiological pathways between MOH and
some forms of drug addiction. Accordingly, preliminary results suggest
an involvement of the endocannabinoid system in MOH. Recognition
of MOH allows appropriate clinical intervention that includes drug
withdrawal. Concerning the management of MOH, a combination of
lifestyle modifications, behavioural therapy, and withdrawal of
overused medications combined with preventive treatment are recom-
mended. However, data from randomized clinical trials to guide the use
of preventive treatment in patients with MOH are lacking.
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ONE-YEAR OUTCOME OF PROBABLE CHRONIC MIGRAI-
NE+PROBABLE MEDICATION-OVERUSE HEADACHE AFTER
AN OUTPATIENT REGIMEN OF ABRUPT WITHDRAWAL OF
THE OVERUSED DRUG AND DETOXIFICATION REGIMEN:
ANALYSIS OF THE NEED FOR OVERUSED DRUGS
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Introduction Successful detoxification is necessary to ensure
improvement in the headache pattern when treating patients with
chronic headaches who overuse acute medications. No rigorous pre-
scribing guidelines are currently to facilitate the management of these
patients. Little research has been conducted to investigate why the dif-
ferent proposed regimens failed, in particular, the aspects related to the
need for analgesics/drugs overused by these patients [1].
Patients and methods A total of 120 patients, 82 females (68.3%) and
38 males (31.6%), mean age 48.6±10.4 years, affected by probable
chronic migraine (PCM) and probable medication-overuse (PMOH)
according to ICHD-II diagnostic criteria were admitted to the study.
Patients were treated in an outpatient regimen with abrupt discontinua-
tion of the medication-overused, intravenous hydration and ademetion-
ine, metoclopramide if necessary, and oral or intravenous administra-
tion of benzodiazepines for 7–10 days. Analgesics or triptans were used
under medical supervision only in cases of severe rebound headache.
Prophylactic medication was started immediately after admission.
The following outcomes at baseline and after one-year of follow-up
were considered: number of days with headache per month; intensity
of headache; duration of headache; headache scores (frequency x
intensity), type of drugs abused and daily drug intake (DDI); and Leeds
Dependence Questionnaire (LDQ) scores.
Results Before detoxification, 59% of patients overused more than
one type of medication. Overused substances included: acetamino-
phen, 29.1%; nonsteroidal anti-inflammatory medications including
aspirin, 65%; combination analgesics, 53%; triptans, 36.6%; and
ergot derivatives, 7.5%.
Of 120 patients enrolled, 68 (56.7%) were successfully detoxified
(group A), while 52 (43.3%) were not (group B). Comparison between
groups A and B after one-year of follow-up showed a decrease in the
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frequency of headache of 71.7% in group A and only 10.1% in group B
(p<0.001). Similarly, the duration of head pain was reduced by 61.2%
in group A and 15.6% in group B (p<0.0002). The headache score after
one year was 17.7 in group A and 52.0 in group B (p<0.0001).
A total of 51 (42.5%) successfully detoxified subjects in group A
returned to an episodic pattern of migraine, compared to 10 (8.3%) in
group B (p<0.003).
The mean LDQ total score was higher in group B (11.10±6.35) than in
group A (9.27±5.51) at baseline. Group B had the highest scores in item
9 (Z=-5.27, p<0.001) addressing the need for the continued administra-
tion of the drug to maintain well-being, and in item 3 (Z=-2.39, p<0.05),
exploring compulsion to start the use of the drug. A significant reduc-
tion of LDQ scores was found at the one-year follow-up in group A
(5.21±2.78) compared with group B (10.20±5.23) (p<0.001).
Discussion The results of the present study suggest that the abrupt
withdrawal and detoxification regimen leds 56.7% of patients to dis-
continue the overused drugs and the majority of them within one year
to return to a pattern of episodic migraine. The remaining patients did
not discontinue the abused drugs and retained a chronic pattern of
headache. They showed a behaviour of drug dependence similar to that
found in the drug-addicted group. Patients who positively responded to
the drug detoxification regimen had, in contrast, a drug dependence
behaviour, which seemed to originate essentially from the necessity for
the analgesic to cope with everyday life [2].
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ADVICE ALONE VERSUS STRUCTURED DETOXIFICATION
PROGRAMMES FOR MEDICATION-OVERUSE HEADACHE:
A 1-YEAR PROSPECTIVE, RANDOMIZED, OPEN-LABEL
TRIAL IN TRANSFORMED MIGRAINE PATIENTS WITH
LOW MEDICAL NEEDS
P. Rossi, J. Faroni
Headache Clinic, INI Grottaferrata, Grottaferrata, Rome, Italy; 
e-mail: paolo.rossi90@alice.it
The aim of this study was to compare the short- and long-term effec-
tiveness of intensive advice to withdraw overused medication with the
effectiveness of two structured, pharmacological detoxification strate-
gies in a cohort of patients diagnosed with probable medication-overuse
headache (MOH) plus migraine and presenting low medical needs. One
hundred and twenty patients participated in the study. Exclusion criteria
included: previous detoxification treatments, co-existent medical or
psychiatric illnesses, and overuse of agents containing opioids, benzo-
diazepines, and barbiturates. Group A received only intensive advice to
withdraw the overused medication. Group B underwent a standard out-
patient detoxification programme (advice+prednisone+preventive treat-
ment). Group C underwent a standard inpatient withdrawal programme
(as in group B+ fluid replacement and antiemetics). Withdrawal thera-
py was considered successful if, after two months, the patient had
reverted to an episodic pattern of headache and to an intake of sympto-
matic medication for fewer than 10 days/month. Relapse was defined as
frequent use of any acute medication on more than 10 days/month for
at least 3 months. After 2 months, we were able to detoxify 75.4% of the
whole cohort, 77.5% of the patients in Group A, 71.7% of the patients
in Group B, and 76.9% of those in Group C (p>0.05). At 1-year follow-
up, the relapse rate was 22.2 % (15.3% of those in Group A, 26.9% of
those in Group B, and 26.2% of those in Group C, p>0.05). In patients
with migraine plus MOH and low medical needs, short- and long-term
effective drug withdrawal may be obtained by just offering advice.
MEDICATION-OVERUSE HEADACHE: AN INTEGRATED
PHARMACOLOGICAL AND BRIEF ANALYTIC PSY-
CHOTHERAPEUTIC APPROACH
M. Altieri, R. Di Giambattista, L. Di Clemente, A. Mercurio, 
L. Tarsitani, G.L. Lenzi, M. Biondi, V. Di Piero
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Introduction Chronic migraine (CM) with medication-overuse
headache (MOH) is a very disabling condition, frequently associated
with psychiatric comorbidity. At present, clear guidelines for the with-
drawal of the overused drug and detoxification are lacking. In this
regard, a role for psychological support has been hypothesized.
Objective We studied the efficacy of an integrated pharmacological
and brief analytic psychotherapeutic approach in these patients.
Patients and methods We enrolled patients affected by probable CM
and MOH (ICHD-II). They underwent a standardized neurological and
psychiatric evaluation before and 6 months after medication withdrawal.
Patients were randomly assigned to pharmacological treatment alone
(group A), or associated with a brief analytic psychotherapy (group B).
We applied the technique of Gillieron (1989), based on the principles of
brief psychodynamic psychotherapy and mainly oriented toward assist-
ing the patients with clarification and understanding of their disorder [1].
Results Twenty-one consecutive patients (M/F: 1/20, mean age 46±10
years) with probable CM and MOH were included. Headache frequency
was 27.9±5.4 days/month, with a mean drug intake of 60.3±35.2 tablets
(25.5% triptans, 13.1% ergotamine, 2.2% codeine, 32.4% NSAIDs, and
26.9% combined analgesics). The mean age of first attack was 19.6±7.8
years and mean duration of MOH was 7.6±9.4 years. Eleven patients
were randomly assigned to group A and 10 to group B. About 70% of
patients presented with psychiatric comorbidity, in particular, anxiety
(42%) and depressive disturbances (32%). To date, 15 patients had com-
pleted the 6-month follow-up (A, 6; B, 9), showing a clinical improve-
ment (headache frequency 16.7±11.4; days/month, drug intake
12.9±11.0 tablets/month). With respect to baseline, patients treated with
the integrated approach showed a greater decrease of headache frequen-
cy (days/month: -48% vs. -32%) and drug intake (tablets/month: -87% vs
-68%, p<0.04) than those only treated pharmacologically. In particular,
they showed a lower relapse rate (10% vs. 36,4%).
Conclusions The integrated approach improved treatment efficacy in
MOH patients, particularly decreasing drug overuse. This practical
form of brief psychological support is effective and may help the
patients in a shorter time and at a lower cost than long-term psy-
chotherapeutic treatments.
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ALEXITHYMIC FEATURES AND PERCEIVED STRESS IN
CHRONIC TENSION-TYPE HEADACHE AND MEDICATION-
OVERUSE HEADACHE PATIENTS
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Introduction The definition of a personality profile in headache
patients is no longer considered an attainable goal for empiric research,
which has focused on specific psychological variables including cop-
ing mechanisms, emotional distress and alexithymia, conceived as dif-
ficulty in identifying and communicating emotions. Recent studies
have found alexithymic features connected with anxiety and depres-
sion in headache patients [1, 2].
Objective The study intended to investigate the relationships between
alexithymia and perceived stress in primary headaches, exploring pos-
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sible differences between clinical subgroups of chronic tension-type
headache (CTTH) and medication-overuse headache (MOH) patients.
Methods A sample of 104 outpatients (25 males, 79 females, mean age
46.1 years, age range 16–69 years), in treatment at the Headache
Centre of the 2nd School of Medicine and Surgery, University of Rome
“La Sapienza”, composed of 70 patients with CTTH and 34 with MOH
(primary headaches: 14 CTTH, 9 MO, 2 MA, 5 MO and CTTH, 3 MO
and FTTH, 1 MO and ITTH), were administered:
a) the Toronto Alexithymia Scale (TAS-20), a paper and pencil ques-
tionnaire measuring 3 dimensions of the alexithymia construct:
(F1) difficulties in identifying feelings; (F2) difficulties describing
feelings; (F3) externally oriented thinking;
b) the Rapid Stress Assessment (RSA, by Tarsitani and Biondi, 1999),
a perceived stress scale providing five clinical scores; Anxiety,
Depression, Somatization, Anger, Lack of social support and a
Total score.
Results and discussion According to the TAS-20 16.3% of the sample
was classified as alexithymic, 20.2% as intermediate and 63.5% as
non-alexithymic. RSA profile did not exceed the cut-off level for
abnormal scores; Anxiety and Lack of social support showed higher
values. Alexithymics scored higher than non-alexithymic and interme-
diate patients (One way-ANOVA) on all RSA scales (Lack of support:
F=8.2, p<0.001; Total: F=7.8, p<0.001; Anxiety: F=5.1, p<0.01;
Anger: F=4.2, p<0.05; Depression: F=3.8, p<0.05; Somatization:
F=2.4, p=.08). Significant positive correlations (Pearson) were found
among RSA scales, F1 and total TAS-20 scores, in both CTTH and
MOH groups (p<0.01). No significant differences (unpaired t-test)
were observed between CTTH and MOH groups on TAS-20 and RSA;
however, MOH patients were more frequently classified as alexithymic
(23.5% vs. 12.9%) and reported higher values on Anger scale (p=.09).
MOH patients with primary diagnozsis of CTTH (n=14) were more
frequently alexithymic (35% vs. 15%) and obtained higher values for
Somatization (p=.09) than MOH patients with migraine.
Conclusions Findings supported the association between alexithymia
and perceived stress as an index of psychological maladjustment.
CTTH and MOH patients showed some distinctive features that require
further research.
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PSYCHOPATHOLOGICAL FACTORS IN HEADACHES
SLEEP, SLEEPINESS AND FATIGUE IN MIGRAINE
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Introduction Several lines of evidence support the association between
migraine on the one hand and sleep and sleep disorders on the other.
Even though several pathogenic hypotheses have been postulated, the
exact nature of this relationship remains enigmatic. Recently, interictal
daily activities and functions were also examined in migraine sufferers.
Low levels of realizable activity and of vigour were, indeed, document-
ed, which could be conceptualised as the consequence of a migraine
specific CNS functioning or alternatively as an acquired habit to antic-
ipate and/or avoid a migraine attack. Moreover, limited data have sug-
gested that daytime vigilance levels are impaired and that the complaint
of chronic fatigue is greater in chronic migraine than in controls. The
aim of this study was to verify sleep quality and daytime functioning
parameters, such as sleepiness and fatigue, in episodic migraine.
Materials and methods One hundred patients diagnosed with
migraine without aura, according to the second edition of the
International Classification of Headaches (2004), were enrolled.
Pittsburgh sleep quality index and Epworth Sleepiness Scale (ESS)
were applied to all patients to evaluate sleep quality and “habitual”
daytime sleepiness. In sixty patients, the Stanford Sleepiness Scale
(SSS) was also administered in the prodromal phase (-24, -12 and -2
hours before attack onset) and during migraine attack, at onset and 1,
2, 4, 12 and 24 hours later to evaluate “critical” sleepiness. Patients
were instructed to treat migraine attack with triptans in the early phase.
Results A total of 62% of migraineurs reported poor sleep quality and
complained of chronic fatigue, while only 12% showed intercritical
excessive daytime sleepiness according to ESS.
Evaluation of the time course of sleepiness by means of SSS confirmed
significant impairment of vigilance levels in the prodromal phase,
respectively, at –12 and –2 hours from the beginning of the episode.
Significant differences in SSS scores were also documented at attack
onset and 1 and 2 hours later compared with interictal values.
At four hours, mean SSS scores did not differ from their interictal val-
ues in the whole group and in patient responders to the treatment (pain
free at 2 hours from drug intake), whereas non responders were sleepi-
er than in intercritical conditions.
Discussion These data confirm the occurrence of sleepiness in the pro-
dromal phase, possibly related to hypothalamic involvement and orex-
in neurotransmission impairment. The evidence that drowsiness, evi-
dent at the start of the attack, is resolved after migraine specific treat-
ment, when efficacious, suggests that critical sleepiness might also be
related to pathogenic mechanisms of migraine, whereas the role of trip-
tans might be absent or minimal.
SLEEP AND HEADACHE DISORDERS: THE INTERNATION-
AL CLASSIFICATION OF SLEEP DISORDERS, 2ND EDITION
(ICSD-2) VERSUS THE INTERNATIONAL CLASSIFICATION
OF HEADACHE DISORDERS, 2ND EDITION (ICHD-II)
M. Savarese, S. Ottaviano, A. Superti, M. Carnicelli, P. Lamberti, 
P. Livrea
Headache Disorders Centre, Neurologic Clinic “FM Puca”,
Department of Neurological and Psychiatric Sciences, University of
Bari, Bari, Italy; e-mail: m.savarese@neurol.uniba.it
In clinical practice and in the literature the co-occurrence of sleep disor-
ders and headache is well known. Conversely, the intimate mechanisms
of this association are not quite known. Surely, in the so-called sleep-
related headaches, a causal and/or temporal relationship is admitted and
both the International Classification of Headache Disorders, 2nd Edition
(ICHD-II) [1] and the International Classification of Sleep Disorders,
2nd Edition (ICSD-2) [2] provide diagnostic criteria for these cases.
The ICHD-II includes two provisions for sleep-related headaches.
Sleep apnea headache is a subclassification of headaches attributed to
hypoxia and/or hypercapnia under the major code heading 10; it had
the same code 10.1.3 in the previous classification but the diagnostic
criteria are well defined only in this edition. According to the com-
ment, it is unclear whether the mechanism of the headache is related to
hypoxia, hypercapnia, or the disturbance in sleep. Hypnic headache is
a new entry in the classification of headaches and is coded 4.5 within
“Other primary headaches”: it is characterized by attacks of dull pain
that may be unilateral or bilateral and always occurs after falling asleep
with no autonomic symptoms. No pathophysiological mechanisms are
purposed.
In the first edition of ICSD, sleep-related headaches were included in
the secondary sleep disorders, within those due to neurologic disorders.
In ICSD-2, the secondary sleep disorders are not included: “following
ICD rules, as soon as the underlying disorder is diagnosed, it becomes
the primary diagnosis, and the previous sleep-related diagnosis is usu-
ally dropped because it is seen as a symptom of the underlying disor-
der”. Thus, the sleep-related disorders are listed in Appendix A within
the sleep disorders associated with conditions classifiable elsewhere.
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The group includes “a heterogeneous group of different headache enti-
ties with the common feature of occurrence during sleep” (during REM
sleep or 3–4 non-REM sleep) or upon awakening.
A singular sleep disorder, listed under “Other Parasomnias”, is the
Exploding Head Syndrome, which consists of the perception of a sud-
den sense of explosion in the head either at the wake-sleep transition
or upon waking during the night followed by sudden arousal with a
sense of fright. Although this experience is typically painless, the pos-
sible simultaneous occurrence of a stabbing pain raises the problem of
a differential diagnosis from sudden-onset headache syndromes.
Knowledge of the diagnostic criteria of sleep-related headaches allows
the headache specialist to better recognize the co-occurrence of the two
disorders, resulting in a clear advantage for the management of the
patient.
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PSYCHIATRIC DISORDERS IN MOTHERS OF HEADACHE
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Introduction Headache and epilepsy are disabling conditions affecting
the life of the patients and their families.
Studies showed a high rate of anxiety and mood disorders in both con-
ditions, but we do not know the direction of influence and the aetio-
logical mechanisms. We know that both disorders may run in families,
as psychiatric disorders do.
The main aim of this study was to examine the psychiatric situations of
the mothers of headache or epileptic patients, compared to the mothers
of healthy children.
Material and methods Sixty-five (37%) (mean age 39.05 years)
mothers of headache sufferers, 50 (29%) of epileptic children (mean
age 38.8 years) and 60 (34%) mothers of healthy children (mean age
40.07 years) were interviewed using the MINI to make diagnoses
according to DSM-IV criteria. The ICHD-II (2004) was used to make
the headache diagnoses and the classification of the International
League against Epilepsy (1989) to classify seizures. All statistical
analyses were carried out using the χ2 test.
Results Comparing data with the healthy sample, both headache and
epileptic samples showed higher numbers of psychiatric disorders than
controls (p<0.05). Among the 65 mothers of headache patients, 25
(38.4%) had at least one anxiety and/or mood disorder, of the 50 moth-
ers of epileptic children, 28 (56%) had at least one anxiety and/or mood
disorder (p=n.s.).
In the group of 65 mothers of children with headache, a subgroup
exists from the 38.4% of mothers who showed at least one anxiety or
mood disorder with 9 (13.85%) showing mood comorbid with an anx-
iety disorder.
In this sample of 25 mothers with a psychiatric disorder, we found that
mothers with an anxiety disorder have a higher percentage of migrain-
ous vs non migrainous children (24% vs 16%); mothers with mood dis-
orders have children who suffer from tension-type headaches, mainly
the episodic type (12%); mothers with an anxiety disorder comorbid
with a mood disorder have the same number of children with migraine
without aura (3) and chronic tension-type headache (3).
Discussion and conclusions Very few studies have investigated the
psychiatric situation of the mothers of children with epilepsy or
headache, while there are many concerning the psychological profile of
children or adolescents with these disorders. Mothers of epileptic chil-
dren showed a greater number of psychological disorders compared to
mothers of headache sufferers, even without a statistical difference.
The meaning of the high prevalence of psychiatric disorders needs fur-
ther study to understand the direction of influence, the etiological
mechanisms and the diagnostic implications.
EFFICACY OF A WORKPLACE COGNITIVE AND PHYSICAL
PROGRAMME ON HEADACHE, NECK AND SHOULDER
PAIN: A LONGITUDINAL COMMUNITY-CONTROLLED
STUDY
1F. Mongini, 1E. Rota, 2G. Ciccone, 2C. Galassi, 1L. Ferrero, 1A. Ugolini
1Headache-Facial Pain Section, Department of Clinical
Pathophysiology, University of Turin, Turin, Italy; 2Unit of Cancer
Epidemiology, San Giovanni Battista Hospital, Turin, Italy; e-mail:
franco.mongini@unito.it
Objective Our purpose was to examine the effects of a cognitive and
exercise instruction programme on frequency of headache, neck and
shoulder pain in a working community.
Materials and methods Three hundred and forty-three employees of the
city of Turin, whose working activities involved public contact (registry
and tax office), were distributed into two groups: study group (n=169) and
controls (n=175). In all subjects data were collected on headache, and
facial, neck and shoulder pain, if present. They were then given a diary in
which to record, on a daily basis, frequency, severity and duration of the
headache and facial, neck and shoulder pain episodes from March to
October 2005. At month 3, an instruction programme was administered to
the study group: it consisted of brief shoulder and neck exercises to be per-
formed several times a day, a relaxation exercise and instructions on how
to reduce hyperfunction of the craniofacial and cervical muscles during the
day. Both groups kept the diary for a further six months (months 3–8). For
each subject, the difference in symptom frequency between each month
and months 1–2 (baseline) was calculated, and the mean differences
between the two groups compared with parametric and nonparametric
tests.
Results The monthly frequency of headache significantly decreased
over time in the study group compared to controls; the same pattern was
observed for the frequency of facial pain, neck and shoulder pain
(p<0.001 at month 8). Moreover, the monthly frequency of drug intake
significantly decreased in the study group (p< 0.05 at month 8). The data
were confirmed in a multiple regression analysis adjusted for gender and
age. The relative benefit at month 8 was: 35% for headache frequency,
38% for frequency of neck and shoulder pain and 35% for drug usage.
Discussion To the best of our knowledge, this is the first, longitudinal
controlled study of this kind, carried out on a relatively extensive
working community. The results demonstrate that the administration of
a simple instruction programme can significantly decrease the preva-
lence of headache, facial and cervical pain in large population samples.
Conclusions The intervention programme employed in this trial is a
powerful and economical instrument to reduce head and cervical pain,
along with drug intake, in an extensive working community.
ANXIETY, DEPRESSION AND HEADACHE: CLINICAL AND
THERAPEUTIC ADVANCES
M.P. Prudenzano, L. Merico, L. Patruno, C. Melgiovanni, 
M. Acquaviva, C. Monetti, S. Genco, P. Lamberti, P. Livrea
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Introduction Several studies on the general population and in the clin-
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ical setting have confirmed the clinical impression that depressive and
anxious symptoms or disorders are common in headache patients [1,
2]. Breslau et al. showed that over a 2-year period, having baseline
depression increased the risk of incident migraine but not the risk of
other severe headaches; in addition, the risk of incident depression was
higher in those with baseline migraine [1]. Merikangas et al. [2] sug-
gested that anxiety might precede headache onset and that headache in
turn might be followed by depression.
Objective The aim of this study was to verify the possibility of a pref-
erential order of onset of psychiatric disorders in relation to headache.
Moreover, several therapeutic options among antidepressant and
antiepileptic drugs were compared.
Patients and methods A broad sample of primary headache sufferers
consecutively referring to the Headache Disorders Centre of Bari and
receiving a diagnosis of primary headache according to diagnostic cri-
teria of the International Classification of Headache Disorders (ICHD-
II) were included. Detailed personal and familial medical histories
were collected. Patients’ psychopathological profiles were evaluated
by means of SCL-90R. Data concerning the natural history of
headache, possible psychopathologic features and therapies were col-
lected at baseline and after a three-month treatment period with anti-
depressant or antiepileptic drugs.
Results No differences were found either in headache onset, age, or
attack frequency between headache patients with and without depres-
sion symptoms. In the same way, anxious patients did not show any
differences between headache onset, age, and frequency when com-
pared with non anxious patients. In about 75% of cases with psychi-
atric comorbidity, headache onset preceded the occurrence of psycho-
logical symptoms. In less than 10%, headache, anxiety and depression
onset were concurrent. In the remaining cases the psychopathological
symptoms occurred before headache. Both antidepressants and
antiepileptic drugs showed good efficacy and tolerability in the thera-
py of chronic headache patients with and without anxiety and depres-
sion irrespectively of symptomatic drug overuse.
Discussion and conclusions The results of this study confirm the high
prevalence of psychopathology in chronic headache even though the
mechanisms underlying these associations remain poorly understood.
Among the possible therapeutic options, antidepressants remain the
gold standard in the treatment of headache associated with psychiatric
symptoms or disorders. The question of comorbidity between headache
and substance-related disorders remains a priority for future research.
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STRATEGIES IN TRIPTAN USE
TRIPTANOGENOMICS
L.A. Pini, S. Guerzoni, V. Ruggieri
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Modena, Italy; e-mail: pinila@unimore.it
Completion of the human genome sequence has opened up new
prospects as far as pharmacological research is concerned. There is great
variability in the way patients affected by the same disorder respond to
medications. This variability results in total or partial inefficacy of the
therapy and side effects. Pharmacogenetics deals with the discovery of
genes involved in drug metabolism, whereas pharmacogenomics studies
the relationship between DNA and administered active principles. Both
disciplines help discover which drug, among the different ones used for
treating a disease, will be the most effective for a certain individual.
It is well known that migraine has a strong genetic component,
although the type and number of genes involved remains unclear.
In view of the treatment options available in migraine, the studies most
relevant here seem to be those analysing the role of genetic variations
in genes involved in the metabolism of dopamine and serotonin (5-
HT), catecholamines both thought to underlie at least part of the mech-
anisms of migraine.
There is evidence to suggest that serotonin-related genes may be
involved in the pathogenesis of migraine. To investigate whether the 5-
HT1A receptor gene contributes to the risk of migraine, Yang et al. per-
formed an association study of C-1019G promoter polymorphism of
the gene in 102 migraineurs and 93 controls [1]. Two functional poly-
morphisms of the serotonin transporter gene (5-HTTLPR and STin2)
were analyzed to assess whether these variants are associated with
migraine. No significant differences in allele (p=0.82) or genotype fre-
quencies (p=0.71) were seen in migraineurs compared with controls.
These results suggest that C-1019G in 5-HT1A is not a major genetic
risk factor for migraine [1]. Similar results were found studying the
Val158Met variant of the COMT gene. In contrast, two functional
polymorphisms of the serotonin transporter gene (5-HTTLPR and
STin2) were studied, and results confirm the association between the
STin2 polymorphism of the 5-HTT gene and migraine with aura using
paediatric probands.
Triptans are commonly used anti-migraine drugs and show agonist
action mainly at serotonin 5-HT1B/1D/1F receptors. It is not known
whether frequent or long-term treatment with these drugs would alter
5-HT receptor function. The effects of protracted (14–18 days) suma-
triptan and zolmitriptan treatment in rats on 5-HT(1) receptor mRNA
expression and function in tissues could be related to migraine treat-
ment results. RT-PCR analysis revealed that 5-HT1B/1D/1F receptor
mRNA was reduced in the trigeminal ganglion after treatment with
either triptan (reduction by: sumatriptan 39% and zolmitriptan 61% for
5-HT1B; 60% vs. 41% for 5-HT1D; 32% vs. 68% for 5-HT1F). Chronic
triptan treatment had no effect in two functional assays [sumatriptan
mediated inhibition (50 mg/kg, i.p.) of electrically induced plasma pro-
tein extravasation in dura mater and 5-nonyloxytryptamine-stimulated
[(35)S]guanosine-5’-O-(3-thio)triphosphate binding in substantia
nigra]. Furthermore, vasoconstriction to 5-HT in isolated basilar artery
was not affected by chronic triptan treatment, while it was slightly
reduced in coronary artery. The authors concluded that, although their
treatment protocol altered mRNA receptor expression in several tissues
relevant to migraine pathophysiology, it did not attenuate 5-HT(1)
receptor-dependent functions in rats.
Other genes have been studied to outline differences, if any, between
migraneurs and “controls”.
It seems that genomic profiles for human peripheral blood T cells, B
cells, natural killer cells, monocytes, and polymorphonuclear cells can
be involved, because a number of the major genes previously reported
to be regulated in ischemic stroke, migraine, and Tourette syndrome
were shown to be associated with distinct cell populations in blood.
Another field explored in migraine pathogenesis was the increased
expression of platelet genes in patients with migraine and chronic
migraine (CM), which suggests similar underlying pathophysiology.
The differences seen between migraine and CM in other genes suggest
an overlapping but not identical pathophysiology.
Recently, the response properties of dural nociceptors in relation to
headache have been reviewed by Strassman and Levy [2]. In exploring
the aspects linked to the presence/absence of allodynia, lack of
response to sumatriptan and other clinical features, the Authors con-
cluded that studies of meningeal sensory neurons have not found evi-
dence of unique properties or qualitative differences that distinguish
them from nociceptive neurons in other tissues.
In addition to the properties of chemosensitivity and sensitization,
dural afferents also exhibit resistance to tetrodotoxin, indicating that
they possess a class of voltage-gated sodium channels that are charac-
teristic of nociceptors in other tissues and that are not found in any
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other type of neurons in the peripheral or central nervous systems.
Meningeal sensory neurons also express the same constellation of neu-
ropeptides that are found in other sensory innervations. Although 5-
HT1D receptors are not unique to meningeal sensory innervation, stud-
ies have not yet investigated the possibility of quantitative differences
in the level (density) of expression.
These results suggest that pharmacogenomics, by studying the prima-
ry differences in number and/or affinity of 5-HT receptors, could play
a significant role in the development of new targeting drugs.
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Background Although triptans are the first-choice drugs for the treat-
ment of migraine attack, a percentage of patients ranging from 25% to
35% had a poor, lacking or inconsistent response to triptan treatment.
Few studies have focused on the clinical characteristics of attacks in
responders and non-responders to triptans. Recent research has sug-
gested that the occurrence of unilateral cranial autonomic symptoms in
migraineurs may predict a better response to triptans [1]. This clinical
observation suggests the potential large-scale recruitment of the
trigeminovascular system and/or peripheral neurovascular 5-HT1B/1D
receptors, the target of the acute antimigraine drugs, in such patients.
No studies have been carried out until now on the clinical and bio-
chemical phenotype of migraine patients responders and non-respon-
ders to triptans.
Objective We tried therefore to verify markers of trigeminal and
parasympathetic systems activation in responders and non-responders
to one new generation triptan after administration of the drug during a
migraine attack.
Patients and methods Ten migraine without aura patients responders
to rizatriptan and 10 migraine without aura patients non-responders to
the same triptan were studied. Patients were admitted to our Clinic to
be assessed when they presented a migraine attack. Its characteristics
as well as the presence of unilateral autonomic signs were recorded at
baseline, before rizatriptan administration, and at 1, 2, 4, 6, and 12
hours after rizatriptan administration. Serial external jugular venous
blood samples were also collected at the same times. Calcitonin gene-
related peptide (CGRP), neurokinin A (NKA), and vasoactive intesti-
nal peptide (VIP) were determined by RIA methods.
Results In all patients, responders to rizatriptan, the attacks were uni-
lateral, severe, and pulsating, and in 5 of them at least one sign sug-
gestive of activation of the parasympathetic system was recorded. Five
non-responders to rizatriptan had a bilateral location and a non pulsat-
ing quality of pain, even though it was of severe intensity in the major-
ity of them. Levels of CGRP and NKA measured in the external jugu-
lar venous blood before rizatriptan administration were significantly
higher in responders than in non-responders (p<0.0001 and p< 0.002,
respectively). In the 5 patients with autonomic signs among rizatriptan
responders, detectable levels of VIP were found at baseline in jugular
venous blood. One hour after rizatriptan administration, a drop in
CGRP and NKA was evident in the internal jugular venous blood of
rizatriptan responders, and this corresponded to a significant pain relief
or alleviation of accompanying symptoms. VIP levels were also signif-
icantly reduced one hour after administration in the 5 patients with
autonomic signs. After rizatriptan administration, CGRP and NKA lev-
els in non-responder patients showed less significant variations at all
time points compared with rizatriptan responders.
Conclusions The present study, although carried out in a limited num-
ber of patients, supports recent clinical evidence of increased trigemi-
nal activation associated with better response to rizatriptan in migraine
patients. This was accompanied by parasympathetic activation in a
subgroup of patients.
In contrast, the poor response to rizatriptan seems to be correlated with
a lesser degree of trigeminal and parasympathetic activation, which is
confirmed by reduced levels of markers of the trigeminal system and
undetectable levels of VIP in the external jugular venous blood [2].
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ALLODYNIA AND EARLY TREATMENT OF MIGRAINE
ATTACKS WITH TRIPTANS
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Migraine is a neurovascular disorder that involves meningeal blood
vessels as well as trigeminal C fibres that provide innervation to the
vasculature. Sensory nerves originating from the trigeminal and upper
cervical ganglia follow meningeal blood vessels but not nonvascular
areas of the dura. C fibres and A-delta fibres originating from the
trigeminal ganglion and C2-C3 dorsal root ganglia contain vasoactive
peptides that are responsible for vasodilatation and plasma protein
extravasation [1]. This complex response has been studied in animal
models and challenged with drugs that provide relief to migraine and
cluster headache attacks. The observation that prolonged or chronic
pain is associated with long-lasting activation and sensitization of
peripheral nociceptors and/or central nociceptive neurons in the dorsal
horn has led to an animal model for long-lasting headache, consisting
in prolonged activation and subsequent sensitization of the trigemino-
vascular system by substances that activate and sensitize somatic vis-
ceral nociceptors. Those substances, including serotonin, bradykinin,
prostaglandins and histamine, are also capable of inducing pain in
humans, and also headache. Meningeal nociceptors are activated and
sensitized over a long period of time and become responsible for throb-
bing pain and its aggravation during physical activities. Cutaneous
allodynia develops in the early phase of a migraine attack, and its
recognition has become important to achieve benefit when treating an
attack. Central sensitization is strictly dependent upon impulses from
the meninges during the early phase of a migraine attack. However, it
is also maintained later in the absence of meningeal sensory input. The
antimigraine drugs, the triptans, are effective in blocking neuronal
hyper-responsiveness in animal models. In humans, early treatment
(within one hour after the onset of a migraine attack) inhibits the devel-
opment of cutaneous allodynia [2]. Patients who do not develop cuta-
neous allodynia benefit from triptan administration at any time during
the attack. This is possibly due to an action of those molecules on the
dorsal horn, i.e., they block transmission of nociceptive signals
between first- and second-order trigeminovascular neurons. Triptans
are not effective in blocking second-order neuron, i.e., established allo-
dynia. Inhibition of cyclooxygenase (COX) production may help to
treat a migraine attack with allodynia. The best treatment option would
therefore be a combination of a triptan + COX inhibitor to act at the
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PRE-HYPERTENSION IN MIGRAINE PATIENTS REDUCES
THE EFFICACY OF ORAL TRIPTANS: AN OPEN CLINICAL
STUDY
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Introduction Meta-analysis on the efficacy of oral triptans has demon-
strated that only 18%–27% of migraineurs have obtained the goal of
sustained pain-free state. In the patients observed at our Headache
Centre, we noted a higher frequency of non-responders to triptans in
those affected by pre-hypertension. The aim of the study was to assess
the efficacy of oral triptans in 12 migraineurs without aura affected by
pre-hypertension before and after antihypertensive treatment
Materials and methods The sample included 12 migraineurs without
aura, diagnosed according to IHS criteria [1] and affected by pre-
hypertension (defined as systolic blood pressure (SBP): 120≤SBP≤139
mm Hg and diastolic blood pressure (DBP): 80≤DBP≤89 mmHg)
before and after antihypertensive treatment (oral terazosin, 2 mg daily).
Mean age (SD) was 38.25±4.75 years, number of migraine attacks per
month (SD) 4±1.04. Patients were invited to take oral triptans (riza-
triptan RPD 10 mg and sumatriptan tablet 100 mg, in casual order) two
consecutive attacks before and after antihypertensive therapy.
Results At baseline, triptans had no efficacy in 7/12 patients, efficacy
in one attack in 4/12 patients, and efficacy in two attacks in only 1
patient. After antihypertensive treatment, triptans had no efficacy in
0/12 patients, efficacy in one attack in 3/12 patients, and efficacy in
two attacks in 9/12 patients.
Conclusions These data point out the possible role of pre-hypertension
as a possible cause of inefficacy of triptan administration in the treat-
ment of migraine attacks, especially in sustained pain-free state.
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AUTONOMIC SYSTEM ACTIVATION AS A PREDICTOR OF
REDUCED RESPONSE TO TRIPTANS IN MIGRAINE
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Background and objective To test the hypothesis that the existence
of allodynia and the activation of the autonomic nervous system
influence the response to triptans during acute attacks of migraine
without aura (MO).
Patients and methods The presence of severe autonomic symptoms
during migraine attacks was carefully evaluated in 76 consecutive sub-
jects (M/F 27/49; mean age 36.2±6.4 years) with history of MO by
both a structured interview and telethermographic investigation. Based
on these findings, the entire group was dichotomized into a subgroup
with severe autonomic symptoms (42 patients, migraine with aura
(MA)) and a subgroup without (34 patients, MO). The two subgroups
were comparable for demographic characteristics and other clinical
variables, including pain severity. Clinical response to triptans (eletrip-
tan 40-mg tablets) during 3 consecutive migraine attacks was recorded
in each subject. End points were pain-relief and pain-free response at 1
and 2 hours.
Results Pain relief was reported in 58.2% of migraine attacks at 1 hour
and in 75.8% at 2 hours, while pain free was observed in 27.3% at 1
hour and 28.0% at 2 hours in MA patients. Pain relief in MO patients
occurred in 75% at 1 hour and 83% after 2 hours, while pain free was
observed in 38% and 42% at 1 and 2 hours, respectively. Response to
treatment was related to the co-existence and complexity of autonom-
ic symptoms. In particular, the more complex the autonomic activation,
the less evident the benefit of treatment.
Conclusions Since the autonomic system contributes to the sensitiza-
tion of nociceptors with consequent peripheral and central allodynia,
and the progressive occurrence of allodynia is supposed to be one of
the most relevant contributors to inefficacy of triptans, our findings
support the assumption that activation of the autonomic nervous sys-
tem plays a pathogenic role in the clinical response to these drugs in
migraine. The degree of activation of the autonomic system might be
used as a marker to predict the clinical outcome to triptan therapy.
TRIPTAN UTILIZATION PATTERNS: A STUDY BASED ON
PATIENTS PRESCRIPTION RECORDS OF AN ITALIAN
HEALTH AUTHORITY IN TUSCANY, ITALY
1A. Panconesi, 2E. Pavone, 2R. Banfi
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Introduction At least 50% of migraine patients are undiagnosed or
undertreated. Studies performed in selected populations show that trip-
tan use for migraine is low in Italy (3%–4% of migraine patients) as
well as in other developed countries. This study was aimed at establish-
ing the patterns of triptan prescription in a large community by using the
drug prescription database of a Health Authority of Tuscany, Italy.
Materials and methods Because of the reimbursement system of the
Italian National Health Service, all prescribed drugs included within
the essential level of assistance (LEA) are recorded by Regional Health
Authorities in association with the demographic characteristics of
patients. Therefore, medication records of individual patients are quite
complete in drug prescription databases. This allows accurate investi-
gations on drug utilization in a given community. The patterns of trip-
tan prescription in the population of Health Authority no. 11 of
Tuscany were investigated. We analysed prescription databases by
using the ATC classification (Anatomical Therapeutic Chemical classi-
fication, NO2CC: triptans) dispensed during 2005.
Results Of a total population of 224 065 residents of Health Authority
no. 11, the total number of triptan prescriptions was 8 982. Oral tablets
accounted for 5 954 prescriptions (66.3%), soluble oral tablets for
[2486 (27.7%), subcutaneous injection for 316 (3.5%), nasal sprays for
147 (1.6%), and rectal suppositories for 79 (0.9%). In the prescription
database, 455 (5%) prescriptions presented incomplete demographic
data and were excluded from this study. Thus, the following analyses
were conducted on 8 527 prescriptions. We found that 6.9 packages on
average were prescribed per patient. At least one prescription of one
triptan package was dispensed to 1 238 (0.55%) individuals in the
study period. Of these patients, 964 were females (77.9%) and 274
were males (22.1%). The patients over 65 years of age received 14%
of the overall number of dispensed packages. Up to 2 packages per
year were dispensed to 714 patients (57.7%), and up to 6 were dis-
pensed to 920 (74%). Forty patients received more than 120 dosage
units (>10 single doses/month). It is remarkable that 5.7% of the
patients received 38% of the overall number of packages.
Discussion In our evaluation we found that 0.55% of the residents in
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our district received at least one prescription of a triptan in one year.
Assuming that the migraine prevalence in Italy is reported to be 12%,
only 6% of our patients received specific triptan antimigraine drugs.
About 60% received only one prescription in one year, supporting a
very low utilization of triptans. Oddly, we found that 14% of the pre-
scriptions were filled for subjects over 65 years old, a population with
higher risk of hypertension and cardiovascular diseases. Oral formula-
tions accounted for the most prescribed route (94%), probably reflect-
ing patients’ and/or physicians’ preferences for the oral route of admin-
istration and better compliance. At least 3.2% of patients could be trip-
tan abusers (>10 dosage units/month).
Conclusions This study shows a very low triptan utilization in the
studied population. These data may imply that most migraine patients
do not achieve adequate relief because of undertreatment and have
need of more effective strategies. Another point to mention regards the
considerable amount of prescriptions in the elderly and the high
dosages utilized by a small cohort of subjects (triptan abusers).
PERSPECTIVES ON PROPHYLAXIS IN HEADACHES
LONG-TERM ECONOMIC ESTIMATION OF BOTULINUM
TOXIN TYPE A USE IN CHRONIC TENSION HEADACHE
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Objective To analyze the efficacy of botulinum toxin type A (BTX-A)
preventive treatment of chronic tension-type headache (CTTH) and the
impact on headache pharmaceutical utilization and cost.
Design/Methods A retrospective chart review of the efficacy of BTX-
A preventive treatment of 100 CTTH patients, diagnosed according to
International Headache Society criteria, was followed by a one-year
prospective analysis of headache pharmaceutical utilization and costs
before and after BTX-A treatment. A direct survey of per patient phar-
maceutical consumption was obtained through appropriate question-
naires [1]. Pharmaceutical average cost and incremental (additional)
average cost criteria were utilized for the periods before and after
BTX-A treatment.
Results The retrospective chart review revealed that BTX-A treatment
resulted in 26 patients reporting a total absence of pain and substantial
reduction in pharmaceutical use; 37 patients reported significant pain
reduction and significant reduction in pharmaceutical use; 22 patients
reported some pain reduction and a slight reduction in pharmaceutical
use; 15 patients reported no effect or “possible” worsening of pain and
no reduction in pharmaceutical use. The one-year prospective analysis
revealed that after BTX-A treatment, there was a 45% of reduction in the
use of analgesics/antimigraine drugs, a 35% reduction of nonsteroidal
anti-inflammatory drugs and a 100% reduction in the use of calcium
channel blockers. The average cost of pharmaceuticals was reduced from
€ 853,43 before BTX-A treatment to € 450,47 after BTX-A treatment.
Conclusions BTX-A was an effective preventive treatment of CTTH
resulting in a substantial reduction of headache medication utilization
and cost as emerged by previous studies by our group [2].
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Objective This was an open label study aimed at evaluating the effica-
cy of pregabalin in reducing the number of days with headache and the
amount of acute medication taken monthly in patients with chronic
headache with medication overuse.
Methods The studied sample consisted of 20 subjects. Pregabalin was
administered at 75 mg a day for 7 days and at 75 mg in two daily
administrations. The study consisted of a titration phase (1 week) and
of a maintenance phase (8 weeks).
Outcome measures
- Reduction in the number of days with headache/28days
- Reduction in the amount of acute medication taken/28 days
- Number of patients who were pain-free at two hours after triptan
intake and headache recurrence rate in the 22 hours following the
pain-free condition
- Tolerability profile
Results The group treated with pregabalin had a significant reduction
in the number of days with headache and in the mean amount of acute
medication taken.
Conclusions Pregabalin proved to be well tolerated and effective in
reversing chronic migraine with medication overuse to episodic
migraine.
HYPOSTIMULATION OF EPICRANIAL NERVES IN THE
PROPHYLACTIC TREATMENT OF MIGRAINE
C.A. Caputi, V. Firetto
Pain and Palliative Care Unit, Department of Medical and Surgical
Neurological Sciences, Riuniti University Hospital, Ancona, Italy; 
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Objective A disorder in the head region can provoke pain in the areas
innervated by the trigeminal and upper cervical nerves due to conver-
gence of the afferent fibers of the three superior cervical roots on the
neurones of the spinal nucleus of the trigeminal nerve. The therapeutic
effectiveness of greater occipital and supraorbital nerve blockade in
262 patients with migraine (ICHD-II classification: migraine without
aura, 230; migraine with aura, 19; and cervicogenic headache, 13)
unresponsive to conventional therapy was investigated.
Methods and results Patients were given repeated daily anesthetic
blocks (range 5–10). Perineural injections of 0.5 to 1.0 mL of 0.5%
bupivacaine were given at the epicranial emergence points of the
nerves in relation to the distribution of the cephalic pain only if the
nerves were conspicuously pain sensitive to pressure. Clinical evalua-
tion was based on a monthly Pain Total Index and recording of the
monthly number of migraine attacks and analgesic consumption.
Patients were considered responsive when the Pain Total Index
decreased by ≥50% in the first month after treatment.
Two hundred and fifteen patients (82%) responded well and main-
tained a favourable response over the 6-month period of observation.
The treatment was considered to be of long-lasting effectiveness and
without side effects. Method and evaluation criteria are exhaustively
described in a previous study carried out by our group [1].
Discussion and conclusions Therapeutic blockade of the greater
occipital and supraorbital nerves may have resulted in inhibition of
the constant trigeminal hyperexcitability, which characterizes
headache, not only by blocking the conduction of noxious stimuli but
also by blocking the antidromic flow of substance P and calcitonin
gene-related peptide (CGRP), mediators of the axonal reflexes that
underlie perivascular neurogenic inflammation. The consequent
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vasodilatation and extravasation of these peptides, local reinforcing
factors of the algogenic stimulation, may have been interrupted by
the anesthetic, resulting in normalization of the response threshold to
the nociceptive stimuli.
Inhibition of axonal transport by local anesthetic is well documented [2].
Repeated anesthetic blocks could produce a long-lasting hypostimula-
tion of the peripheral nociceptors, rebalancing their activation threshold
and consequently arresting induction of the neuroplastic mechanism of
central hypersensitization that may clinically produce chronic pain.
Repeated anesthetic nerve blockade, albeit not influencing the under-
lying cause, would interfere in the central pathogenic mechanism of
formation and transmission of trigeminal nociceptive stimulation of the
migraine crisis.
The treatment appeared to be effective in these forms of unresponsive
migraine and in the chronicized form with drug abuse. We hope that this
clinical experience, together with a correct neurophysiological study,
may prove useful in clarifying the pathogenic aspects of migraine.
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LANGUAGE DISTURBANCES AS A SIDE EFFECT OF PRO-
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The present study was aimed at verifying the occurrence of language
disturbances as a side effect of topiramate treatment for at least 3
months in 30 migraine patients (86.7% in the chronic form). Twenty
migraine patients treated with other prophylactic drugs, but not
antiepileptic drugs, for at least three months and 20 migraine patients
without prophylactic treatment, with similar characteristics of
headache and distribution of migraine subtype and subform diagnoses,
were used as control groups. Language functions were explored with
neuropsychological tests, including the Trail Making Test, a test of
Phonemic and Semantic Verbal Fluency, and a Denomination test.
Language disturbances were referred by 26.7% (n=8) of patients under
topiramate treatment but by none of the patients of the two control
groups. The majority of patients were accompanied by other side
effects. In only one case they were moderate in intensity, but mild in
the other cases.
Regarding neuropsychological testing, a significant difference between
the topiramate group and the two control groups emerged for the TMT-
B subtest of TMT and two of the three categories of semantic verbal
fluency (flowers and cities) with the worst scores for the topiramate
group. When patients with referred language disturbances in the topi-
ramate patient group were compared with those without, the former
had scores indicative of a worse performance for all neuropsychologi-
cal test variables, and a statistically significant difference was reached
for TMT-A, TMT-B and denomination test. Patients without referred
language disturbances in the topiramate group showed, in all cases, a
worse performance on all tests compared to patients in other prophy-
lactic treatments or untreated migraine patients.
It can be hypothesized that a disorder such as migraine, which involves
numerous cortical and subcortical circuits implicated in pain processing as
well as behavioural and emotional processing of pain, represents a facili-
tated substrate for the occurrence of language disturbances due to topira-
mate [1, 2]. This can be the expression of a more generalized impairment
of cognitive processing. These aspects should be investigated in prospec-
tive studies involving larger migraine patient samples, and research should
not be limited to topiramate prophylactic treatment but should also extend
to prophylactic treatment with other antiepileptic drugs.
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Background and aims The revised edition of the International
Headache Classification (ICHD-II) seems to have resolved most of the
diagnostic controversy concerning chronic headaches: migraine is con-
sidered chronic if attacks occur at least 15 days a month for at least 3
months as well as the criteria already stated for tension-type headache
[1]. Amitriptyline has been extensively studied and can be considered
as the gold standard in the preventive treatment of chronic headache.
Contemporary concepts of headache pathogenesis provide an account
for the use of antiepileptic drugs as preventive drugs [2]. Therapeutic
indication for topiramate is limited to migraine preventive therapy. The
aim of this study was to compare amitriptyline and topiramate in the
preventive therapy of chronic headache.
Methods A sample of 110 adult subjects consecutively referred to
the Headache Disorder Centre, Department of Neurological and
Psychiatric Sciences, University of Bari were included. All of them
were affected by chronic migraine or tension-type headache accord-
ing to ICHD-II criteria. The Symptom Check List 90R was adminis-
tered to all of them for possible psychopathological disorders.
Patients were randomly assigned a therapy of amitriptyline, 20 mg
or topiramate 50 mg. The two groups were age- and sex-matched.
Drug efficacy and tolerability were assessed after a three-month
therapy period.
Results A ≥50% decrease in attack frequency was shown in 63% of
cases after topiramate and in 65% after amitriptyline treatment, with-
out significant difference between drugs. No significant difference was
found between amitriptyline and topiramate efficacy both in the sam-
ple of chronic tension-type headache and in the sample of chronic
migraine. No difference was found between the two drugs in patients
with and without symptomatic abuse. Patients with anxiety and depres-
sive symptoms showed a greater improvement when treated with
amitriptyline. Both drugs were well tolerated.
Discussion and conclusions These results suggest that topiramate as
well as amitriptyline can be effective and tolerated in chronic
headache. Although the exact mechanism of action of this drug in
headache prevention is still unclear, it might act by means of the mod-
ulation of the nociceptive system preventing both peripheral and cen-
tral sensitization, which predisposes to attack recurrence [2].
Amitriptyline should be the first choice drug in the case of headache
comorbidity with psychopathological symptoms.
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Introduction In the 2nd edition of the International Classification of
Headache Disorders [1] we find at chapter 8.1.2 the “Phosphodiesterase
(PDE) inhibitor – induced headache”. The diagnostic criteria are A)
Headache with at least one of the following characteristics and fulfill-
ing criteria C and D: 1 bilateral, 2 frontotemporal location, 3 pulsating
quality, 4 aggravated by physical activity; B) A single dose of a phos-
phodiesterase inhibitor has been given; C) Headache develops within 5
hours of PDE inhibitor intake; D) Headache resolves within 72 hours.
PDEs are a large family of enzymes (11 types) that break down cAMP
and cGMP; the inhibition of PDEs raises intracellular levels of cAMP
and cGMP. Sildenafil, the most widely known PDE-5 inhibitor, seems
to determine headache through other mechanisms in addition to arterial
dilatation, such as stimulation of perivascular pain sensitive fibers or
central neurons of pain-pathways. We report on the effect of PDE-5
inhibitors in four patients (suffering from impotence), three affected by
migraine and one by cluster headache.
Materials and methods Of three migraine patients (mean age 39
years) suffering from impotence, two were treated with vardenafil 10
mg, one with sildenafil 50 mg. One patient, affected by cluster
headache (CH), was treated with sildenafil 50 mg. All patients were
asked to refer the possible effect of PDE inhibition on their headache.
Results and discussion Two of the three migraine patients, one treat-
ed with vardenafil and one with sildenafil, referred headache similar to
their usual migraine attacks within 5 hours from ingestion of the drug.
The third patient, referred within 5 hours from taking vardenafil 10 mg
a “cluster-like” attack, of less than one hour duration. The CH patient,
after taking sildenafil 50 mg, referred headache similar to his usual
cluster attacks.
Conclusions Whereas in two of three migraineurs the headache that
followed consumption of a PDE inhibitor was like their usual
headache, the symptoms of the third migraine patient were novel, in
that he developed a “cluster-like” headache. Also remarkable was the
headache of the patient affected by CH, who referred after taking the
drug, a typical cluster attack. Thus both migraineurs [2] and CH
patients should be informed of PDE-5 inhibitor-induced headache.
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PLACEBO AS A PROBLEM OR A RESOURCE?
PLACEBO AND ANALGESIA: FROM THE LABORATORY TO
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The placebo effect has long been a source of debate in order to identi-
fy its nature and real power. The effect that follows the administration
of an inert treatment, pharmacological or not, is the consequence of
several endogenous mechanisms, including conditioning and expecta-
tion of clinical benefit.
Electrophysiological studies in humans have highlighted the role of
opioids and non-opioid systems in placebo analgesia. Several studies
show that placebo analgesia is antagonized by the opioid antagonist,
naloxone, suggesting a role for the endogenous opioids, but the role
of opiates is still far from clear. The use of different methodologies
for exploring pain perception, including intense and prolonged stim-
ulation (i.e., for ischaemic pain) instead of strong painful phasic
electrical stimulation (i.e., nociceptive withdrawal reflex) seems to
play a different role in inducing the activation of the opioids system
and analgesia.
Anticipation of pain and prolonged intense stimulation seem to be nec-
essary in producing the so-called “stress-induced analgesia”, which is
typically opiate-mediated and naloxone-reversible; in contrast, the
placebo effect generated by expectation of analgesia is absolutely irrel-
evant on the excitability of the nociceptive withdrawal reflex or plas-
ma endogenous opioids system.
The mechanisms of the placebo response carry significant implications
for clinical trial designs and thus clinical practice. The importance of
the expectation of a benefit in the treatment outcome has been empha-
sized in several reports in recent years, and it could represent a signif-
icant limitation during placebo-controlled trials.
The utilisation of a hidden injection coupled with standard administra-
tion is known as the open-hidden paradigm, a paradigm that may pro-
vide an excellent alternative to placebo-controlled trials.
These considerations are particularly relevant in the headache field,
where the placebo effect in the treatment of the attacks has been esti-
mated to be from 6% to 47%.
Further research identifying and quantifying the factors involved in the
mechanisms of the placebo response can increase the outcomes of the
treatment and enhance our knowledge of the mind-brain-body interaction.
PREVALENCE OF THE PLACEBO AND NOCEBO RESPONS-
ES IN PATIENTS WITH MIGRAINE AND TENSION-TYPE
HEADACHE
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University of Turin, Turin, Italy; e-mail: marghfer@yahoo.it
Introduction Placebo and nocebo responses have not been adequately
investigated in patients with primary headaches. In randomized clini-
cal trials of analgesic, approximately 30% of the patients with migraine
showed a placebo effect. However, a tremendous variation among the
different studies was observed. The purpose of this study was to eval-
uate the prevalence of placebo and nocebo responses in a large group
of patients with migraine or tension-type headache recruited from a
university-based Headache Centre.
Methods A total of 726 consecutive patients (208 men, 518 women;
mean age±SD=41.9±16.0 years), attending the Headache Centre of the
University of Turin (Italy), were involved in the study. The diagnosis
of migraine was made according to ICHD-II criteria. The patients
underwent an extensive physical and neurological examination.
Psychological evaluation was performed using the BDI, the STAI X-1
and STAI X-2 tests. A standardized record of all the clinical and psy-
chological characteristics of headache was obtained. Patients were
divided into three groups: A) migraine (with and without aura): 258
patients; B) tension-type headache (episodic and chronic): 137
patients, and C) mixed headaches (migraine and tension-type
headache): 331 patients. Patients received a tablet containing talcum
powder and were told, according to the presence or absence of pain,
that the pill was able to produce a pain decrease or increase (extinction
or induction of pain). Three hundred and twenty-five patients per-
formed the placebo test and 401 the nocebo test. Patients recorded on
the headache diary the presence or absence of headache in the 4 hours
following the test.
Results A placebo response was observed in 31.1% of migraine
patients, in 38.7% of patients with tension-type headache and in
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34.0% of patients with mixed headache. A nocebo effect was reported
by 12.% of migraine patients, 22.7% of patients with tension-type
headache and 19.7% of patients with mixed headache. Placebo and
nocebo effects were not influenced by age, gender or headache diag-
nosis. Nocebo responders had a longer duration of the disease than
non-responders.
Discussion Our study showed that approximately one-third of
patients with migraine or tension-type headache presented a placebo
response. The nocebo effect was reported by 15% of the patients. The
placebo and nocebo responses were not influenced by age, gender or
disease diagnosis. Duration of the disease may influence the nocebo
response.
LESSONS FROM PLACEBO EFFECTS IN MIGRAINE TREAT-
MENT
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The word “placebo” is derived from Latin, meaning “I please”.
Although placebo is regarded as an “inactive” substance, its impact can
be profound, such that if the effects of placebo are not measured in
clinical trials, placebo response may obscure a true pharmacological
effect of an active comparator. It is well reported that the variability of
placebo response in clinical trials of acute migraine can be high, rang-
ing between 6% and 47% of patients, and this has led to the recom-
mendations that active drugs for migraine must be shown to be signif-
icantly superior to placebo. Bendtsen et al. (2003) [1] evaluated the
placebo response in placebo-controlled randomised clinical trials of
analgesics in migraine attacks that met International Headache Society
criteria (ICHD-II). Eleven studies qualified for inclusion in their
review. For “headache response”, a placebo response occurred in 30%
(mean) of migraineurs, although the range (variability) was large
(7%–50%). Even though the placebo effects on 2-hour pain-free rates
were lower (mean 9%), variability ranged between 7% and 17%, indi-
cating that this is a more robust outcome measure. A review of the lit-
erature of placebo-controlled trials with triptans in acute migraine has
been reported by Loder et al. (2005) [2] with 31 trials meeting their cri-
teria for inclusion. The mean standard deviation (SD) proportion of
patients with a headache response to placebo at 2 hours was 28.5±8.7%
(range 15%–50%), while the mean (SD) proportion of patients with a
pain-free response to placebo at 2 hours was 6.1%±4.4% (range
5%–17%). Placebo response in children and adolescents with migraine
represents a particular challenge not least because placebo effects
appear to be enhanced in this young group. Other authors have
reviewed the limited data on the use of analgesics and triptans in place-
bo-controlled trials of migraine in children and adolescents and found
a large variability in placebo response: 37%–53% of patients treated
with placebo analgesics/non-steroidal anti-inflammatory drugs
(NSAIDs) and 28%–65% of patients treated with placebo triptans.
Alongside placebo response for efficacy outcomes, placebo is associ-
ated with a spectrum of adverse events (AEs) reported across placebo-
controlled clinical trials – the “nocebo” effect. This underscores the
need to attempt to disentangle AEs associated with placebo from those
associated with active medications to enable a more accurate profile of
the tolerability and safety of the active medication. In placebo-con-
trolled trials of migraine, AEs may occur with placebo in >30% of
patients and in triptan trials the mean (SD) proportion of patients
reporting an AE to placebo was 23.4±14.1% (range 5%–74%). As
placebo-response rates in clinical trials in migraine may be affected by
many variables, placebo-subtracted outcome data may facilitate a more
accurate picture of the profile of active medication. In summary,
although Medical Ethics Committees are becoming increasingly resis-
tant to the use of placebo in acute migraine trials, placebo remains the
pivotal comparator in trials of migraine medications.
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THE “PLACEBO” EFFECT IN CHILDREN AND ADOLESCENTS
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There is no unique definition of placebo (or placebo effect), and the
most common is “any effect attributable to a pill, potion, or procedure,
but not to its pharmacodynamic or specific properties”. The mecha-
nisms of the placebo effect have not been definitively understood; we
are dealing with the intriguing field of mind/brain relationship, psy-
chology and biology. The mechanisms of placebo are related to psy-
chological aspects, as “desire”, “expectation”, or “conditioning”. Of no-
te, recent studies showed that placebo has implications also in the biolo-
gical field; antidepressants influence both brain structure and function.
Placebo is a significant issue in headache disorders. Studies on triptans
showed a placebo response from 18% to 35% in adults and from 25%
to 61% in children and adolescents [1]. In preventive therapy, response
to placebo has been estimated as high as 40%–50% in children [2]; in
adults, the placebo effect in preventive therapy is about 50% [3]. While
the high placebo response in headache trials is an obstacle, it may yield
new insights into understanding the mechanisms involved in triggering
and relieving headache.
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SOCIO-ECONOMIC ASPECTS OF HEADACHES
HEADACHE MANAGEMENT IN A DIFFERENT TERRITORY
OF SOUTHERN ITALY: PROPOSAL FOR A NEW OPERA-
TIONAL MODEL
1D. Conforti, 2R. Iannacchero, 2E. De Caro
1Department D.E.I.S. UniCal Cosenza, Cosenza, Italy; 2Regional
Headache Centre, “Pugliese-Ciaccio” Hospital, Catanzaro, Italy; 
e-mail: rosarioiann@tiscali.it
In this new operational model of headache management, its practice
means integrating individual clinical expertise with clinical evidence
from systematic research, and its main principle is that clinical decision
should be based on the best available scientific evidence from previous
experience and the conclusion based on such evidence should stimulate
quality improvements in patient care. The impact of migraine headaches
is one of the major public health problems in several industrialized
countries, with many patients reporting frequent and significant disabil-
ity. In order to effectively and efficiently support the medical-clinical
management of the patients affected by headache disorders, we propose
to devise, develop and validate an innovative web-based platform of
services, which is able to optimally support physicians in all the
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processes related to diagnosis, prognosis and treatment of headache dis-
orders. This general goal can be achieved by providing the technologi-
cal platform of a suitable set of functionalities that are able to:
1. integrate biomedical data within electronic health record systems,
for easy and ubiquitous access to heterogeneous patients’ data;
2. provide services for both healthcare professionals and patients,
including education and learning, knowledge and support for spe-
cific actions, teleconsulting;
3. support clinical decisions in the medical domain, based on pattern
recognition in historical data, knowledge discovery analysis and
inferences on patients’ clinical data.
Moreover, the real application of the platform could bring a substantial
increase in the quality of treatment of the individual patient, by ensuring
the possibility to personalize the therapy and provide continuous assis-
tance to the same patient. On the other hand, optimisation of the thera-
peutic processes will assure control and reduction of the overall econom-
ic and social costs of medical care, by decreasing the frequency of hos-
pital admissions and healthcare migration. In Calabria, the majority of
drug expenditures is partly or wholly borne by the patient, and the costs
of hospitalisation and working days lost are significant. Therapeutic con-
trol, based not only on pharmacological therapy but also on the integrat-
ed assistance of headache sufferers would dramatically reduce social
costs while improving the quality of life of these individuals. Patients,
clinicians, and the healthcare system influence different types of barriers
to migraineurs who receive early intervention with triptan therapy.
THE MEDICALLY UNRECOGNIZED MIGRAINE: LONG-TERM
EFFECTS OF A SENSITIZATION CAMPAIGN ON BOTH GEN-
ERAL PRACTITIONERS AND THE POPULATION
B. Petolicchio, M. Altieri, G. Sirimarco, G.L. Lenzi, V. Di Piero
Headache Centre, Department of Neurological Sciences, University of
Rome “La Sapienza”, Rome, Italy; e-mail: vittorio.dipiero@uniroma1.it
Introduction Migraine disorders are, despite the heavy burden they
impose on individuals and society in general, largely unrecognised and
untreated. In general practice, few patients consult a physician for
headache. In this view, we investigated the impact of a sensitization cam-
paign on migraine in a large cohort of patients, living in a district of Rome.
Objectives The aim of the present study was to evaluate the long-term
effects on migraineurs of this sensitization campaign. Three-years
later, patients were re-investigated by means of a semi-structured tele-
phone interview.
Patients and methods The initial study had involved the “Cooperativa
dei Medici per il Territorio” (10 general practitioners (GPs)) and a popu-
lation of about 12 000 people, who had been contacted by mail and
posters located in the clinics of the GPs. The study recruited 195 patients,
of whom 92% (n=179) were migraineurs, according to the IHS criteria
(1988). A total of 73% of the patients were diagnosed for the first time.
Results Out of 179 migraineurs, 90% (162 cases, mean age 40.7±15
years, 139 females) underwent follow-up study. Migraine with aura
was present in 25% (n=41) of the cases. At follow-up, a significant
improvement was observed in the mean pain intensity (on a scale
0–10) (8.6±1.5 vs. 7.4±2.1; p<0.0001), the mean headache duration
(37.1±24.9 vs. 33.7±24.5 hours: p<0.006) and the mean HIT-6 score
(61.3±7.6 vs. 57.4±10.9; p<0.0001). About 70% of the patients consid-
ered the sensitization campaign useful and 58% reported an improve-
ment of their clinical status. Comparison between improved versus
worsened or unchanged migraineurs showed a significant decrease in
the mean pain intensity (-33%; p<0.0001), mean headache duration
(-24%; p<0.001), mean days of headache per month (-72%; p<0.0001),
and mean HIT-6 score (-14%; p<0.0001).
Conclusions Our data indicate that a simple awareness campaign is
likely to identify a high percentage of previously undiagnosed
migraineurs, who could thus receive more appropriate acute care and
prophylactic treatment than that offered by uncontrolled self-medica-
tion. This positive effect persists for a long time after the sensitization
campaign and stresses the crucial role of patient education to medical
and non-medical management of migraine. This study further supports
the need for development of new interventions or educational strate-
gies aimed at reducing the burden of migraine.
INCREASING PATIENT INFORMATION TO REDUCE THE
BURDEN OF MIGRAINE: A NEW PROJECT: “THE HEA-
DACHE DAYS”
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Despite the prevalence, disability and burden of migraine, many
patients (30%–70%) have never seen a doctor and only 4% of headache
sufferers are referred to a pain specialist for their problem [1]. Possible
causes may be unsatisfactory patient - physician relationships, lack of
information and the insufficient ability to recognize migraine in pri-
mary care. Last year we held free meetings for a week in a Headache
Centre: “The Headache Week Project” (La Settimana delle Cefalee) to
understand patients’ requests about their headache. This initiative was
very useful for enlightening migraineurs who do not refer to physicians
for their headache (“invisible migraineurs”) and pointing to the lack of
patient information about headache. Of the 180 participating subjects,
with severe headache, 78% had never visited a headache centre nor a
specialist and had never taken preventive drugs and their major request
was which headache centre or pain specialist to refer to to improve
their headache [2]. These results highlighted the need to extend and
give continuity to initiatives for patient information, by increasing the
number of sites (more headache centres) and their overall period of
activity. To favour the participation of as many headache centres as
possible, we have now reduced the duration of activity of each infor-
mation site to one or two days, calling the initiative “The Headache
Days” (Le Giornate delle Cefalee).
Nine headache centres are now scheduled to participate in the “The
Headache Days Project” in the city and province of Palermo, covering
a period of about two months (May - June 2006). The initiative has
been advertised in local newspapers and television programmes and
the list of centres involved can be found on the national website
www.cefalea.it.
Participating patients will receive informative material about headache
(including headache diaries and a list of the headache centres in the city
and province of Palermo); moreover, they will complete a question-
naire concerning their headache, physician and specialists visited,
knowledge and usage of symptomatic (triptans) and preventive treat-
ments; they will also undergo the ID Migraine questionnaire to screen
for migraine.
We hope that this will increase patients’ knowledge about headache,
and also provide more insight about “invisible migraineurs” with the
final goal (through more appropriate diagnosis and treatment) to
reduce the disability and burden of migraine.
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HEALTHCARE RESOURCES AND MANAGEMENT OF
HEADACHE IN PATIENTS REFERRED TO A REGIONAL
HEADACHE CENTRE
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Objectives Primary headaches are a public health problem with socio-
economic burden and related disability. Despite impairing quality of
life, headaches remain underdiagnosed and undertreated with a low
healthcare utilization rate. We investigated the use of healthcare
resources and the management of headache in patients referred to a
headache centre.
Methods All consecutive patients referred for a first visit to our
Headache Centre in 2000 and 2005 were considered. We investigated
the primary headaches classified according to the International
Classification of Headache Disorders, the management of the headache
pain before access to the Headache Centre, and causes of delay in seek-
ing a specialist medical referral.
Results We enrolled 533 patients (316 women and 217 men; mean age
45±31 years) from 2000 and 624 patients (423 women and 201 men;
mean age 42±28 years) from 2005. Patients with migraine were 336
(63%) in 2000 and 443 (71%) in 2005 (p<0.05); those with tension-
type headache were 192 (36%) and 175 (28%) (p <0.05); while those
with cluster headache were 5 (1%) and 6 (1%) (p=0.79), respectively.
Before referring to the Headache Centre, patients who had never con-
sulted a physician were 320 (60%) in 2000 and 281 (45%) in 2005
(p<0.005); patients who consulted a general practitioner were 160
(30%) and 237 (38%) (p<0.005); patients who asked for a neurologist
were 53 (10%) and 106 (17%) (p<0.05). Reasons discouraging patients
from referring to a headache centre were: lack of information about
specialist centres in 53 (10%) patients in 2000 and in 38 (6%) in 2005
(p<0.05); self-management of pain with over-the-counter medication
in 160 (30%) and in 243 (39%) (p<0.05); and the attempt to live with
the pain in 320 (60%) and in 343 (55%) (p<0.05), respectively.
Conclusions In 2005, the diagnosis of migraine was more frequent
than that of tension-type headache in 2000 showing a trend in patients
with more severe headaches to search for a specialist consultation. The
increased proportion of patients consulting a neurologist in 2005 and
the reduced proportion of those who did not refer to a headache centre
because of a lack of information suggests that a better understanding of
the opportunity to refer to a headache centre represents the proper
approach in headache management. These results were achieved by
improving communication between general practitioners and neurolo-
gists, and explaining to patients that a specific approach to headache
may improve their quality of life, and reduce the frequency and sever-
ity of the headaches.
IMPROVED PRESCRIBING IN PRIMARY CARE OF
MIGRAINE THERAPY IN THE CALABRIA REGION
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Introduction Most people with headache in the Calabria Region are
treated at the primary care level. General practitioners (GPs) play a
substantial role in the detection and management of headache and it is
of primary importance to investigate their clinical practice.
Materials and methods A random sample of 500 GPs from the list of
GPs in Calabria, received a questionnaire by mail. The questionnaire
consisted of four sections focusing on: demographic and practice char-
acteristics; knowledge about the role of studies aimed at testing effec-
tiveness and cost-effectiveness of alternative treatments of headache;
and sources of information for headache management and educational
needs perceived in this field.
Results A total of 453 (91%) completed and returned the questionnaire.
Data from the questionnaire were collected, analysed and produced in
tabular form. The study of almost 450 headache patients consulting their
primary care physician indicated that only 9% were referred to a neu-
rologist as part of their migraine management. In the study, the pattern
of referral was not dissimilar, despite the notable differences between
these healthcare systems, with only 15% of migraine patients being
referred to a neurologist and only 2% seen by a headache specialist.
Discussion This pattern reflects three important and persistent barriers
to improved migraine care: failure to consult, failure to diagnosis, and
failure to appreciate disease severity, by not recognizing and assessing
the impact of migraine on the sufferers’ quality of life. Approximately
50% of people with migraine consult a physician about their
headaches. Of these patients, only 21% continue under a physician’s
care with the majority of patients who do consult quitting after just a
single consultation. The quality of migraine diagnostic skills at the pri-
mary care level may be compared with other conditions such as asth-
ma, which has a similar occurrence, and like migraine, is managed
almost exclusively at the primary care level. Physicians may be overly
concerned with excluding secondary headache, at the expense of effec-
tively managing primary headache syndromes.
Conclusions Despite the major advances achieved in migraine diagno-
sis and treatment, primary care physicians still face major challenges
in making the correct diagnosis and selecting the most appropriate
treatment for this common disabling condition.
HEADACHE AS AN EMERGENCY IN CHILDREN
HEADACHE AND CRANIAL TRAUMAS
1D. Moscato, 2G. Mazzotta, 1M.I. Peracchi
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Perugia, Italy; e-mail: dmoscat@tin.it
Children’s head traumas represent one of the most widespread causes
of mortality and morbidity in childhood. Cranial trauma is a function-
al or structural injury, which affects the central nervous system caused
by physical mechanical forces. The trauma may be open or closed, in
relation to the presence or not of a communication between the CSF
and external spaces.
Various types of traumas may cause different types of damage: concus-
sion, contusion, oedema, herniation, (subdural or epidural) haematoma,
haemorrhages, diffuse axonal injury and cranial fractures [1].
The criteria of the ICHD-II do not focus on the characteristics of the
pain but concern above all the temporal and pathogenic relationships
with the traumatic event. It is possible that a trauma worsens, in
terms of frequency and intensity, a pre-existing primary headache
(ICHD-II, 2004).
Given the high frequency of mild cranial traumas, we shall focus our
attention on these forms.
Because posttraumatic headache (PTH) follows moderate cranial trau-
ma, the question is whether this headache is truly secondary to the trau-
ma or is only the trigger factor. This has already been doubted by sever-
al authors, starting with Bille, Sinlappa, Raskin, Haas, Lanzi and Russell.
The indications that summarize all these doubts are reviewed by
Linder [2].
1. CPT may develop after light, moderate or severe trauma.
2. Often the symptoms appear more severe than the trauma itself.
3. Even though these headaches resemble migraine, they do not
respond to migraine relieving/pain killing drugs.
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4. It is just as important to treat comorbidity problems such as anxiety
and depression.
All the above data have led us to evaluating the real incidence of PTH
secondary to moderate cranial trauma in the population of certain
Italian headache centres. The data on more than 2 000 patients (4–18
years) have given an incidence of PTH of approximately 3%. We con-
firm that the first cause of PTH are the falls when playing, followed by
traffic accidents. Also, in this case there is no direct relationship
between the intensity and type of trauma and the onset of headache.
PTH is more frequent in the age range of 6–12 years. The more fre-
quent type of headache is migraine without aura.
In the period close to the trauma there are more anxiety manifestations,
such as sleep disturbances and panic crises; this may be due to the same
traumatic event as well as to possible axonal micro-damage. It is also
true that after some months these disturbances diminish, due to a reas-
surance mechanism and also due to restoration of the axonal damage.
The poor evidence of headache after moderate cranial trauma leads
us to actually doubt the existence of this classifying diagnosis. It
leads us, conversely, to confirm this event as a triggering moment of
the headache.
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Clinical experience suggests that headache occurring in children and
adolescents may be related to the presence of psychological triggering
factors, as major or minor life events. Parents, sometimes, may feel
more confident in asking for help for a “neurological” problem than a
“psychiatric” one. From a psychiatric point of view, we know that
young patients also exhibit a lot of physical disorders: Livingston et al.
(1990) found that between 25% and 30% of children admitted to a psy-
chiatric hospital had physical symptoms, including headache, food
intolerance, abdominal pain, nausea and dizziness [1].
These aspects have clinical and research implications. On the one
hand, we should be able to recognise factors (from headache charac-
teristics to psychological triggers), which suggest that facing the psy-
chiatric problem is compelling. On the other hand, we are dealing with
the subtle link where mind interacts with body, a field whose compre-
hension may also furnish elements for understanding the pathophysiol-
ogy of headache.
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Cluster Headache Cluster headache (CH) is infrequent and is one of
the most painful primary headaches. Its prevalence in the general pop-
ulation is 0.1%, and it begins after the age of 20. Onset in adolescence
is rare and its observation under 10 years of age is quite singular;
despite the typical clinical features, it is not ever correctly diagnosed,
especially in young patients. Children affected by CH have a bizarre
behaviour and frequently are excited, typical characteristics of this
headache, and they are often considered affected by a psychiatric
headache. According to the 2nd edition of the International
Classification of Headache Disorders [1], CH crises in childhood have
a short duration (15–180 minutes); they may repeat several times in a
period of 10–20 days (“minicluster”) and pain has a severe intensity,
strictly unilateral, in orbital, temporal or zygomatic sites. Autonomic
signs, homolateral to the pain, are also present (lacrimation, conjuncti-
val hyperemia, nasal obstruction or rhinorrhoea, miosis, eyelid oede-
ma). In the following years, the autonomic signs increase in intensity
and the cluster periods are longer (1–3 months). Scientific evidence
and our personal experience suggest that clinical features of juvenile
CH remain until adolescence, especially for site and type of pain.
Paroxysmal Hemicrania In chapter 3 of the International Headache
Classification, we also find Episodic and Chronic Paroxysmal
Hemicrania (EP): the attacks are shorter (2–45 minutes) and their num-
ber is higher (4–20/day) than CH. It occurs frequently in females and
responds well to indomethacin, but this last characteristic is less
observed in young patients. Like CH, pain has a severe intensity, strict-
ly unilateral, in orbital, temporal or zygomatic regions. One of the
autonomic signs on the pain side has to be present (lacrimation, con-
junctival hyperemia, nasal obstruction or rhinorrhoea, miosis, eyelid
oedema). The rarity of this headache in childhood is confirmed by the
lack of articles in the scientific literature; from 2000 to 2005, accord-
ing to MEDLINE, we can find only two case reports, both primary, one
in a boy of 6 years [2] and the other in a girl of 10 years.
Conclusions When a strictly unilateral headache of severe intensity
accompanied by autonomic signs is observed in a child, the possibility
of CH or EP (or another trigeminal autonomic cephalalgia - TAC) has
to be considered, for providing the best symptomatic and/or prophy-
lactic therapy.
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Headaches are initially present in 20% of patients with brain tumours
and increase to about 60% during the disease. They are a more com-
mon symptom of brain tumours in children (90%) than in adults (60%).
The overall incidence of headaches was 62%, ranging from 70% with
infratentorial lesions to 58% with supratentorial tumours, to 35% in
patients with spinal canal tumours [1]. Headache is a rare initial symp-
tom in patients with pituitary tumours, craniopharyngiomas, or cere-
bellopontine angle tumours. It is a very common initial symptom in
infratentorial tumours, occurring in 80% to 85% of patients. Headache
can occur intermittently and mimic migraine. Paroxysmal headaches
are a unique feature of some patients who have a colloid cyst of the
third ventricle or other tumours that may obstruct CSF flow. They may
be a cause of brief losses of consciousness or “drop attacks”. Headache
was typically associated with other signs or symptoms and was rarely
an isolated symptom (<1%). Battistella et al. (1998) [2] showed that in
10% of children with tumours, headache is the only symptom, and
occurs at presentation with others symptoms in a further 17%.
Wilne et al. (2006) reported that headache is the first symptom in
41% of patients with tumour more than in seizures (9%), and vom-
iting (12%) [3].
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We report 2 cases. Case 1: 3-year-old male, suffering from a daily glob-
al pounding headache and sleep disorders. These had begun 3 months
previously and ataxia started during the last week. MRI showed defor-
mity, displacement and partial obstruction of the right ventricle by mass
with characteristics of supratentorial primitive neuroectodermal tumours.
Case 2: 11-year-old male, presenting at the hospital because of a
seizure during sleep, followed by severe headache. Headache in the
last year mimicked migraine. MRI showed an intracortical occipital
cystic lesion (dysembryoplastic neuroepithelial tumour).
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Headache is a common presenting complaint to the Paediatric
Emergency Department (about 1%–2%) and although the majority of
headaches are benign and self-limited, it may be the initial symptom of
life-threatening disorders. It is therefore essential for physicians to have
a rational approach in the evaluation of a child or adolescent with
headache who presents to the Emergency Department, because the
headache may be the presenting complaint of serious diagnoses such as
meningitis, brain tumour, cerebrovascular diseases or other dangerous
illness. The majority of headaches in the Paediatric Emergency
Department are secondary to concurrent diseases like viral illness,
sinusitis and minor head trauma, while primary headaches (migraine and
tension headache) are less frequent compared to those in adult studies
where they are the most common. The prevalence of serious neurologi-
cal diseases is about 5%–7% and the most reported causes are meningi-
tis, brain tumour, ventriculoperitoneal shunt malfunctions, subdural
hematoma and intracranial haemorrhage. The cause or type of most
headaches can be determined by a careful clinical history supplemented
by a general and neurological examination. The first important step is to
identify the temporal pattern of the headache, acute, acute-recurrent,
chronic-progressive, chronic-nonprogressive or mixed. The general
physical examination must include blood pressure and temperature and
a detailed neurological examination is essential. Several “red flags” in
the patient’s clinical history and general and neurological examination
should lead to more attention and further important diagnostic testing.
Special attention is warranted if the acute headache is occipital in loca-
tion, or if papilloedema, ataxia, paresis or altered levels of consciousness
are present. Also, a history of (i) increase in intensity and frequency of
headache; (ii) abrupt onset of headache; (iii) persistence of headache
despite analgesics; (iv) alteration of the characteristics of headache
should lead to suspicion of a serious illness, also in the presence of a
negative neurological examination. The American Academy of
Neurology [1] formulated evidence-based recommendations regarding
the evaluation of children and adolescents with recurrent headaches sug-
gesting that EEG and neuroimaging are not indicated in children with
recurrent headaches and a normal neurological examination.
The majority of headaches in the Paediatric Emergency Department
can require only treatment for the secondary illness, no pharmacologi-
cal treatment or simple treatment with minor analgesics. However,
sometimes it may be necessary to manage the paediatric headache in
the Emergency Department and most available acute treatments are
extrapolated from adult studies. Recently, in Italy the use of sumatrip-
tan nasal spray has been approved, and it has shown to be effective in
the treatment of acute migraine in children over 12 years.
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Objective In Western Europe less than 5% of strokes occur in subjects
under 45 years. In Italy, a recent study reported only a 2% incidence of
young stroke cases.
Subarachnoid haemorrhage prevails in young cases and in the sub-
group of patients with cerebral infarction, interatrial septum defects
and inherited thrombophilic disorders seem to play an important role.
Risk factors for stroke in older patients, e.g. blood hypertension, hyper-
cholesterolemia, diabetes, smoking, can be significant also in younger
patients. Moreover, in this age group the association of migraine with
aura and the use of oral contraceptives seem to amplify the impact of
these risk factors, especially in women younger than 45 years of age.
As illustrated in a recent study of our group, the recurrence of acute cere-
brovascular and cardiovascular events is higher in first degree relatives
of migraine patients then controls [1]. This link could be explained con-
sidering stroke and migraine as two possible phenotypic manifestations
of a common genetic background as clearly demonstrated in CADASIL
and MELAS. Moreover, it is known that migraine can be characterized
by stroke-like episodes and that it can also be a direct cause of ictus (i.e.,
migraine infarction). Finally, recent studies have hypothesized that the
link between migraine and stroke could be the patent foramen ovale [2].
In children and adolescents, migraine is a frequent disorder and rarely
could be the presenting symptom of stroke.
Material, methods and results Two patients came to our clinic pre-
senting symptomatology of migraine diagnosed according to ICHD-II
criteria. In one case, a patient was admitted to our clinic for migraine
without aura attack that started in relationship with a first episode of
substance abuse. Neuroimaging revealed the presence of a stroke. The
second case was diagnosed as affected by basilar-type migraine.
Neuroimaging showed the presence of a stroke involving the basilar
artery territory.
Discussion and conclusions Headache is a frequent disorder in child-
hood and adolescence. Occasionally it could be the presenting symp-
tom of a stroke. The relationship between these two entities is still con-
troversial due to its complexity under clinical, epidemiological and
genetic points of view.
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Introduction The treatment of paediatric migraine requires a balance
between non-pharmacological and pharmacological measures. This
includes acute symptomatic treatment and more rarely a judicious use
of prophylactic agents.
Acute treatment The most rigorously studied agents for symptomatic
treatment of juvenile migraine are acetaminophen, ibuprofen and
sumatriptan nasal spray, all of which have shown efficacy and safety in
controlled trials. However, no differences in efficacy were found
between oral triptans and placebo, probably because of shorter dura-
tion of attacks and migraine associated gastric stasis.
Preventive treatment Prophylactic drug therapy is indicated only for
children with severe and frequent attacks (about 30%). However, the
results of daily preventive medication of paediatric migraine is more
controversial. Older drugs, i.e., antihypertensive agents (propranolol
and clonidine), antidepressants (amitriptyline and trazodone), sero-
tonin modulators (pizotifen and cyproheptadine), have shown insuffi-
cient or conflicting data. In the calcium channel blockers class, only
flunarizine resulted effective and superior to placebo. There is not yet
sufficient evidence for the emergent class of antiepileptic drugs (i.e.,
divalproex sodium and topiramate). Two open trials, using levetirac-
etam and gabapentin, have given encouraging results, even with the
bias due to the open design and the small sample. Most of these drugs
were well tolerated, but clinical efficacy in children and adolescents
may differ from that in adults.
Two recent reviews summarized all the criticism on the present data in
the literature [1, 2]. The major cause of negative results in controlled
trials must be attributed to the elevated percentage of placebo-respon-
ders migrainous children both in the prophylactic (from 16% to 55%),
and symptomatic (from 20% to 60%) approach.
Conclusions Future trials must take into account: a) larger multicentric
sample sizes, patients recruited from primary care centres, and IHS cri-
teria for diagnosis; b) some methodological suggestions: migraine for
at least one year, three-month retrospective history, one-month
prospective baseline period, randomised, double-blinded placebo-con-
trolled trials of at least three-months’ duration; c) expanded measures
for efficacy of treatment: clinical improvement in headache, quality of
life, lack of attendance at school, satisfaction of child and parents; d)
new primary end-points incorporating both “pain” and “disability”,
and “migraine-free” as an important measure of efficacy; and e) new
scales with a broader range of measures of pain, and lower age of chil-
dren (six to twelve years).
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The management of paediatric migraine requires an individually tai-
lored regimen of both pharmacologic and psychological treatment,
which is based on individual and integrative approaches using sympto-
matic and preventive measures.
Prophylactic medication is not indicated in all cases. In published sta-
tistics, less than about 30% of children require daily preventive agents,
because of high frequency and/or significant disability due to
headaches. Follow-up studies demonstrated that the spontaneous out-
come of headache in children is the complete remission in many cases.
Moreover, we know that family and environmental interventions often
reduce headache frequency. Psychiatric comorbidity and family dys-
functioning are to be evaluated in all our patients because they are
often part of the clinical picture and may play a critical role in the prog-
nosis of headache. Recently, a Cochrane review summarized the evi-
dence about the effectiveness of different psychotherapeutic approach-
es for migraine and tension-type headache.
With reference to prophylactic drug treatment, there is a paucity of
controlled clinical research. Older therapies (ß-blockers, antidepres-
sants, serotonin modulators and calcium channel blockers) have shown
conflicting results or furnished insufficient data, and the more recent
therapies (antiepileptic drugs), generally well tolerated in paediatric
epilepsy, are in need of placebo controlled trials.
In conclusion, tension-type headache and migraine treatments need
an integrative approach, where pharmacological therapy is to be
considered only one of the different options for the care of children
and adolescents.
PROS & CONS: ANTIEPILETICS
ANTICONVULSANT DRUGS IN MIGRAINE PROPHYLAXIS:
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A variety of clinical trials have consistently shown the benefits of
antiepileptic drugs (AEDs) in improving migraine [1]. Prophylactic
treatment is often necessary, not only to improve the quality of life
but also to avoid the development of analgesic abuse. AEDs could
have benefits in migraine prophylaxis because of specific neuro-
modulation in the pain pathways and, more specifically, in the
trigeminal system. AEDs could have a role not only in reducing cor-
tex excitability but also, probably, on the neurotransmitters impli-
cated in the transmission of sensory information in the trigemino-
vascular system, such as glutamate, calcitonin gene-related peptide,
nitric oxide, and 5-HT. These increase GABA-A modulation on
nociceptive afferent traffic or regulate the descending anti-nocicep-
tive system from peri-acqueductal grey, which suggests, in this case,
that AEDs could act at a distant site from the trigeminovascular sys-
tem. Pappagallo [2], suggests seven mechanisms of action, which
are shared by one or more of the newer AEDs that relate directly to
the pathophysiology of migraine, any or all of which may account
for its effectiveness. Moreover, there are other possible mechanisms
that may be important for migraine but do not seem to be important
in epilepsy, such as inhibition of the trigemino-cervical complex
directly, or by influencing the neural network that controls sensory
inputs, elevation of the cortical threshold for spreading depression
propagation, attenuation of glutamate release and others. A recent
Cochrane review for use of AEDs in migraine prophylaxis showed
that AEDs are efficacious for the prophylaxis of migraine. The mean
frequency was significantly reduced with AEDs as compared to
placebo and patients were more than twice as likely to have a 50%
or greater reduction in the number of migraine attack with AEDs
than with placebo. AEDs do not appear to give rise to an unexpect-
edly high rate of adverse events when used for migraine prophylax-
is, although clearly nausea is a problem with the use of valproate and
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paraesthesia with topiramate. Moreover, valproate is known to be
teratogenic. Gabapentin has beneficial effects but this drug needs
further evaluation. In conclusion, valproate, topiramate and, to a
lesser extent, gabapentin, have demonstrated efficacy in random-
ized, placebo-controlled trials. Lamotrigine may be effective at con-
trolling migraine aura, but has not demonstrated effectiveness at
controlling migraine headache.
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Until a few years ago, the prophylactic treatment of migraine relied
mainly on two classes of drugs: beta-blockers and calcium channel
antagonists. Recently, there has been great interest in the use of
antiepileptic drugs (AEDs) in preventing migraine. The use of
AEDs, however, must be carefully evaluated, balancing pros and
cons. AEDs employed in migraine prophylaxis can be divided into
three groups: group 1, includes drugs (e.g., valproic acid and topira-
mate) highly effective but with several side effects that can affect
compliance and quality of life; group 2, contains drugs (e.g.,
gabapentin) which are well tolerated but with marginal efficacy; and
group 3, consists of drugs (e.g., levetiracetam, oxcarbazepine, zon-
isamide) for which only anecdotal experience and case series are
available or drugs (e.g., lamotrigine) effective only in certain
migraine subtypes. So far, only group 1 drugs are a real option for
migraine prophylaxis, but, in our opinion, they should not be used as
first choice drugs. Their side effects, such as nausea, asthenia,
fatigue, memory complaints, weight gain or loss, tremor, dizziness,
vertigo, depression etc., limit their use to cases resistant to other,
better tolerated, drugs or to difficult-to-treat patients, such as those
with chronic migraine.
ROMAN JUNIOR MEMBERS MEETING
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Background and objective The nociception-specific blink reflex
(nBR) [1] explores the trigeminal nociceptive system, which is pivotal
in migraine pathophysiology. Migraine without aura patients (MO) are
characterized interictally by a deficient nBR habituation [2]. This could
be related to the habituation deficit of evoked cortical responses, which
has a familial character, or to central trigeminal sensitisation due to
repeated attacks.
We have compared nBR habituation in healthy volunteers (HV)
devoid of personal or family history of migraine, and in MO
patients and in HV with a family history of migraine in first degree
relatives (HV-F).
Subjects and methods We elicited the nBR by stimulating the right
supraorbital region with a custom-built electrode in 16 MO patients
between attacks, 15 HV and 14 HV-F. Only the responses obtained in
the ipsilateral orbicularis oculi will be considered here. Habituation
was measured as the % area-under-the-curve (AUC) decrease in 10
consecutive blocks of 5 averaged, rectified EMG responses.
Results nBR habituation was clearly reduced in MO and HV-F com-
pared to HV. AUC decreased between the 1st and 10th block by 55%
in HV, by 25.7% in MO (p=0.001 vs HV) and by 26.7% in HV-F
(p=0.04 vs HV). HV-F had an abnormal response more pronounced
than MO in the 1st four blocks where they showed potentiation
instead of habituation.
We found a positive intraindividual correlation between attack fre-
quency and habituation in MO (r=0.621; p=0.01).
Conclusions Migraine patients have interictally a deficient habituation
of the nBR, which is inversely related to attack frequency, as shown
here, and normalizes during the attack [2], suggesting that it is not due
to central trigeminal sensitisation. Surprisingly, a pronounced habitua-
tion deficit is found in asymptomatic individuals with a family history
of migraine. Deficient nBR habituation could thus be a trait marker for
the genetic predisposition to migraine.
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There is a general consensus on the crucial role played by activation of
the trigeminovascular system in the genesis of migraine attack.
The presence of cutaneous allodynia and of decreased pain thresholds
in the first trigeminal division (V1) on the headache side, as well as the
electrophysiological finding of an increased area of the nociception
specific blink reflex R2 (nBR) during migraine attacks suggest tempo-
rary sensitization in the spinal trigeminal pain system.
Recently, an interictal habituation deficit of the nBR was demonstrat-
ed in migraineurs with a custom-built electrode preferentially activat-
ing nociceptive Aδ fibres. This habituation deficit is in line with simi-
lar findings described for cortical evoked potentials.
Numerous migraine patients complained of cervical tenderness and
many of them also complained of the neck as the starting point of their
headache. In these cases, the headache surpassed the trigeminal level
and involved the first cervical innervations.
In the last decade a functional and anatomical connection between
trigeminal pathways and both motor neurons in the neck and upper
limb muscles was revealed.
It is well known that the trigemino-cervical reflex allows exploration
of the activity of the neck muscles innervated by the great occipital
nerve (GON), and that the blink reflex explores the activity of the first
trigeminal division.
Therefore, the aim of our electrophysiological investigation was to
study the activity of the trigemino-cervical complex in migraine and in
a group of healthy volunteers, through the simultaneous recordings of
the blink and trigemino-cervical reflexes. The latter are elicited by a
nociception specific electrode, which preferentially stimulated the Aδ
fibres. The area under the curve of the first 5 rectified responses, as
well as the time course of the 3 blocks of 5 responses in a habituation
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paradigm, were considered as parameters of investigation.
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Background It has been shown that migraine and temporomandibular
disorders (TMDs) share several epidemiological and clinical features.
Nevertheless, a pathophysiological link between diseases of the cran-
iomandibular system and cervical spine as well as between the cervi-
cal spine and migraine has been discussed.
Objective The aim of this study was: 1) to compare the clinical aspects
of migraine of patients who referred to the Odontostomatological
Department for their TMDs with those observed in patients who
referred to our Pain Centre for migraine; 2) to perform a multidiscipli-
nary approach in both groups of migraine patients to better understand
the potential pathophysiological link between migraine, cran-
iomandibular system and cervical spine.
Materials and methods According to IHS criteria (2004), we consec-
utively enrolled migraineurs with TMDs and migraineurs without
TMDs with the following inclusion criteria: 1) age between 18 and 55
years; 2) patients with no preventive therapy; and 3) patients studied
during the interictal phase. A control group composed of healthy sub-
jects was also recruited. All subjects of the study underwent the fol-
lowing clinical evaluations: 1) a clinical investigation of pericranial
muscle tenderness according to “Tenderness Total Score” (TTS); 2) a
clinical investigation of the temporomandibular system according to
“Craniomandibular Index” (CMI); and 3) physical examination of the
cervical spine (PECS) by also using a chiropractic approach.
Results We enrolled 35 migraine patients with TMDs (mean age
35±10 years), 32 migraine patients without TMDs (mean age 34±11
years) and 25 healthy controls (mean age 32±12 years). All migraine
patients showed significantly higher scores in TTS, CMI and PECS
than healthy controls (p<0.05). When we considered separately the
three groups of subjects, we found that those with TMDs showed high-
er scores in TTS, CMI and PECS scales than both those without TMDs
and healthy controls (p<0.05). Similar differences were observed when
we compared migraineurs without TMDs and healthy subjects
(p<0.05). Duration of illness, frequency of attacks as well as MIDAS
and HIT-6 scores were higher in migraineurs with TMDs than those
without (p<0.05).
Conclusions Our data suggest that TMDs and cervical spine disorders
are present in all migraineurs and that TMDs may represent a conse-
quence of “migraine pathology” and at the same time a risk factor for
high migraine disability. It may be important to pick out these clinical
features in a multidisciplinary manner for therapeutic implications and
to better understand the comorbidity and the pathophysiological link
between migraine, masticatory system disorders and cervical spine
dysfunctions.
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Introduction A chronic pain condition due to analgesic drug overuse is
more likely developed by migrainous than other headache patients:
about 10% of migrainous patients will develop as a complication of
their clinical picture a chronic form of headache sustained by medica-
tion-overuse (MOH). The biological basis of this difference could be
genetically determined. For instance, polymorphisms in genes regulat-
ing dopaminergic transmission were found associated with migraine,
alcoholism and drug abuse. It is also well known that psychiatric
comorbidity is more prevalent in MOH than migrainous patients. Many
studies, with contrasting results, were conducted in the past to explore
the association of MOH with the same genes known to be involved in
abuse behaviour or psychiatric disorders, comparing migrainous to
MOH patients. Here we propose a different approach to the problem,
looking for the clinical variability in MOH related to genetic variabili-
ty. If the commonly used approach is considered a categorical one (com-
paring two different diseases), the one we propose is a dimensional
approach (observing the variation of degree of a clinical parameter).
Materials and methods Seventeen MOH patients were recruited, and
diagnosis was confirmed after 2 months of drug discontinuation. All
the patients, after a complete headache history, were interviewed using
the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-
I), to obtain a categorical psychiatric diagnosis and completed the Beck
Depression Inventory (BDI), and the Cloninger’s Tridimensional
Personality Questionnaire (TPQ). After obtaining the patients’ written
informed consent, the genotype was determined for the DRD4 120bp
tandem repeat polymorphism, the wolframin His611Arg polymor-
phism, the BDNF G196A, and the 5HTTPLR polymorphism.
Results A linear logistic regression indicated that the examined poly-
morphisms are predictors of a high monthly consumption of analgesic
drugs. ANOVA analysis showed that the DRD4 polymorphism is relat-
ed to TPQ novelty seeking (NS) and BDI score, 5HTTPLR to TPQ
harm avoidance (HA) and BDI score, and wolframin His611Arg to
monthly number of analgesics and BDI.
Discussion Until now, all genetic research in MOH was based on geno-
type–phenotype association studies, looking for genetic differences bet-
ween migrainous and MOH patients. Some of these studies have not been
able to verify a genetic influence in MOH. We used a different quantita-
tive approach, preferred to the categorical one, to scan the influence of
genetic variability on MOH clinical features, which yielded promising
results.
Conclusions The clinical picture of MOH is influenced by the studied
genes. This evidence confirms the usefulness of dimensional tools
when seeking to associate biological markers with clinical disorders.
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Trigeminal Autonomic Cephalalgias (TACs) are a group of primary
headache syndromes including cluster headache (CH), paroxysmal hem-
icrania (PH) and short-lasting unilateral neuralgiform headache attacks
with conjunctival injection and tearing (SUNCT). These forms are clin-
ically recognized on the basis of their strictly unilateral, orbital or tem-
poral, severe stabbing pain, associated with one or more homolateral
autonomic symptoms and signs. Differential diagnosis is based on fre-
quency and duration of attacks, quality of pain and temporary pattern of
attacks. CH is more frequently found in males and is characterized by
attacks of strictly unilateral excruciating pain, lasting 15–180 minutes,
with a frequency between 1 every other day and 8 daily and grouped in
cluster periods followed by remissions. Attacks are accompanied by at
least one of the following: lacrimation, conjunctival injection, nasal con-
gestion, forehead and facial sweating, miosis, ptosis, rhinorrhoea or eye-
lid oedema on the side of the pain; moreover, during the attack the
patient is restless and “paces the floor”. PH is similar to CH, but more
prevalent among females, with shorter (2–30 min) and more frequent
attacks (more than 5 daily). SUNCT is a male preponderance headache
form with short (5–240 seconds) but very frequent (up to 200 daily)
attacks. Chronic PH and all forms of SUNCT can be precipitated by
mechanical triggers. When dealing with short-lasting headache forms,
primary and secondary neuralgias form part of the differential diagnosis.
Trigeminal neuralgia can be differentiated on the basis of lack of auto-
nomic signs and very short duration of pain (less than 2 minutes), pre-
cipitated from trigger areas or by trigger factors. CH attacks can be treat-
ed with sumatriptan 6 mg s.c., and a lower percentage of patients respond
to oxygen 100% at 7 l/min for 15–20 minutes. When required, vera-
pamil, lithium or valproate can be used for preventive treatment of acute
and chronic CH. PH responds completely to indomethacin 100 mg daily
(range 25–300 mg), which can be used as a diagnostic test. Antiepileptic
drugs (i.e., lamotrigine and topiramate) have shown efficacy on SUNCT.
Trigeminal neuralgia typically responds to carbamazepine and other
antiepileptics. Therapeutic guidelines represent a useful tool for the rou-
tine treatment of TACs and short-lasting neuralgias.
RELATION BETWEEN PATENT FORAMEN OVALE (PFO)
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A potential relationship between patent foramen ovale (PFO) and
migraine, in particular with migraine with aura (MA), has been recent-
ly suggested, based on the results of scarce epidemiological studies,
which demonstrated two to three times higher prevalence of this inter-
atrial abnormality in patients with MA than in controls. These obser-
vations support the hypothesis that PFO closure might be an alternative
and effective treatment option for patients with migraine, and in sever-
al recent studies, a decrease in migraine attacks has been observed.
However, these data must be interpreted with caution because of sev-
eral methodological shortcomings and potential biases, including recall
bias, use of anti-platelet drugs, and also the placebo effect of any
migraine treatment, in particular, those treatments that are invasive. A
large double-blind randomised trial on PFO closure in MA prophylax-
is is underway in the United Kingdom. At present, whether the associ-
ation is a mere comorbidity or there is a cause-effect relation remains
to be determined. Furthermore, the possibility that the PFO related MA
might be another example of symptomatic migraine having little to do
with migraine as a primary disorder (i.e., migraine without aura) can-
not be ruled out a priori. The available evidence suggesting that PFO
closure could be a treatment for migraine seems to be very simplistic.
WARNING HEADACHES
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Headache is a syndrome due to various etiologies. Most of the
patients usually suffer from migraine or other primary headaches.
However, headache can also be an early symptom of a life-threaten-
ing condition.
Subarachnoid haemorrhage (SAH) is a condition associated with high
morbidity and mortality. The cardinal symptom is headache (severe,
sudden, and occipital), which is present in nearly all patients; fre-
quently, motor deficits, altered consciousness and meningeal signs are
symptoms associated with headache. When bleeding is of minor enti-
ty, thunderclap-like headache could be the only symptom. This clinical
scenario needs to be evaluated with brain CT and CSF evaluation.
Spontaneous dissection of carotid and vertebral arteries preferentially
affects the fifth decade of life and accounts for 20% of all early onset
strokes. The typical patient presents with one-sided pain of the face,
head or neck (ipsilateral to dissection) followed hours or days later by
neurological motor deficits. Magnetic resonance imaging (MRI)
angiography can show the intramural hematoma and is replacing con-
ventional angiography as the diagnostic gold standard [1].
Cerebral venous thrombosis (CVT) is a vascular disorder that affects
young female adults. A prothrombotic risk factor is identified in
about 85% of patients with CVT. Headache is the most frequent but
non-specific symptom. Usually, focal neurological signs, seizures
and intracranial hypertension develop in one-half of patients. The
diagnosis should be considered in a young woman with recent unusu-
al headache or with stroke-like symptoms. The most sensitive tech-
nique is MRI venography.
Giant-cell arteritis is an inflammatory vasculopathy that affects
patients usually older than 50 years of age. Headache is frequent but
non-specific. Typical symptoms include ocular disturbances, jaw
claudication and scalp tenderness. Evidence of systemic inflamma-
tion is essential for the diagnosis. Temporal artery biopsy is the diag-
nostic gold standard, and corticosteroid therapy induces dramatic
improvement.
Early recognition of meningitis is imperative for appropriate therapy.
The classic clinical presentation of fever, neck stiffness and altered
mental status has a low sensitivity. However, almost all patients present
with at least two of the four symptoms of headache, fever, neck stiff-
ness and altered mental status. CSF examination is mandatory to con-
firm the clinical suspicion.
Idiopathic intracranial hypertension (IIH) is a condition of increased
intracranial pressure without clinical, laboratory or radiological evi-
dence of intracranial pathology [2]. The syndrome is typical of obese
women in childbearing age. The more frequent symptoms are attribut-
able to raised CSF pressure (headache, transitory visual deficits,
diplopia, and papilloedema). Cerebral MRI is the technique of choice,
followed by measurement of CSF pressure.
Headache can be a late or early symptom of brain tumour. Traditional
features of brain tumour are present in a minority of patients. Headache
is non-specific and tension-type-like. Long-lasting isolated headache
as the presenting symptom of a brain tumour is uncommon. The fea-
tures of headache suggestive of a space-occupying lesion are recent
and/or progressive course, nocturnal occurrence, worsening by postur-
al changes and any abnormal neurological sign.
Hypertensive encephalopathy represents an acute organic brain syn-
drome resulting from failure of cerebral vascular autoregulation. These
patients require emergency blood pressure reduction. Clinically this
condition is characterised by acute onset of confusion, headache, visu-
al disturbances and seizures.
Because of the wide differential diagnosis, the physician must be pre-
pared to perform a meticulous patient work-up, with thorough clinical
history and examination.
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Introduction Migraine and headache have been linked, mainly in ret-
rospective case-control studies, in general to a subsequent risk of cere-
brovascular stroke. Limited data from prospective studies have evalu-
ated the real association among various forms of headache and
increased risk of cerebro- and cardiovascular pathologies.
Materials and methods The AINAT (Italian Association of
Ambulatorial and Territorial Neurologists) boasts in Campania a vast
network of neurologists that have been involved in the management of
an epidemiological study in which the various forms of headache are
compared with cerebrovascular risk factors.
They have recruited about 100 (the study is still ongoing) subjects
affected by various forms of migraine. The risk factors considered
were: hypertension, diabetes mellitus, smoking, atrial fibrillation,
familiarity, left ventricular hypertrophy, carotid stenosis (>70%),
hypercholesterolemia, hypercysteinemia, and oral contraceptives.
Results Preliminary results seem to confirm, in agreement with the
limited data present in the literature, that migraine patients and, in par-
ticular, an elevated percentage of those affected by migraine with aura,
show a higher association with cardiovascular risk factors.
Discussion This study confirms that patients affected by migraine, par-
ticularly with aura, have a higher cardiovascular risk compared with
subjects without a history of migraine.
Conclusions Our data could offer a possible biological explanation for
the increased risk of ischemic stroke among subjects affected by
migraine. However, since the presence of these cardiovascular risk fac-
tors alone cannot fully explain the link between migraine and early
stroke and coronary heart disease, it seems clear that other etiological
factors must be involved.
ESTABLISHMENT OF A TERRITORIAL NETWORK FOR THE
STUDY OF MIGRAINE HEADACHE IN THE CAMPANIA
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In the Health Programme for 2003–2005, the Minister of Health, Dr.
Sirchia, introduced the so-called “devolution” plan. This has led to a
more rational and economic use of the health services offered with bet-
ter utilization of human resources and available funds, and has also led
to the search for new models and diagnosis assistance programmes dif-
fering from those available at the national level.
One of the characteristics of the Campania Region has been to signifi-
cantly increase, in recent years, its specialized assistance throughout
the territory, so as to have a more capillary presence of ambulatory
neurological services throughout the Region.
Based on these considerations, it has been decided, together with the
Regional Coordination of the Italian Society for the Study of
Headaches (SISC) of the Campania Region, to create a regional net-
work of first level ambulatory structures dedicated to migraine and
headaches, by using the neurologists working in the territory.
The first phase consisted of these specialists attending an educational
course organized together with the SISC Regional Section Campania
and the Italian Association of Ambulatorial and Territorial
Neurologists. The course had a basic didactic scope and served to stan-
dardize current methods such as patient charts.
The second phase, which is still ongoing, foresees that every local
health organization will activate an automatic system whereby each
patient requiring treatment for migraine headache will be sent to the
nearest specialist adhering to this network.
The third phase, which has not yet been implemented, will have each
ambulatory dedicated to the treatment of migraine headaches connected
to a 2nd and 3rd level centre for further diagnostic therapeutic problems.
It is worthy to note that the practical outcome of this type of organiza-
tion is zero management costs, while, at the same time, guaranteeing:
- a uniform and codified diagnostic system throughout the territory;
- improvement in the diagnostic treatment offered;
- an efficient filter for the Headache Centres which will be freed from
routine work that engulfs current waiting lists;
- and also the economic aspect.
HEADACHE ACCORDING TO SCIENTIFIC TRADITIONS OF
THE SALERNO MEDICAL SCHOOL
D. Cassano
Neurological Outpatients Department, ASL SA 1, Nocera Inferiore,
Salerno, Italy; e-mail: info@domenicocassano.it
The origins of the Salerno Medical School go back to the beginning of
the Medieval Age. Legend attributes its foundation to four doctors, the
Hebrew Helinus, the Greek Pontus, the Arab Adela and the Latin
Salernus, epitomizing that the Ars Medica of Salerno was born from
the confluence of these four cultures.
In the scientific world of the 12th century – corresponding to the “gold-
en period” – various personalities stand out: Masters as Bartolomeo,
Ferrario, Salerno and Nicolò Salernitano wrote a series of exhaustive
books on general pathology, diagnosis and pharmacological therapy
widely used at the School.
Master Salerno, in his work Catholica, distinguishes severe headache,
in which the pain is “total” from migraine, which only affects one half
of the head [1].
Master Bartolomeo, in his manual Pratica, defines migraine as “passio
capitis in media parte aut in destra aut in sinistra” [2].
Pathogenesis can always be explained by the humoral theory: various
external and internal factors are quoted, which can affect and change
the organic humours. The qualitative distinction of pain was given
attention: acute, periodic, irregular, persistent, continuous and grave.
The distinctive characteristics for the “blood headache” were: sensa-
tion of burning in the head, heaviness of the forehead, pulsation of the
temples and dilatation of the veins.
The diagnosis was aided by a rich urinary semeiology.
One of the therapies for the “blood headache” was bleeding or appli-
cation of blood-sucking leeches in different parts of the head. The use
of purging agents, in particular, diets and remedies (such as coffee)
were also advised, according to the type of headache.
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Introduction Headache is frequently reported by patients affected by
connective tissue diseases (CTDs), especially patients with Systemic
Lupus Erythematosus (SLE) or Behcet’s disease (BD). Virtually all
kinds of headaches ranging from migraine to tension-type are repre-
sented. Establishing whether a headache has a specific link with the
underlying disease is often a difficult clinical challenge, because
headache can have a number of causes other than CTDs. For instance,
it may be a pre-existing condition or may be the consequence of a psy-
chological reaction to a chronic, disabling disease.
Matherials and methods Migraine of SLE patients is still a debated
entity and evidence of brain impairment is controversial. SLE-
migraine has been investigated as a prototype of headache complicat-
ing CTDs. Perfusion SPECT was performed to investigate brain
impairment in SLE patients with migraine-like headache either since
diagnosis or later in the course of the disease. Eighteen SLE patients
(mean age: 40.8±13.6 years) matching these requisites underwent brain
SPECT with 99mTc-HMPAO in the interictal period. EEG and MRI
were performed in twelve and ten patients, respectively. SPECT was
analyzed through visual and asymmetry combined analysis as well as
by voxel-based statistical analysis (Statistical Parametric Mapping,
SPM99) versus a control group of matched normal subjects (height
threshold: p=0.01).
Results Fifteen (83%) patients disclosed focal hypoperfusion, often in
keeping with the main side of pain location, whereas both EEG and
MRI gave a positive result in 50% of cases. By voxel-based analysis,
significant hypoperfusion was found in 8 (44%) patients, either later-
alized to one side or localized to the anterior cingulate cortex (ACC),
independent of pain location.
Conclusions Brain perfusion SPECT is a sensitive tool to disclose
brain impairment in SLE-related migraine, although the mechanisms
of brain damage remain to be elucidated. Besides confirming focal
hypoperfusion in a part of the patients, statistical analysis highlighted
in four patients interictal hypofunction of ACC, a key structure in the
midline network for the cortical elaboration of pain. An integrated neu-
roimaging and neurophysiological approach is required to disclose the
pathophysiological correlates of headaches during CTDs.
CARDIOVASCULAR DISEASES AND HEADACHE
A. Carolei, S. Sacco
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A complex relationship exists between cardiovascular diseases and
headache. In particular, stroke has been associated with both migraine
and nonmigraine headache [1].
It has long been debated whether migraine might be considered a pos-
sible risk factor for cerebral ischemia. To describe this association, a
clearly clinically defined stroke syndrome must occur remotely in time
from a typical attack of migraine [1]. A history of migraine may con-
tribute to the risk of stroke through the presence of activation of the
clotting system and/or cerebral vasospasm. Several case-control stud-
ies investigated the relationship between migraine and stroke and
showed that migraine was an independent risk factor for stroke with
odds ratios ranging from 2.8 to 4.3 [2]. The association between
migraine and cerebral ischemia was limited to women below the age of
35 years, and odds ratios were higher in patients with a history of
migraine with aura than in patients with a history of migraine without
aura. Other risk factors for stroke might interact with the migraine-
induced pathogenesis. Concurrent use of oral contraceptives, high
blood pressure, or smoking had more than multiplicative effects on
odds ratios for ischemic stroke associated with migraine. Moreover,
migraineurs, particularly with aura, have a higher cardiovascular risk
profile than individuals without migraine [1]. In fact, compared to con-
trols, migraineurs were more likely to smoke, less likely to consume
alcohol, and more likely to report a parental history of early myocar-
dial infarction [1].
Another condition that might help explain and contribute to the asso-
ciation of migraine and stroke is patent foramen ovale (PFO) [1].
PFO has been associated with cryptogenic stroke episodes caused by
paradoxical embolism. Moreover, PFO is over represented in
migraineurs, and conversely, the frequency of migraine in PFO-asso-
ciated cryptogenic stroke is twice than expected. Therefore, the
excess stroke risk of migraine could result from the association with
PFO through paradoxical embolism. Closure of the patent foramen
has been associated with suppression of migraine attacks, possibly
because a venous to arterial passage of activated platelets or chemi-
cal substances may trigger headache by overwhelming the filtering
capacity of the lung.
Recognition of the interaction between migraine and cardiovascular
disorders as well as comorbid vascular risk factors in migraineurs is
important since it may impose therapeutic challenges, life-style
modifications, and further investigation to reduce the global vascu-
lar risk.
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Headache is the most common neurological symptom presenting to
family physicians, neurologists, and to the Emergency Department.
Some endocrinological disturbances can be associated with headache.
Recently, in chronic migraine patients with medication-overuse, a
reduction of growth hormone (GH) and TSH responses after GHRH
and THRH as well as an increase of ACTH and cortisol levels after
hCRH have been described. In contrast, headache can be an important
symptom of disease of the endocrine system.
Pituitary tumours are often associated with troublesome headache,
both chronic and episodic. Although dural stretch and cavernous sinus
invasion are widely considered the mechanism responsible for pain,
evidence demonstrates that headache is a recognized feature of small,
non invasive functional tumours, and pituitary size itself is unrelated to
headache, suggesting that tumour activity may be important in some
forms of pituitary tumour-associated headache. The commonest
tumours are prolactinomas, which are microadenomas in 52% of cases,
and GH-secreting pituitary tumours, which are 68% macroadenomas.
Short-lasting unilateral neuralgiform headache with conjunctival injec-
tion and tearing (SUNCT) has been found only in these kinds of pitu-
itary tumours, and primary stabbing headache is also more common in
these two groups. In acromegaly, headache may occur in 55%–85% of
presentations as well as in about 60%–70% of prolactinomas.
The mechanism of pituitary tumour-associated headache is currently
unknown, and also, the involvement of some neuropeptides as in pri-
mary headache is not supported.
Headaches due to endocrine diseases in childhood are rare, but any
child with chronic headaches should be given serious consideration.
The most serious etiology is a tumour of the hypothalamic-pituitary
region such as craniopharyngioma, characterized by headache, visual
disturbances, GH and gonadotropin failure.
The role of thyroid dysfunction in headache remains uncertain. In
102 hypothyroid patients, approximately 30% had bilateral, continu-
ous, non pulsatile headache, which disappeared with hormone thera-
py. In contrast, a larger population-based study reported that TSH
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was lower amongst headache sufferers than in those without
headache complaints.
The association between hypertension, including endocrine hyperten-
sion, and headache has been a contentious issue. Recently, it has been
found that headache and hypertension classified at moderate to severe
stage were not associated. On the other hand, pheochromocytoma is
related to a paroxysmal catecholamine release from the tumour, and
headache occurs in more than 80% of patients: it may be severe, frontal
or occipital and throbbing or steady.
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Introduction Epidemiological studies show that a number of chron-
ic/recurrent pain conditions, both somatic (fibromyalgia-FMS) and vis-
ceral (dysmenorrhea-DYS, Irritable Bowel Syndrome-IBS) are signif-
icantly more frequent among headache sufferers than in the general
population. Conversely, the percentage of FMS patients, as well as of
DYS and IBS patients who also suffer from headache is significantly
higher than that of headache patients in the population not affected
with these diseases. These data support the notion of some common
underlying mechanism for the pain of all these conditions, at least in
subsets of patients. Based on these premises, the aim of the present
study was to evaluate and compare the state of general sensitivity to
painful stimuli in different groups of headache patients concomitantly
affected or not with one or more of the chronic/recurrent pain condi-
tions described above.
Methods Four groups of headache patients (H) were considered: 1)
without concomitant FMS/DYS/IBS; 2) with FMS; 3) with DYS or
IBS; 4) with FMS + DYS and/or IBS. All groups were age- and sex-
matched. Patients of the various groups did not differ significantly
regarding the number of years they had been suffering from headache
(tension-type or migraine) and mean number of monthly attacks.
Patients of the FMS groups did not differ significantly regarding the
number of years they had been suffering from diffuse chronic muscu-
loskeletal pain. In all groups, pain thresholds to electrical stimulation
in skin, subcutis and muscle were measured in multiple body sites (del-
toid, trapezius and quadriceps) not coinciding with the areas of sponta-
neous pain from any disease. Measurement was made in the pain-free
interval and with a wash-out of at least 72 hours from any drug poten-
tially interfering with pain sensitivity.
Results The lowest electrical thresholds at all body sites and all tissues
were found in group 4 (H+FMS+DYS/IBS), followed by group 2
(H+FMS), group 3 (H+DYS/IBS) and group 1 (H), in that order. The
trend for variation among groups was significant (p<0.01).
Conclusions The results indicate a progressively higher state of gener-
alized hypersensitivity towards painful stimuli in headache patients
when concomitant chronic/recurrent pain conditions are present. They
suggest different levels of central sensitization in subgroups of
headache patients, which are expressed clinically with progressively
higher manifestations of chronic/recurrent pain conditions, both somat-
ic and visceral, but all typically characterized by the lack of any iden-
tifiable organic cause, such as FMS, DYS or IBS.
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HEADACHES: PATHOGENETIC ASPECTS
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Background and aims In migraineurs, nitroglycerin (NTG) induces
severe delayed headache, resembling spontaneous migraine attacks.
The temporal summation threshold (TST) of the nociceptive flexion
reflex (NFR) is considered an objective method that offers the poten-
tial to examine pain processing in the central nervous system. The aim
of the present study was to evaluate the NFR-TST during NTG-
induced migraine. 
Methods Twenty-nine patients (19 females and 10 males, mean age
36.2±7.67, range 18–55 years), suffering from migraine without aura
(1.1 ICHD-II, 2004) were selected. Headache was induced by sublin-
gual administration of 0.9 mg of NTG. NFR-TST and the subjective
painful sensation were measured before and 30, 60, 120 and 240 min
after drug administration.
Results All patients exhibited a significant (p<0.01) reduction of the
NFR-TST 120 min after drug administration. In particular, a sub-group
of patients experiencing severe attack showed a significant (p<0.01)
reduction of NFR-TST at both 60 and 120 minutes.
Conclusions NTG appears to support a reliable experimental model of
migraine, based on the neuronal effects on the integrative-nociceptive
structures. The NFR-TST facilitation during NTG-induced attack
reflects an extracephalic generalized hypersensitivity of pain pathways
during migraine attack that provides the susceptibility for triggering
migraine attack and probably its persistence.
CAN HIGH-FREQUENCY rTMS RESTORE NORMAL INTRA-
CORTICAL EXCITABILITY IN MIGRAINE WITH AURA?
EFFECTS OF PRIMING STIMULATION ON 1 HZ rTMS
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Introduction We showed that motor intracortical inhibition (ICI) is
reduced in patients affected by migraine with aura. Consequently, 1 Hz
rTMS-induced paradoxical effects increase motor intracortical facilita-
tion (ICF) in these patients. In conditions of enhanced excitability due
to reduced inhibition, high frequency rTMS acts by potentiating intra-
cortical inhibition [1, 2].
On this basis, we used high frequency priming stimulation of the motor
cortex to enhance intracortical inhibition and reverse paradoxical facil-
itation induced by 1 Hz rTMS in migraine with aura patients. To dif-
ferentiate the possible different effects on ICF or ICI, we applied the
double-pulse TMS technique that allows evaluation of the intracortical
circuits.
Methods Seven patients with migraine with aura and six controls
underwent a paired-pulse TMS paradigm to evaluate ICI and ICF of the
motor cortex before and after a conditioning high frequency rTMS fol-
lowed by 1 Hz rTMS train. Patients were examined interictally at least
48 h before or after an attack. The hot-spot for the right abductor pol-
licis brevis (ABP) was checked by mean of a figure-of-eight coil and
motor threshold (MT) on this recorded point. ICI and ICF were
assessed by means of a conditioning stimulus (CS) at 80% MT fol-
lowed by a test stimulus (TS) at 120% MT, with two different inter-
stimulus intervals: inhibitory: 2 msec and facilitatory 10 msec. Priming
rTMS (900 stimuli at 10 Hz frequency, in trains of 50 stimuli separat-
ed by 45 s intervals) was followed by a single 15-min-long train (900
stimuli) at 1 Hz rTMS. rTMS was delivered at 90% of MT over the hot-
spot. Motor evoked potential (MEP) amplitude of TS post-rTMS was
expressed as percentage of baseline MEP. Amplitude of MEPs record-
ed at 2 and 10 ms ISIs before and after rTMS were expressed as per-
centage of change from the respective mean TS alone. 
Results At baseline, ICI was significantly lower in migraineurs with
respect to controls. In healthy controls, MEP amplitude and ICF were
significantly reduced by priming 1 Hz treatment with respect to base-
line values. In contrast, the priming stimulation significantly increased
ICI in migraineurs, leaving quite unchanged MEP amplitude and ICF
values with respect to baseline.
Conclusions In migraineurs, rTMS-priming potentiates intracortical
inhibition and reverses the paradoxical increase in ICF observed with
1 Hz rTMS [1]. These findings strengthen the hypothesis of reduced
inhibition in migraine with aura and might open perspectives for new
treatment strategies.
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Introduction In a previous study a different modulation of trigeminal
laser evoked potentials (LEPs) was detected in migraine patients vs
controls during topical application of capsaicin on the supraorbital
skin. The inhibiting central effect exerted in controls by capsaicin on
trigeminal LEPs was less evident in migraine, suggesting a disturbed
pattern of pain modulation at the cortical level, which may subtend the
onset and persistence of migraine [1].
Objective The aim of the present study was to detect the functional
changes of trigeminal LEPs during topical application of capsaicin
over a remote site of the body in migraine patients outside the attacks
vs. non migraine healthy controls.
Methods Ten patients suffering from migraine without aura (ICHD-II,
2004), free from pain and symptomatic drugs for at least 72 hours and
not taking preventive treatment for migraine were selected for the
study. Eight age- and sex-matched healthy controls were also exam-
ined. LEPs were recorded by 31 scalp electrodes, referred to the
nasion, stimulating the dorsum of the right hand and the right supraor-
bital zone in basal conditions and 30 minutes after application of 3 mL
of 3% capsaicin in a cream base (Teofarma), which was applied topi-
cally on the entire surface of the dorsum of the left hand, within an area
J Headache Pain (2006) 7:282–310
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of at least 6 cm2. The subjective pain induced by both laser stimulus
and capsaicin was rated by a 0–100 visual analogue scale (VAS).
Results In normal subjects, the N2-P2 vertex complex showed
32.3%±3.4% rate of amplitude reduction at the trigeminal level and
30.2%±7.8% at the hand level, caused by remote capsaicin application.
In migraine, the rate of N2-P2 amplitude reduction at the hand level
was similar to controls (31.3±9.8; F=0.67, n.s), while it was signifi-
cantly lower at the face level (2.1%±4.5% F=16.5, p<0.001). The N1
amplitude was not significantly modified by capsaicin, when both the
face and the hand were stimulated. N2-P2 amplitude modifications
were reversed after capsaicin removal in both patients and controls.
Discussion The N2-P2 amplitude reduction induced in normal sub-
jects at both the hand and face levels could be due to a diffuse nox-
ious inhibitory control and to the distraction induced on LEPs by
concurrent capsaicin-induced pain. Both the pain-inhibiting mecha-
nisms appeared inadequate in reducing experimental trigeminal pain
in migraine patients.
Conclusions In migraine patients trigeminal pain is not inhibited by
the anti-nociceptive endogenous control system.
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Introduction Primary headaches have an intimate relationship with
sleep. Although strictly sleep-related headaches, such as hypoxemia-
related headache, cluster headache (CH) and hypnic headache (HH) are
less prevalent and more easily recognized, other primary headaches are
often impacted to some degree by sleep.
Objective The aim of the study was to describe the results of sleep
studies performed in different forms of primary headache and their
pathophysiological correlates.
Methods Patients underwent a full-night laboratory nocturnal video-
polysomnography following adaptation. Patients slept in a sound-proof
room. A wrist actigraphic study was also performed in patients with
HH and CH.
Results Hypnic Headache: The most relevant finding regarding sleep
structure was the quantitative reduction of rapid eye movement (REM)
sleep. Actigraphic recordings showed that the index of motor activity
was consistently increased following the start of effective drug treat-
ment. This might constitute further support for the hypothesis of
hypoarousal as a pathogenic mechanism for HH.
Cluster Headache: No modifications of polysomnographic arousal
parameters across the recordings were observed in the acute phase,
when compared with the interictal phase, except for the arousal index
in REM sleep. At a microstructural level, the arousal index calculated
in REM was much lower in the nights in which attacks occurred.
Actigraphic recordings revealed, moreover, that the patient’s sleep-
wake schedule was irregular during the CH period and progressively
modified, becoming more regular after remission. All the observed
modifications are consistent with an abnormal function of the posteri-
or hypothalamus.
Sleep-related migraine: Evaluation of the pattern of arousal from sleep
in a group of patients affected by sleep-related migraine showed a
lower continuous airway pressure (CAP) rate in non REM sleep and,
in particular, a lower number of A1 phases (low-frequency, high-ampli-
tude EEG bursts) compared with controls. Migraineurs also showed a
lower index of high-frequency EEG arousals during REM sleep.
Reduction in the CAP rate indicates a lower level of arousal fluctuation
in non REM sleep. The reduced arousal index in REM sleep suggests
a dysfunction in neural structures involved in both the control of REM
sleep and the pathophysiology of migraine, such as the hypothalamus
and the brainstem.
Conclusions We believe that sleep studies, including both macro- and
microstrucural analysis of sleep and actigraphy, may be useful in clar-
ifying the pathogenic mechanisms of primary headaches.
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Objective The aim of this study was to assess the presence of destabi-
lizing inputs that, by acting on vestibulospinal pathways, are able to
induce postural changes and imbalance conditions in migraine patients
during the interictal period, by computerized static stabilometry.
Material and methods Twenty patients were studied (14 F and 6 M;
mean age 32.6 years) affected by migraine without aura (MO)
according to ICHD-II, 2004 criteria and were compared with 35 con-
trols. The stabilometric parameters considered were: statokinesigram
surface (S) in eyes open (EO) and closed (EC) conditions, EC with
head retroflexion (ECR), EC condition with occlusal bite, and opto-
kinetic stimulation (OKN). Regarding the OKN condition, we used
two different kinds of stimulation: the “look” (active) type, in which
the patient must follow with the eyes the visual stimulation running
through the monitor, and the “stare” (passive) type, in which the
patient must look at a fixed point on the monitor and not the visual
stimulation crossing the monitor.
Results We found a significant statistical difference (p<0.045)
between patients and controls in only one stabilometric condition, the
OKN stimulation. In particular, the OKN “stare” stimulation was
more destabilizing for migraine patients than for controls, inducing
conditions of imbalance.
Conclusions In MO patients, the alterations appear under optokinetic
stimulation and support a control impairment in involuntary oculo-
motility of central origin. This is suggested by recent stabilometric
findings of our group [1].
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1A. Fiorentini, 1L. Tubani, 1R. Valente, 2E. Celletti, 1L. Baratta, 
1A. Perciaccante, 2M. Granata
1Cardiology and 2Headache Centre, Department of Clinical Medicine,
University of Rome “La Sapienza”, Rome, Italy; e-mail:
massimo.granata@uniroma1.it
Introduction Some studies suggested that migraine is associated with
an impaired activity of the autonomic nervous system [1]. It is known
that the subject with migraine has a reduction in R-R intervals and a
reduction in the increase of the heart rate during “handgrip” in com-
parison with the control group [2].
Objective The objective of our study was to analyse in subjects with
migraine with aura the heart rate variability (HRV), evaluated in time
and frequency domains by means of ECG holter during 24 hours.
Patients and methods We recruited subjects with migraine with aura
during headache-free periods, without treatment. The control group
consisted of age- and sex-matched healthy control subjects.
Autonomic nervous system function was evaluated by HRV analysis
during 24-hour ECG recording, SDNN (millisec, total autonomic
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activity), RMS-SD (millisec parasympathetic component), low fre-
quency (LF, modulated by the sympathetic system) and high fre-
quency (HF, mediated by the parasympathetic system) were calculat-
ed. The day was divided into two periods: diurnal (7–12 a.m.) and
nocturnal (0–6 a.m.).
Results Autonomic function measures: SDNN day (millisec): migraine
146.16±28.41, control 175.92±30.13, p=0.38; SDNN night: migraine
116.26±22.23, control 121.98±26.59, p=0.63; RMS-SD day:
121.98±26.59, control 121.98±26.59, p<0.001; RSM-SD night:
migraine 48.19±15.28, control 48.19±15.28, p=0.75; LF day (normal-
ized unit): migraine 61.20±2.27, control 69.90±8.34, p=0.003; HF day:
migraine 38.80±2.27, control 22.95±7.31, p=0.002; LF night: migraine
55.13±10.72, control 34.92±5.99, p=0.03; HF night: migraine
44.95±10.69, control 58.62±6.77, p=0.03.
Conclusions In subjects with migraine, the data showed the increase
of parasympathetic activity during the day and the predominance of
the sympathetic component at night with loss of circadian rhythms.
It remains unclear if the alteration of the autonomic nervous system
is a risk factor for migraine, or instead, is a consequence of the
pathology.
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Background Recently, studies using FDG-PET techniques have
reported hypoactivation of nuclei belonging to the “pain network” in
patients with medication-overuse headache (MOH). In particular, it
has been shown that the ventral posteromedial thalamic nuclei were
hypometabolic in migraineurs suffering from MOH [1]. Since the
high-frequency oscillations (HFOs) embedded in the common
somatosensory evoked potentials (SSEPs) recording reflect spike
activity in thalamo-cortical cholinergic fibers (early HFOs phase) and
cortical inhibitory GABA-ergic interneurons (late HFOs phase), we
studied a group of MOH patients with this neurophysiological
approach.
Materials and methods Right median nerve SSEPs were recorded
from the contralateral parietal area in 9 patients affected by medica-
tion-overuse headache (MOH, ICHD-II 8.2) and in 9 healthy volun-
teers (HV). Digital off-line filtration (band-pass between 450 and 750
Hz) was employed in order to extract the high frequency (600 Hz)
oscillations embedded in the broad-band SSEPs.
Results The amplitudes and latencies of conventional broad-band
SSEPs showed no between-group differences. After applying the digi-
tal filter, we found a significant decrease of maximal amplitude
(p=0.030) and area under the rectified curve (p=0.038) of the early
SSEP HFO component in patients compared to HV. By contrast, no dif-
ference was found for the late SSEP HFO component.
Discussion These results show thalamo-cortical hypoactivity in
patients with MOH. This is in line with the previous FDG-PET study
showing thalamic hypometabolism. The absence of SSEP HFO late
component changes suggests normal intracortical inhibition at the level
of the somatosensory cortex in this patient group.
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Background Experimental findings from animal pain models support
the role of nerve growth factor (NGF) and brain-derived neurotrophic
factor (BDNF) as putative candidates intervening in the pathogenesis
of chronic pain. Few studies have been carried out to establish their
role in maintaining the pain states in humans and their involvement in
chronic migraine (CM) and fibromyalgia [1, 2].
Objective The present study was aimed at investigating cerebrospinal
fluid (CSF) levels of NGF and glutamate measured by sensitive
immunoassay and by HPLC respectively in CM patients and patients
affected by primary fibromyalgia syndrome (PFMS), comparing values
with those of 20 age-matched control subjects.
Material and methods Twenty consecutive patients suffering from
CM according to ICHD-II classification and attending the Headache
Centre of the Neurologic Clinic of the University of Perugia were
admitted to the study.
A further patient group included 20 patients affected by PFMS.
Diagnosis of PFMS was made according to the American College of
Rheumatology Criteria (1990).
All patients were admitted to the Neurologic Clinic to undergo lumbar
puncture. Control CSF specimens were obtained from 20 age-matched
subjects who underwent lumbar puncture for diagnostic purposes. In all
subjects CSF and blood tests excluded CNS or systemic diseases. All con-
trol subjects were drug-free for at least two months and none of them were
taking any medication at the time of CSF sampling nor had a personal or
family history of migraine nor suffered from tension-type headache. None
of the above controls developed post-lumbar puncture headache.
Results Significantly higher levels of both neurotrophins were found
both in patients with CM (p<0.0001, p<0.0005) and PFMS (p<0.001
and p<0.001) compared with control subjects, without significant dif-
ferences between the two patient groups. Both patient groups had sig-
nificantly higher CSF levels of glutamate than controls (p<0.001 and
p<0.003, respectively). A significantly positive correlation emerged
between CSF values of BDNF and those of NGF (r=0.61, p<0.001;
r=0.53, p<0.01) and glutamate (r=0.44, p<0.02; r=0.51, p<0.01) in
both CM and PFMS patients, respectively.
Conclusions These findings suggest the possibility of an NGF-mediat-
ed up-regulation of BDNF in central sites involved in long-term sensi-
tization, which plays a key role in persistent, chronic painful condi-
tions, such as CM and fibromyalgia. NGF might indirectly exert its
effect through enhancement of glutamatergic transmission via BDNF.
The above mechanisms could account for sustained central sensitiza-
tion in both chronic pain states but cannot be considered specific for
just one of these two disorders. They may rather be considered expres-
sion of the pathogenic mechanisms underlying chronic pain per se.
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ENDOCANNABINOIDS IN PLATELETS OF MEDICATION-
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Background Based on experimental evidence of the antinociceptive
action of endocannabinoids [1], we hypothesized a dysfunction of this sys-
tem in medication-overuse headache (MOH) and chronic migraine (CM).
Objective To test this hypothesis, we determined the levels of the
endogenous cannabinoid 2-arachidonoylglycerol (2-AG) and arachi-
donoylethanolamide (anandamide, AEA) in platelets of 15 patients
affected by MOH according to ICHD-II and 15 patients with CM with-
out medication overuse, as well in 15 age-matched control subjects. We
also investigated the intra-platelet levels of serotonin.
Methods Endogenous cannabinoids were purified from platelet pellets
by high-performance liquid chromatography (HPLC), and quantified
by isotope dilution gas-chromatography/mass-spectrometry. Serotonin
levels were also measured by HPLC.
Results In both patients and controls levels of 2-AG were about 20-
fold greater than that of AEA. 2-AG and AEA levels were signifi-
cantly lower in medication overuse and CM patients than in controls
(p<0.02 and p<0.04, respectively), without significant differences
between the two groups. Serotonin levels were strongly reduced in
both patient groups (p<0.001 and p<0.002, respectively) and were
significantly correlated with 2-AG and serotonin levels (r=0.48,
p<0.01 and r=0.46, p<0.02).
Conclusions The finding of reduced 2-AG and AEA in platelets corre-
lated with reduced serotonin levels may reflect an imbalance in the
endocannabinoid system, which occurs in parallel with serotonergic
dysfunction in these two chronic head pain conditions. The parallelism
in the failure of these two systems is in line with experimental findings
of mutual interaction of 2-AG and 5-HT in modulating different sig-
nalling pathways, which can also be relevant for pain control.
Variations in activity of AEA transporter and AEA hydrolase in periph-
eral platelets, as recently shown in female but not male migraineurs
[2], remain to be established in MOH and CM.
This study has been partially supported by the Lega Italiana
Cefalalgici.
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Introduction The wolframin gene (WFS1) is mentioned as being possi-
bly responsible for a heterogeneous combination of psychiatric disorders;
in a number of studies it has been suggested that common variants in
WFS1 are associated with psychiatric illnesses. For instance, homozygous
carriers of the His611Arg polymorphism (R/R genotype) are at increased
risk of attempted suicide and generally score higher than non-R/R indi-
viduals on both novelty seeking (NS), impulsivity and depression scales.
It is well known that psychiatric comorbidity is widely represented in
medication-overuse headache (MOH). In the present study we investigat-
ed the wolframin His611Arg polymorphism in a sample of MOH patients
who submitted to psychiatric, psychometric and clinical assessment.
Materials and methods Fifty-two consecutive, unrelated MOH
patients (42 women and 10 men) were recruited. Mean age was
46.37±11.35 years; mean analgesic-drug consumption was 44.81±28.24
doses/month. All the patients were interviewed using the Structured
Clinical Interview for DSM-IV Axis I Disorders (SCID-I), to obtain a
categorical psychiatric diagnosis, and completed the Beck Depression
Inventory (BDI), a self-reported questionnaire for a dimensional assess-
ment of depressive symptoms. The BDI mean score was 13.15±10.01.
Thirty-seven lifetime and 36 current psychiatric disorders were diag-
nosed. After obtaining the patients’ written informed consent, the geno-
type for the wolframin His611Arg polymorphism was determined.
Results R/R genotype carriers (10 patients) showed significantly high-
er drug consumption (62.3±35.35 vs. 40.64±25.00 doses/month;
t=2.266, p=0.028) and more severe depressive symptoms on the BDI
questionnaire (19.40±10.57 vs. 11.66±9.40; t=2.285, p=0.026) than
non-R/R individuals (42 patients). No significant correlation was
found between monthly drug consumption and depression score in our
MOH patients (r=0.137, p=0.334), even when their genotype was con-
sidered (R/R r=0.172, p=0.635; non-R/R r=0.004, p=0.979).
Discussion Even if it has been reported that depression predicts dis-
ability and increased drug consumption in headache patients, in our
MOH patients we found no direct correlation between depression
scores and monthly intake of analgesic drugs. We believe that the
increased drug consumption observed in R/R carriers is a consequence
of increased impulsivity and NS traits, irrespective of depression.
Conclusions WFS1 R/R genotype appears to be an aggravating factor
in drug overuse in MOH patients.
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Objective Our aim was to analyse the diagnosis, prescribed medica-
tions and examinations conducted on patients attending a specialized
Headache Centre of the Calabria Region over a one-year period.
Methods An audit of clinical records of patients attending the
Headache Centre of the “Pugliese-Ciaccio” Hospital in Catanzaro,
from January 2005 to January 2006, was conducted. Data regarding
diagnosis, current medications, prescribed medications, and examina-
tions conducted were collected.
Results Four hundred and fifteen patients attended the clinic during the
audit period. Two hundred (48%) of them were diagnosed with chron-
ic daily headache (CDH), 160 (39%) with migraine, 32 (8%) with clus-
ter headache, and 19 (5%) with neuralgia headache TACs. All other
diagnoses involved only one patient (<1%) in each case. Most common
medications used by patients with CDH at the time of initial consulta-
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tion were: analgesics (64%), prophylactic drugs (17%), triptans (14%),
and diazepam (3%). Following the consultation, prophylaxis was pre-
scribed for 51% of patients while triptans for only 1%. At the time of
initial consultation, patients with migraine were taking: analgesics
(59%), triptans (26%), prophylactic drugs (19%), and ergotamine
(2%). Following the consultation, prophylactic drugs was recommend-
ed for 75% of patients, triptans for 49%, manipulation for 13%, and
analgesics for only 10%. Examinations were arranged for 19 patients
(9%) and were negative in all cases.
Conclusions Most patients attending our headache centre were suffer-
ing from CDH or migraine. Cluster headache was rarely diagnosed.
Despite this being a secondary care clinic, most patients were taking
analgesics and relatively few specific acute therapies or prophylactic
drugs. In contrast, triptan consumption markedly increased following
consultation. In all clinical cases, further examinations were negative
and were primarily conducted to reassure the patients.
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Introduction Migraine is a highly prevalent and disabling disease that
is substantially underdiagnosed in primary care. Recently, the ID
Migraine, a self-administered questionnaire, consisting of only three
items, was shown to be a valid and reliable screening instrument for
migraine in primary care in the U.S.A. The aim of the present study
was to validate an Italian version of the “ID Migraine” questionnaire.
Methods A total of 222 consecutive headache patients referring to eight
headache centres in Sicily (Italy) completed an Italian version of the ID
Migraine. The responses to the questionnaire were compared with the
diagnosis of headache made by a headache specialist who did not know
the results of the questionnaire. Sensitivity, specificity, positive and neg-
ative predictive value and accuracy level for migraine were calculated.
Results The statistical analysis on 222 patients examined showed a
very good performance of the ID Migraine with high sensitivity: 0.95
(95% CI, 0.91–0.98), specificity: 0.72 (95% CI, 0.62–0.82) and posi-
tive predictive value: 0.88 (95% CI, 0.82–0.93). ID migraine also
showed a very good accuracy level: 0.87 (95% CI, 0.83–0.92).
Conclusions This study demonstrated “ID Migraine” to be a valid tool
for migraine screening also in Italian patients referring to headache
centres. If confirmed in a primary care setting, these results would
establish the “ID Migraine” as a valid screening instrument for
migraine in the Italian population.
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HEADACHE DIARY
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Introduction One of the most important tools in the approach to a
headache patient is the headache diary, whose compilation is a funda-
mental step in the formulation of the definitive diagnosis and in the
organization of a therapy, which must be appropriate to the individual
patient. The Headache Centre of the University of Turin began many
years ago to use such a diary which, though modified and improved in
the course of time, is still fundamentally the same.
Objective The purpose of this study was to evaluate the patient com-
pliance to the compilation of the headache diary.
Materials and methods A total of 575 patients (133 males and 442
females, age range 18–85 years) attending for the first time the
Headache Centre of the University of Turin in the period January 1 -
December 31, 2004, were enrolled in the study. They all suffered from
various kinds of primary headache diagnosed according to the
International Headache Society criteria (ICHD-II).
The usual diagnostic approach to the patients at the Headache Centre
of the University of Turin starts with a first visit, in the course of which
as much information as possible is collected from the patient’s inter-
view, and a symptomatic therapy is suggested. This is followed after
three months by a second visit, when a more definitive diagnosis is for-
mulated and, if it is deemed necessary, prophylactic therapy is sug-
gested to the patient. 
The patients are given the headache diary at the first visit. They are
instructed how to complete it and are asked to be as careful as possible
in its compilation.
They have to record many different characteristics of their headache
(pain, duration, intensity, localization, aggravation by routine physical
activity, presence of other symptoms, and drugs used).
It was evaluated how the diary had been filled in by all the patients who
came to the second visit, considering their age, level of instruction,
type of work, and comprehension of the language.
Results After the first visit 393 patients came back, while 182 did not.
Among those who came back, 324 (82.45%) filled the diary complete-
ly, while the remaining 69 (17.55%) filled it in only partially or did not
fill it in at all.
Discussion and conclusions On the basis of these data it is possible to
affirm that the majority of patients showed a very satisfactory compli-
ance to the diary compilation.
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Introduction The usual diagnostic approach to the patients at the
Headache Centre of the University of Turin starts with an initial visit,
in the course of which as much information as possible is collected
from the patient’s interview, and a symptomatic therapy is suggested.
This is followed after three months by a second visit, when a more
definitive diagnosis is formulated and, if it is deemed necessary, pro-
phylactic therapy is suggested to the patient.
According to some critics, this diagnostic approach is too long, and the
patients do not like it. 
Objective The purpose of this study was to evaluate how many
patients do not come back for the second visit that forms the usual pat-
tern of our approach, and why they do not return, to clarify if this crit-
icism is correct.
Materials and methods A total of 575 patients (133 males and 442
females, age range 18–85 years), attending for the first time the
Headache Centre of the University of Turin in the period January 1 -
December 31, 2004, were enrolled in the study. All patients suffered
from various kinds of primary headache diagnosed according to the
International Headache Society criteria ICHD-II. It was determined if
they had returned for the second visit or not. All patients who did not
return were contacted by phone to explain their reasons.
Results After the first visit 393 (68.35%) patients returned, while 182
(31.65%) did not. The principal reasons for their not returning, as report-
ed by those same patients were: the therapy was effective at the first
attempt or viceversa; headache attacks reduced their number after the
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first visit; the diary compilation was too complicated (it was a very dif-
ficult task for the patients with chronic headache); the diary was a nui-
sance because the headache attacks were so few; the fee paid for the visit
was too high and the visit itself did not offer a solution to their problem;
and the patient did not like the doctor’s approach at the first visit.
Discussion and conclusions On the basis of these data it is possible to
note that the majority of the patients accept and understand this diag-
nostic approach, so the criticism towards it does not seem to be realis-
tic. Considering the most frequent motivations reported by the patients
who did not come back, it appears likely that providing more informa-
tion could improve the situation.
PREVALENCE OF ARTERIAL HYPERTENSION IN THE REL-
ATIVES OF MIGRAINE PATIENTS
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Introduction Migraine and some cardiovascular disorders should have
common pathogenic mechanisms, and genetic factors should play an
important role in the possible development of migraine in a subject
with a positive gender for cardiovascular disorders [1]. Moreover, in
the clinical history of patients affected by migraine the presence of
arterial hypertension in their relatives is frequently observed.
Objective The aim of our study was to assess how common this phe-
nomenon is in a population of children and adults.
Materials and methods The study sample included 190 patients
affected by episodic migraine without aura (according to ICHD-II cri-
teria, 2004 [2]), without other forms of headache and without other
comorbidity. Seventy-four subjects (38.94%, 50 F, 24 M, age range
10–72 years, mean age 39.05 years – Group A) did not refer gender
positivity for arterial hypertension, while 116 (61.06%, 86 F, 30 M,
range 6–77 years, mean age 33.97 years – Group B) referred the pres-
ence of arterial hypertension in almost one relative of first (parents),
second (sister, brother, grandparents) or third degree (uncles or aunts).
Before the visit, a dedicated, specific and simple questionnaire was
given to the patient for compilation.
Results In Group B, 83 subjects referred the presence of arterial hyper-
tension in one or both first degree relatives, 76 in second (with or with-
out first) degree relatives, 20 in third (with or without second and first)
degree relatives. The mean number of attacks per month was 4.51 in
Group A and 5.49 in Group B.
Conclusions This study has two limitations, the small patient cohort
and the absence of a control group (without migraine). Nonetheless, we
can suppose that migraineurs have a remarkable prevalence of relatives
with arterial hypertension, according to previous studies, and that the
number of attacks seems to be higher in the group with gender positiv-
ity for arterial hypertension.
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Objective Several factors can trigger migraine; among them, dietary
factors play a very important role in the onset of migraine attacks. The
aim of our study was to evaluate the incidence of food intolerances in
a group of migraineurs, by using the Cytotoxic test.
Materials and methods Thirty consecutive patients suffering from
migraine presenting to the Headache Centre of S. Luca Hospital, Vallo
della Lucania (SA) were examined. Twenty-three were women, mean
age was 28.2 years, range 13–47 years; 7 were men, mean age was
39.33 years, range 28–62 years. The Cytotoxic test is capable of identi-
fying the presence of specific food intolerances by observing the
appearance, the size, the shape or the integrity of leukocytes exposed to
extracted food antigens or other materials derived from specific foods.
Results An intolerance was found to: tyramine in 12 women (52.17%)
and 3 men (42.85%); milk, 3 women (13.05%); yeast, 4 women
(17.39%) and 1 man (14.28%); solanaceae, 4 women (17.39%) and 1
man (14.28%); coffee, 5 women (21.74%); cocoa, 5 women (21.74%);
tea, 2 women (8.69%); eggs, 1 woman (4.35%) and 1 man (14.28%);
pork, 1 woman (4.35%); and sugar, 1 woman (4.35%).
Conclusions Our study showed a high incidence of food intolerance in
migraineurs (in women more than in men). The dietary factors which
gave more significant results were tyramine, yeast, solanaceae, coffee
and cocoa. These results are in agreement with those of other studies
found in the literature, proposing tyramine, coffee and cocoa as very
important migraine-precipitating factors. Conversely, there is little evi-
dence of a comorbidity between migraine and intolerance to
solanaceae. For this reason, further studies are warranted to confirm
this hypothesis.
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Introducion Migraine is characterized by a complex biochemical dys-
function attributed to a disorder of the trigeminal and hypothalamic path-
ways. Impairment of glucose and insulin metabolism has been reported in
migraine [1], and insulin alterations seem to be specific to migraineurs.
Objective The main aim was to verify if a proper diet, eventually asso-
ciated with a insulin-sensitizing drug where indicated, could modify
the headache severity together with the glucose-insulin metabolic alter-
ation in migraineurs who presented alterations in glucose-insulin
metabolism.
Patients and methods The study population included all migraineurs
consecutively seen at the headache centre of our hospital during a one-
year period; all the recruited people underwent a general blood test and
a standard oral glucose tolerance test (OGTT) after a 12-hour fasting
period, measuring levels of glucose and insulin. A daily fragmented
low-percentage carbohydrate diet was suggested to those patients who
showed an alteration in glucose and or insulin metabolism. Each
patient was followed-up during a 3–6 month period, and another stan-
dard OGTT was performed, following a 3–6 month period of diet after
a 12-hour fasting period, measuring levels of glucose and insulin.
Evaluation of headache severity was expressed in severity index, cal-
culated on the basis of number of days with headache and each day
headache severity in 1–3 severity scale (1 mild, 2 moderate, 3 severe).
Results In a 12-month period, we recruited 173 migraineurs (138
women, 35 men), 132 patients had a metabolic glucose-insulin alter-
ation (102 women, 30 men), and 41 patients had normal metabolic pro-
file. Until now, 64 patients have been followed-up for at least 3–6
months. Headache severity index of the studied population was 31
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(SD±27) before diet and 12 after diet (SD±21) (p<0.000). Fasting blood
glucose levels (FBG) and after OGTT (in mg/dL) were slighty lower
after dieting (before diet, FBG: 96, at 30 minutes: 143, at 60 minutes:
113, at 120 minutes: 93; after dieting, FBG: 99, at 30 minutes: 131, at
60 minutes: 104, at 120 minutes: 83; p<0.3). Migraineurs after dieting
presented significantly lower insulin levels at any time of the test, both
fasting and after glucose loading (before dieting, FBG: 10, at 30 min-
utes: 100, at 60 minutes: 99, at 120 minutes: 55; after dieting, FBG: 7,
at 30 minutes: 74, at 60 minutes: 75, at 120 minutes: 38; p<0.1).
Discussion and conclusions A daily fragmented low percentage carbo-
hydrate diet can be useful as migraine non-pharmacological therapy. A
clinically positive impact of diet correlates with glucose and even more
with insulin levels, both fasting and after glucose loading. High insulin
levels are recorded in migraineurs, and these data seem to be specific to
this headache type. These findings are in keeping with recent reports on
the effects of insulin on brain functions and lend support to the possible
involvement of insulin in the pathogenesis of migraine [2].
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POST-PRANDIAL MOTILITY INDEX IS SIGNIFICANTLY
REDUCED IN MIGRAINE PATIENTS WITH DYSPEPTIC
SYMPTOMS
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Background and aims We have recently shown that in patients with
migraine and dyspepsia the intake of a low-caloric low-fat meal
induces a significant reduction of post-prandial discomfort thresh-
olds. This abnormality is not evident in patients with functional dys-
pepsia, thus suggesting that post-prandial reduction of discomfort
thresholds may characterize migraine patients. As variations of gas-
tric motility index (MI) were described in a subset of dyspeptic
patients, the aim of this study was to evaluate whether abnormalities
of this parameter may have a role in the pathophysiology of dyspep-
tic symptoms in migraine patients.
Materials and methods Eighteen patients with migraine without aura,
diagnosed according to ICHD-II criteria and dyspeptic symptoms (11
F, mean age 32±5 years), 16 patients with functional dyspepsia, diag-
nosed according to Rome II criteria (10 F, mean age 39±5 years) and
16 healthy volunteers (HV) (9 F, mean age 28±6 years) underwent gas-
tric barostat test, which monitors gastric motor activity (contraction or
relaxation) as changes in intraballoon volume (reduction or increase,
respectively) at a constant intrabag pressure. After an overnight fast, a
double lumen polyvinyl tube with an adherent, infinitely compliant
plastic bag (1200 mL capacity), finely folded, was inserted into the
stomach through the mouth. The polyvinyl tube was connected to a
computer-driven programmable volume-displacement barostat device.
During the test we evaluated gastric accommodation reflex and phasic
contractility, quantified using MI during fasting and during the first and
second 30-min period after administration of a low-caloric liquid meal.
A baseline reconstruction was performed using a computerised algo-
rithm and MI was calculated as the area between the signal and the
baseline normalised over time.
Results Both in dyspeptic patients with migraine and without migraine,
the mean increase of post-prandial gastric volume was indicative of a
physiological accommodation. Fasting MI was similar in patients
(migraine 27.5±7.1 mL x min; dyspepsia 26.9±4.6 mL x min) and HV
(24.8±4.3 mL x min). On the contrary, during the first post-prandial 30-
min period, post-prandial MI was significantly reduced (p<0.003,
ANOVA) in patients with migraine (13.4±4.8 mL x min) than in HV
(19.6±6.6 mL x min) and in dyspeptic patients (22.6±7.4 mL x min).
Conclusions Our results show that patients with migraine and dyspep-
tic symptoms suffer from an alteration of post-prandial gastric sensori-
motor function. In addition to the previously shown post-prandial
hypersensitivity, a reduction of post-prandial MI is also present.
EPIGONE MIGRAINE VERTIGO (EMV): A LATE MIGRAINE
EQUIVALENT
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Introduction The term Migrainous Vertigo (MV) [1] describes all the
vertiginous and postural disturbances that are variably expressed by
migrainous subjects. In 1988, Pagnini [2] proposed a classification of
the vestibular symptoms in migraine using a specific criterion: the
temporal relationship between headache and vertigo. According to
this classification we can find two large groups of MV: the associated
and the equivalent. The first represents the vestibular disorder that
adds to headache. The second represents the vestibular crisis that sub-
stitutes the single spell of headache. The equivalent form can occur
before the onset of headaches (precocious equivalent). It could appear
during the headache period (intercritical equivalent), or it can develop
after the headache ceases (epigone equivalent). This study concerns
the latter form.
Subjects and methods In a clinical observation of 13 years at the
Audiological Clinic of the University of Florence, we studied 28
migrainous patients with some features of recurrent vestibular disor-
ders: they suffered from late vertigo with onset only after headache had
ceased; their vertigo was not specific for other recurrent otoneu-
ropathies; there were no specific radiological signs or blood risk fac-
tors. With a follow-up at least of two years, we studied this patient
group with audiovestibular and neurological examinations and imag-
ing, focusing on the characteristics of headache and vertigo and how
they interchanged between each other.
Results and discussion Females represented 82% of the study group,
mean age of headache onset was 18 years and for vertigo was 38 years.
Migraine without aura was present in 78% of patients, kinetosis in
78%. The vertigo described by the patients was variable: 64% of
patients referred exclusively rotatory crises (mean duration 15 hours);
14% described dizziness or postural instability (mean duration 73
hours); 22% suffered from a combination of these features. The
headache passed to vertigo with a free interval in 26% of patients. A
period of alternation of headache and vertigo was present in 29% of
patients. In 45% of patients headache passed directly into vertigo.
There were no specific signs from audiovestibular examination during
intercritical periods, but in 36% we found a vestibular hyperreflectivi-
ty during stimulation. We saw a specific highly repetitive behaviour for
this new entity: the response to migraine prophylaxis. Vertigo
improved in all patients, furthermore, full recovery from vestibular
symptoms was obtained in 68% of patients.
Conclusions With this clinical observational study, we attempted to char-
acterize a new clinical picture of migraine, the epigone migrainous verti-
go, which should be considered when considering vertigo in migraine.
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MUSCLE TENDERNESS IN CRANIOMANDIBULAR AND
CERVICAL REGIONS AND PSYCHOMETRIC CORRELATES
IN A POPULATION OF MIGRAINE PATIENTS WITH AND
WITHOUT CHRONIC TENSION-TYPE HEADACHE AND
HEALTHY CONTROLS
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Background A relationship has been shown between pericranial mus-
cle tenderness and psychiatric disorders in migraine patients. In partic-
ular, this association has been observed in patients with both migraine
and chronic tension-type headache (CTTH).
Objective The aim of the study was: 1) to evaluate the function of the
temporomandibular system and of the cervical spine in a population of
migraineurs with and without CTTH; 2) to evaluate the relationship
between muscle tenderness, personality profile and psychiatric symp-
toms in migraine patients with and without CTTH.
Materials and methods Migraineurs with and without CTTH were
consecutively recruited according to IHS criteria (ICHD-II). A healthy
control group was also recruited. All subjects of the study were sub-
mitted to: 1) clinical investigation of the temporomandibular system
according to the “Craniomandibular Index” (CMI); 2) pericranial mus-
cle evaluation according to “Total Tenderness Score” (TTS); 3) physi-
cal examination of the cervical spine (PECS); and 4) electrognathogra-
phy (EGG) of the temporomandibular joint. As regards personality pro-
file and psychiatric symptoms, the following tests were administered:
Tridimensional Personality Questionnaire (TPQ), Toronto Alexithymia
Scale – 20 items (TAS-20), State and Trait Anxiety Inventory (STAI-1-
2), and Beck Depression Inventory (BDI). All migraineurs underwent
Migraine Disability Assessment (MIDAS) and Headache Impact Test –
6 items (HIT-6) for evaluation of migraine disability.
Results Forty-two migraineurs (mean age 35±10 years), 35 migraineurs
with CTTH (mean age 34±12 years) and 32 healthy controls (mean age
32±11 years) were admitted to the study. All migraineurs showed sig-
nificantly higher scores in CMI, TTS and PECS than healthy controls
(p<0.05). Comparing EGG data between migraineurs and healthy con-
trols, we observed in the migraine population a reduction of mandibu-
lar movement associated with muscle rigidity (p<0.05). In regard to the
psychometric data, migraineurs showed higher scores in BDI and STAI,
Harm Avoidance dimension of the TPQ and TAS-20 than healthy con-
trols (p<0.05). All clinical and psychometric findings cited above were
more evident in migraineurs with CTTH than those without (p<0.05).
Duration of illness, frequency of attacks as well as MIDAS and HIT-6
scores were positively correlated with the total number of cran-
iomandibular and cervical tender points (p<0.05).
Conclusions Migraine patients present subclinical temporomandibular
and cervical spine disorders. These clinical findings are more evident
in migraineurs with CTTH and are associated with psychiatric symp-
toms and with a peculiar personality profile. It might be important to
identify these clinical features not only for the therapeutic implications
but also to prevent and understand the pathophysiological mechanisms
that may lead to chronic migraine.
MIGRAINE AS PRESENTING SYMPTOM OF CEREBRAL
AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCOR-
TICAL INFARCTS AND LEUKOENCEPHALOPATHY
(CADASIL)
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Background CADASIL is an inherited (autosomal dominant) vascular
disease clinically characterized by recurrent transient ischemic attacks
and/or strokes, migraine, mood disorders, cognitive impairment, and
seizures. Radiological hallmarks are diffuse white matter abnormalities
and/or lacunar infarcts visible on MRI or CT. Genetic mutations are
located on chromosome 19p13.1 on the Notch3 gene.
Migraine is the symptom of onset of the disease in 40% of cases [1]
and has been described in up to 77% of patients in the advanced phase
of the disease. Migraine with aura has been reported in up to 40% of
cases. About 30% of patients have atypical aura, and atypical plus typ-
ical aura has been described in 27% of cases [2].
Methods We describe the clinical characteristics of 14 consecutive
CADASIL patients (5 males) belonging to 9 unrelated families.
Results The time of the first neurological evaluation was at an
advanced age (mean 51±15 years). Onset of the disease was retrospec-
tively judged to be earlier (mean age 29 years±16) with migraine as the
presentation symptom in 64% of patients. On presentation no patient
had migraine with aura. Migraine was present in 86% of patients in the
advanced phase of the disease. Three patients (21%) had migraine with
aura, 2 of them (14%) had typical and prolonged aura. The other clin-
ical features were TIA/strokes (57%), cognitive deficits (71%), and
mood disturbances (79%).
All patients presented confluent or partly-confluent MRI white matter
changes with the exception of 2 young patients (26 and 28 years) clin-
ically characterized by isolated migraine. Involvement of the temporal
lobes was variable in terms of severity. Family history was positive for
at least one CADASIL clinical hallmark in all cases. Notch3 mutations
involved exon 11 (3 families), 19 (2 families), and exons 3, 4, 6, and
10 in one family each.
Conclusions CADASIL appears to be an underestimated disease.
The phenotypic spectrum is variable ranging from pauci-sympto-
matic cases to severe disease. Migraine is frequently the earliest
symptom of the disease occurring at a relatively young age.
CADASIL should be suspected in patients with migraine who have
MRI white matter alterations of moderate to severe degree and
a positive family history for at least one clinical hallmark of the
disease. 
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PRIMARY CHRONIC HEADACHES IN ITALY: ANALYSIS OF
DIAGNOSES WITH THE AID OF A DEDICATED SOFTWARE
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Background We recently developed a software, the Primary
Headaches Analyser 1.0 INT (PHA), to analyse the clinical data from
patients affected by primary headaches [1]. This programme is based
exclusively on the International Classification of Headache Disorders
2nd edition (ICHD-II) criteria [2]. This software examines all the diag-
noses of primary headaches on the basis of the variables needed to ful-
fil these mandatory criteria.
Methods We tested the diagnoses of chronic primary headaches with
the aid of the software PHA, by entering and analyzing data reported
in the clinical chart and headache diaries from 200 consecutive patients
affected by primary chronic headaches and evaluating the correspond-
ing output diagnoses.
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Results The diagnosis of 1.5.1 Chronic migraine was obtained in 68
cases (34%), and that of probable 1.6.5 Chronic migraine + 8.2.8
Probable medication-overuse headache in 46 (23%). 2.3 Chronic ten-
sion-type headache and 2.4.3 Probable chronic tension-type headache
+ 8.2.8 Probable medication-overuse headache were diagnosed in 24
(12%), and 2 (1%) patients, respectively. Probable medication-overuse
headache (n=46) included combination analgesics (n=12), analgesics
(n=11), triptans (n=9), a combination of acute medications (n=7), opi-
oids (n=4), and ergot derivatives (n=3). In the two patients with a diag-
nosis of 2.4.3 Probable chronic tension-type headache + 8.2.8 Probable
medication-overuse headache, combination analgesics were responsi-
ble for medication overuse. Moreover, 4 and 12 patients, respectively,
received both the diagnosis of 1.5.1 Chronic migraine +2.3 Chronic
tension-type headache and of 1.6.1 Probable migraine without aura
+ 2.3 Chronic tension-type headache. In the remaining 44 cases (22%),
none of the chronic primary headaches defined by ICHD-II were given
as an output diagnosis by our software. This was mainly due to the fact
that insufficient criteria were fulfilled for the diagnoses of 1.1 Migraine
without aura + 1.5.1 Chronic migraine or, more infrequently, 2.3
Chronic tension-type headache.
Output diagnoses included 1.1 Migraine without aura, 1.6.1 Probable
migraine without aura, 2.4.1 Probable infrequent episodic tension-type
headache + 2.4.2 Probable frequent episodic tension-type headache,
and 14.1 Headache not elsewhere classified. None of the patients
whose clinical sheets were examined received a diagnosis of 4.7
Hemicrania continua or 4.8 New daily-persistent headache.
Conclusions Our software (PHA) allowed the diagnoses of chronic
migraine or chronic tension-type headache or their probable forms in the
case of medication overuse in 78% of the patients with more than 15 days
per month examined. In the remaining cases, the inability to provide the
above diagnoses can be explained in about one quarter of cases by the fact
that the mandatory criteria for both diagnoses are too stringent and do not
reflect modifications of the headache patterns in these chronic forms.
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Introduction The present study was conducted in order to compare the
sensitivity of the newly developed World Health Organization
Disability Assessment Schedule II for detecting disability due to chron-
ic pain with two established instruments, one generic (SF-36) [1] and
one specific for headache (HIT-6) in patients affected by chronic daily
headache (CDH) with and without analgesics overuse. WHO-DAS II
consists of 36 items, grouped into 6 domains, 5 being related to per-
sonal activities and 1 to social life events: D1 communication abilities;
D2 mobility impairment; D3 self care; D4 interpersonal relationship;
D5 familial/working daily activities; D6 social life participation rate.
Methods Forty consecutive patients (30 females and 10 males),
affected by CDH with or without analgesic overuse and observed
during a 6-month period were interviewed through SF-36, HIT-6 and
the 36-item version of WHO-DAS II scales, each one in its validated
Italian version. Headache diagnosis was made according to ICHD-II
criteria [2]. No patient had taken prophylactic medications for
headache during the 6 months preceding the observation. Statistical
analysis included partial correlation tests between items of the three
instruments and alfa Cronbach parameter for evaluation of WHO-
DAS II internal consistency.
Results A positive correlation was found between all items of SF-36
and some items of WHO-DAS II, in D4, D5 and D6 domains, with sta-
tistically significant differences (p<0.01). D5 and D6 WHO-DAS II
domains correlated positively with all HIT-6 items (p<0.01), D4
domain correlated with items 3, 4, 5, 6 of HIT-6 (p<0.01), D1 domain
with items 4, 5, 6 (p<0.05) and D2 domain with item 3 only (p<0.05).
Discussion and conclusions The above findings show that WHO-DAS
II is comparable to SF-36 and HIT-6 as a tool for disability measure-
ment. No correlations were found between WHO-DAS II items and
headache clinical features, such as disease duration or duration of anal-
gesic overuse. Some SF-36 items, instead, showed a statistically sig-
nificant correlation with duration of illness, but not with the duration
of analgesic overuse. To identify internal consistency between all items
of WHO-DAS II, we used alfa Cronbach parameter. Its value was
between 0.8 and 0.9 for all domains analysed indicating a high internal
consistency, which supports the use of WHO-DAS II as a sensitive
instrument for detecting disability in headache patients, In particular, it
may prove to be a valuable measurement tool for disability in chronic
headache patients, and it could be useful for indicating effectiveness of
therapy and guiding clinical management in these patients.
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CLINICAL CHARACTERISTICS OF MEDICATION-OVERUSE
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Introduction The International Classification of Headache Disorders
(ICDH-II, 2004) remarkably modified the diagnostic criteria of med-
ication-overuse headache (MOH), and also proposed clinical criteria to
differentiate headache between different overused medications.
Subsequently, these clinical criteria were excluded in the revision of
the International Headache Seminar held in Copenhagen in March
2004, due to lack of reliable data from the literature.
Objective The aim of the present study was to analyse, for the first
time in a systematic way, the clinical characteristics of headache in a
sample of patients suffering from MOH.
Patients and methods We studied 51 patients with chronic daily
headache who took analgesics ≥ once per day for more than three
months, and were treated for detoxification as in-patients. The study
included 46 women (90.2%) and 5 men (9.8%), with a mean age of 53
[SD 12] years. The patients were divided according to the medication
overused. The quality, the site, the severity, and the accompanying phe-
nomena were evaluated, taking into account also the characteristics of
the pre-existing headache and the response to the medication used. The
data were analysed using the Statistical Package for the Social
Sciences (SPSS 12.0).
Results The overused medications were: combination analgesics in 20
patients (39.2%), simple analgesics in 17 patients (33.3%), triptans in
10 patients (19.6%), and ergotamine in 4 patients (7.8%). The more
common pre-existing headache was migraine without aura (39 patients,
76.5%). The pain was more frequently pulsating (28 patients, 54.9%),
bilateral (29 patients, 56.9%), and of severe intensity (34 patients,
66.7%). Accompanying phenomena were present in 43 patients
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(84.3%), the more frequent being nausea associated with phonophobia
and photophobia. The quality, site and intensity of pain, and the type of
accompanying phenomena did not differ significantly among overusers
of different medications (p=NS). The overused medications were
effective in reducing headache and the mean time to the resolution of
pain was 72 [SD=87] minutes.
Conclusions The headache in this sample of patients with MOH was
more frequently pulsating, bilateral, severe and associated with nausea
and phonophobia and photophobia. The clinical characteristics were
not different according to the various types of overused medications,
supporting the revision of the International Headache Seminar of
Copenhagen (2004). The pre-existing headache and the response to
overused medications did not influence the characteristics of MOH.
SUICIDE RISK IN CHRONIC DAILY HEADACHE
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In the Western world, 2%–4% of deaths are due to suicide, incidents
and murders. Suicide is experienced as a predictable, and therefore pre-
ventable death; its occurrence causes a sense of anguish in relatives and
frustration and impotence in physicians. Chronic somatic pathologies,
such as diabetes, cardiopathy, cancer, stroke and correlated problems
like pain, weight loss, insomnia etc. increase vulnerability and predis-
pose to the risk of suicide. Our aim in this study was to evaluate the
presence of both humoral disorders and suicide risk in 300 patients
affected by chronic daily headache and medication-overuse headache,
who were observed for 24 months in our Centre.
We based our work relying upon interviews, collection of anamnestic
data related to the premorbid period, information given by patients
concerning the sufferers’ behaviour during the day, attitudes towards
others, maintaining of previous interests, and modifications of the bio-
logical rhythm.
Moreover, psychometric tests were administered, revealing a remark-
able correlation between humoral disorders and headache, impairment
of working activity, relationships and family life.
Through structured interviews with patients and family, the presence of
both depressive symptomatology and suicide ideation before the
appearance of chronic daily headache has been evaluated.
Finally, our purpose was also to establish if, unlike other pathologies,
suicide risk was high or remained just intentional.
Preliminary data indicate 42 patients (21%) with positive results; more
specific tests (SSI, BRFL) were performed in order to quantify the
importance, intensity and pervasiveness of suicide ideation.
CASE REPORTS
DIFFICULTIES IN MIGRALEPSY DIAGNOSIS: A CASE
REPORT
1G. Sances, 1N. Ghiotto, 1E. Guaschino, 1M. Loi, 1N. Arce Leal, 
1F. Balsamo, 2R. Manni, 1,3G. Nappi
1Headache Unit, University Centre for Adaptive Disorders and Hea-
dache (UCADH), Pavia, Italy; 2Unit of Sleep Medicine and Epilepsy,
IRCCS “C. Mondino” Institute of Neurology Foundation, Pavia, Italy;
3Department of Clinical Neurology and ORL, University of Rome “La
Sapienza”, Rome, Italy; e-mail: grazia.sances@mondino.it
Migraine and epilepsy are paroxysmal disorders showing clinical and
epidemiological comorbidity whose possible relationship remains to be
clarified. When a seizure begins during or close to post-aura symp-
toms, we refer to migralepsy. This phenomenon is described in subjects
suffering from migraine with aura; the ICHD-II (2004) diagnostic cri-
teria codify this new entity at 1.5.5 (in the chapter on migraine). A 36-
year-old man was referred to our headache centre with aura symptoms.
The patient’s history (birth, physiological history and psycho-physical
development) was normal. His history of migraine (without aura and
showing a weekend pattern) started at age 20. At 34, he began experi-
encing frequent visual bilateral symptoms lasting 10 minutes and never
followed by headache (12 episodes/month). These occurred, in partic-
ular, in the evening, after work. He described flashing lights, diffuse in
the visual hemifield on the headache side, lasting 5–10 minutes. He
also recalled two episodes of dejà-vu symptoms associated with nau-
sea. At age 36, he reported an episode of his typical visual symptoms
associated with a dejà-vu perception, perception of a “clean” smell (of
fresh laundry), and nausea, lasting about 10 minutes. He then lost con-
sciousness, fell to the ground, and displayed tonic seizure of the limbs
with laceration of the tongue. After about five minutes, he resumed
normal respiration, but remained rather unresponsive and confused
until the arrival of rescue workers. Apparently, this episode was not
followed by headache. MRI and basal EEG were normal, whereas
sleep deprivation EEG showed a diffuse and large theta frequency in
the left cerebral hemisphere. The diagnosis was tonic seizure in
migraine with/without aura. The patient began treatment with topira-
mate (200 mg daily).
This patient was referred to us with recurrent migraine attacks and the
appearance of visual symptoms sometimes followed by headache. We
investigated possible comorbidities of the aura: patent foramen ovale
was excluded by transcranial Doppler; we found heterozygous C677T
mutation in the methylene tetrahydrofolate reductase gene. We pre-
scribed acetylsalicylic acid (100 mg daily).
At follow-up (the most recent was three years after the first visit), he
reported a reduction of aura symptoms (about five episodes/month) not
always followed by headache and no migraine attack without aura. No
other seizure occurred and the most recent EEG was normal. 
Migralepsy is a rare form with very few reported cases. Even in the
cases that have been described, the diagnosis is not clear-cut. The dif-
ficulty of arriving at a precise differential diagnosis of visual distur-
bance (aura versus occipital partial seizures and elementary hallucina-
tions) does not support the hypothesis that migralepsy is a primary
entity in its own right.
ACUTE MANIA INDUCED DURING A CLUSTER HEADACHE
EPISODE: A CASE REPORT
1,2R. Iannacchero, 2M. Gallo, 2A. Scardamaglia, 2M.A. Massimo,
1E. De Caro
1Regional Headache Centre, “Pugliese-Ciaccio” Hospital, Catanzaro,
Italy; 2Department of Mental Health, A.S. 6, Lamezia Terme, Italy; 
e-mail: rosarioiann@tiscali.it
Background Cluster headache often leads to mood changes in
patients, in particular, to depressive reactions and sometimes to sui-
cide. However, there are no controlled studies on the comorbidity of
cluster headache and affective disorders such as manic-depressive ill-
ness. We report on a patient who developed his first manic episode
while suffering from a cluster episode.
Case report A 34-year-old male patient has been suffering from
episodic cluster headache according to IHS criteria for 8 years. He
experienced one cluster episode per year with a duration of about 2
months. The left-sided cluster attacks occurred about 4 times a day
with a single duration of about half an hour. Oxygen inhalation, and
subcutaneous sumatriptan promptly aborted an attack. In recent
episodes, verapamil at a dosage of 360 and 480 mg per day was effec-
tive as prophylactic agent. At the beginning of his last cluster episode,
he received steroids from his general practitioner at a daily dosage of
125 mg per week, which was progressively decreased. At first the
attacks stopped, but then recurred after 10 days; thus the patient was
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admitted to our Headache Centre. However, a few days later, while still
under steroids, the patient rapidly developed manic symptoms and had
to be admitted to a psychiatric isolation ward. Treatment with quetiap-
ine 300–600 mg per day was started, and after 10 days the manic symp-
toms disappeared; cluster attacks occurred occasionally under this
monotherapy.
Conclusions To our knowledge, this is the first report on the onset of
manic symptoms during a cluster episode. Since the patient had some
endogenous depressive episodes in the past, the diagnosis of manic-
depressive illness was made according to the International
Classification of Disease, 10th edition (ICD-10). The manic episodes
were probably induced by steroids or by steroid withdrawal. We con-
clude that cluster headache patients with a history of affective diseases
should not be treated with steroids but with quetiapine or lithium,
which are effective in both conditions.
HYPNIC HEADACHE WITH A SPORADIC PATTERN
1F. Mainardi, 2C. Lisotto, 3F. Maggioni, 1F. Paladin, 3G. Zanchin
1Headache Centre, Neurological Unit, SS Giovanni and Paolo
Hospital, Venice, Italy; 2Headache Unit, San Vito al Tagliamento
Hospital, San Vito al Tagliamento, Pordenone, Italy; 3Headache
Centre, Department of Neurosciences, University of Padua, Padua,
Italy; e-mail: fmainardi@iol.it
Hypnic headache (HH) is a primary headache disorder, classified in the
fourth chapter of ICHD-II, which occurs exclusively during sleep and
usually begins after the age of 60 years [1]. The natural evolution of
HH is not well known, but it is assumed that it tends to be chronic
unremitting. A follow-up of at least 2 years is described for only 25
patients among the 85 cases reported in the literature; according to the
outcome data obtained from these patients, we recently proposed to
distinguish between chronic and episodic HH [2].
A 63-year-old woman complained of a dull, severe headache in the
vertex, which developed only during sleep and awakened the
patient, without any accompanying signs or symptoms; the headache
completely resolved 30 minutes after awakening. She referred the
first episode two years before our visit and its recurrence with a very
low rate (one attack every six months, for a total of four episodes,
the last one just before the observation). Due to the short duration of
the attack, the patient did not take any drug. A detailed interview
revealed the presence of two more forms of primary headache
(migraine without aura and infrequent episodic tension-type
headache). General and neurological examinations, laboratory tests,
and brain MRI with gadolinium were normal.
To our knowledge, this is the first case of a headache fulfilling ICHD-
II criteria for HH with an infrequent pattern, and it supports our previ-
ous observations regarding the possibility of an episodic evolution of
this rare primary headache.
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PRIMARY STABBING HEADACHE IN THE ELDERLY: A
CASE REPORT
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We present the case of a 74-year-old man referred because of the onset
in the previous month of a severe head pain occurring as a series of
stabs (generally 3–5) in the left parietal area, lasting up to two seconds
and recurring with irregular frequency without any accompanying
signs or symptoms. He never experienced a recurrent headache before.
The pain occurred every hour during the morning, and two or three
times in the afternoon. The stabs presented with an average frequency
of four days per week. His medical history revealed the presence of
ischemic heart disease with atrial fibrillation and hypertension.
Because of his heart condition, a cardiac pacemaker was implanted and
he regularly took anticoagulants and hypotensive drugs. The general
and neurological investigations were normal. A brain CT scan with
contrast medium revealed no alteration; it was not possible to perform
a brain MRI because of the presence of the heart pacemaker. We sug-
gested indomethacin at the dose of 50 mg daily. From the second day
of therapy the stabs disappeared. He is still headache-free after 3
months of follow-up.
Primary stabbing headache is classified in ICHD-II within chapter 4
“Other Primary Headaches”. The short-lasting duration and the irregu-
larity of its frequency justify the low rate of consultation, despite the
relative diffusion of the condition, which occurs in 35% of the general
population, according to recent data. In the same population-based
study, the peak was reached in the third decade; the onset in the elder-
ly is rarely reported [1].
The peculiarities of our case are: i) the sudden onset in the elderly; ii)
the prompt response to low indomethacin dose. Further studies are
warranted to better specify the diagnostic criteria for this form of pri-
mary headache and its treatment.
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A MIGRAINE-LIKE HEADACHE
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The cornerstone of migraine diagnosis, in the absence of pathognomon-
ic biological or imaging markers, are the anamnestic data, with particu-
lar regard to the clinical features of the headache, and the general and
neurological examinations. Neuroimaging or laboratory tests are useful
to exclude a secondary origin, when: i. the characteristics of the
headache do not fulfil ICHD-II criteria for the diagnosis of migraine; ii.
the general or neurological examinations are abnormal; iii. the anamnes-
tic data show the presence of alarm features, the so-called red flags. 
A 37-year-old woman presented with a one-month history of daily,
severe, diffuse headache with phonophobia, photophobia, nausea, and
vomiting. She attributed these symptoms to migraine, a condition she
suffered from since her twenties with an average frequency of 2 attacks
per month. She decided to undergo a medical consultation because of
the lack of response to the usual therapy (triptans and NSAIDs) and the
progressive worsening of the symptoms. General and neurological
examinations did not reveal any abnormalities. A brain CT scan
showed the presence of several metastases in both hemispheres with a
dislocation of the mid-line structures. Further investigations demon-
strated a primary ovarian neoplasm. The patient died two months later. 
The possibility of a secondary origin was suggested by the accelerating
pattern of a previous well-known headache and the lack of response to
treatment, both of them to be considered as red flags. The peculiarity
of this case is essentially represented by the normal general and neuro-
logical examinations despite the dramatic neuroimaging picture.
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Secondary headaches fulfilling ICHD-II criteria for the diagnosis of a
primary headache are described also for other forms (e.g. cluster
headache, TACs) [1–2]. The adherence to major TACs ICHD-II crite-
ria and a normal general and neurological visit are necessary, but not
sufficient to exclude a secondary process. Thus, the appearance of a
“red flag” in a headache patient should always prompt a re-evaluation
to exclude the presence of a secondary cause.
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TRIPTAN OVERUSE AND EPISODIC SEROTONIN SYN-
DROME
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Serotonin syndrome (SS) is a rare pathological condition related to the
concomitant use of drugs that increase 5-HT availability; the patho-
physiology of SS seems to be ascribed to the stimulation in the brain-
stem of 5-HT1A receptors and the inhibition of 5-HT1A dopaminergic
transmission, secondary to serotonergic hyperactivity. SS includes sev-
eral neurological and autonomic manifestations that follow administra-
tion or an increased dosage of serotonergic drugs, and is clinically
defined in the presence of at least three of the following signs/symp-
toms: mental status changes, myoclonus, hyperreflexia, tremor, fever,
diaphoresis, shivering, and diarrhoea [1]. Because of their actions, trip-
tans have been implicated in the pathogenesis of SS, in particular, if
taken with drugs which increase 5-HT levels. We describe the case of a
61-year-old woman, who presented at a first visit a headache fulfilling
ICHD-II criteria for probable chronic migraine without aura and proba-
ble triptan overuse headache. She treated her attacks with triptans, tak-
ing an average 29–30 doses per month for at least 6 months; sometimes
(once a week) she had to take triptans twice daily. Furthermore, she took
mirtazapine 30 mg/day for a depressive syndrome. She referred episodes
of intense sweating, mental confusion, shiver, tremor, and inconstant
diarrhoea, lasting 3–4 hours and leaving her prostrate. She complained
of such episodes a few hours after taking a second dose of triptan. She
first reported these symptoms five months before our observation, but
she attributed them to her depressive status. Symptoms disappeared after
the withdrawal of mirtazapine and a detoxifying treatment (follow-up 3
months), whereas the headache frequency remained unchanged; there-
fore, the final diagnosis was chronic migraine without aura.
The peculiarities of this case are: i. the temporal pattern and the sponta-
neous remission of each episode, indicating a recurrent and mild form of
SS; ii. the correlation between taking a double dose of triptans and the
onset of SS symptoms, documented by a diary; iii. the concomitant use
of mirtazapine, a drug rarely implicated in generating this syndrome.
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CONTRIBUTION OF NEUROBIOLOGICAL AND PSYCHO-
LOGICAL TRAITS IN MEDICATION-OVERUSE HEADACHE
(MOH) DEVELOPMENT: A CASE REPORT
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Even though it is not yet clear whether the misuse and/or abuse of anal-
gesics or triptans in migraine may be involved in headache chronicity,
chronic pain and pain relief are considered the most important features
in inducing a habitual behaviour as therapeutic need. It is well known
that complex brain areas, as well as different neurotransmitter systems
and complex responses participate in the biology of the reward brain
system. Comorbidity for psychiatric disorders, such as anxiety and
depression, as well as negative life events, exacerbate headache and
quality of life in patients suffering from headache [1]. Stressful peri-
ods, can induce disruption in these interneural interactions and result in
a craving for drugs to relieve the pain and bad feelings. Serotonin plays
an important role in migraine pathogenesis, and drugs such as triptans,
5-HT1B/1D agonists, are the first choice for acute migraine therapy.
Recent findings support the hypothesis that serotonin could contribute
to the development of mechanisms underlying the reward system in the
brain, inducing a compulsive habit for consumption of antimigraine
analgesics [2]. The present paper would like to contribute to clarifying
the above described mechanisms. For this purpose, a case report is
introduced and discussed.
A 45-year-old woman complained of primary migraine for many years.
The headache occurred two, sometimes three times a week. Prodromic
symptoms, such as tension in the orbital region and nausea, preceded
the headache. For about two years, the patient abused of analgesics
(NSAIDs), and during the last year she took triptans (9 to 10 times a
month during the last three months) and analgesics. Despite the drug
treatment, headache recurred more frequently, and the characteristics of
the pain changed, from being sharp and starting abruptly to often pre-
senting in one hemiscalp and spreading subsequently to the entire head.
The clinical story of the patient revealed psychiatric co-morbid disor-
ders for anxiety and depression following a stressful period for job-
related problems (mobbing?). A genetic study was carried out to inves-
tigate inherited predisposition to thrombophilia and verify the possibil-
ity of sinus venous thrombosis. A Factor V gene mutation was found.
Moreover, neuroimaging investigations (MRI and intracranial venous
MR angiography) did not show any pathological brain conditions but
revealed a dominant dilated and tortuous right transverse sinus, where-
as the left transverse sinus was hypoplastic. During hospitalization,
drug treatment was stopped and prophylaptic therapy was started.
In conclusion, this case report suggests that headache chronicity might
be caused by biological as well as psychological traits. Correct man-
agement of migraine and headaches may contribute to modifying habit-
ual behaviour and reducing consumption of drugs in chronic sufferers.
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A CASE OF UNSATISFACTORY HEADACHE MANAGEMENT
SUPPORTING THE NEED FOR INFORMATION AND EDUCA-
TION ABOUT HEADACHE DISORDERS
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Introduction With this case report we want to emphasize how impor-
tant it is, and how much work still needs to be carried out in terms of
patient education and divulgation of information about headaches.
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Case A 41-year-old man suffered from headache (the first episode
occurred about 15 years ago). This affection became worse in frequency,
intensity and refractory to the rescue dose in the last 12 months, com-
promising his job. The characteristics of this headache were: daily fre-
quency; right-sided localization, beginning in the posterior region of the
head; absence of aura except for tension located in the cervico-occipital
area over the paravertebral muscles, associated with pain in the point of
emergency of Arnold’s nerve; bilaterally lasting ≥24 hours. Pain intensi-
ty was measured with Visual Analogue Scale (VAS). Phonophobia and
photophobia were so strong during the crises that they forced the patient
to abandon his activity. Under prescription, the patient had taken 500 mg
effervescent tablet as rescue dose. Consecutively, because the headaches
did not resolve, he took 10 mg of rizatriptan RPD, which he defined has
being unsatisfactory for pain relief. The patient did not receive any infor-
mation about the rescue dose nor prophylactic drugs from the previous
doctors, even though he had been suffering from headache for the past
15 years and was experiencing increased headache frequency.
The patient underwent algological examination: finger pressure caused
pain at the paravertebral cervical muscles conserving flex extension
and laterality of the first trigeminal branch. The trigger point was on
the right trapezoidal muscle.
Chronic sinusitis was found in the patient, who worked in an area sub-
ject to climatic variations. He was allergic to acetylsalicylic acid.
Instrumental diagnosis, x-rays of the head and cervical spine in two
separate moments (23/02/06), showed a reduction of physiological cer-
vical lordosis, which resulted in osteoarthritis. The patient was pre-
scribed the following therapy:
Fluxarten 5 mg at 9 p.m.
Laroxyl 5 mg gtt at 9 p.m.
Sirdalud 1/2 tablet bid
Rizatriptan RPD 10 mg s.l., when needed.
Therapeutic efficacy was and is still being evaluated monthly by VAS.
Results The described therapy was followed continuously considering
the high tolerability of the prophylactic drugs. After 4 weeks, the
monthly frequency of crisis decreased to three, with VAS=7 and the
patient responded to rizatriptan taken at the beginning of the crisis.
After 8 weeks, the frequency decreased to 2 crises, VAS=5, and the
patient responded to rescue dose. Currently, the patient is drug free and
refers two headache crises per month. He has returned to work and now
considers his social life normal.
Conclusions This case represents the paradigm of an incorrect treat-
ment for headache symptoms, regarding both the most suitable strate-
gy to use and when to take the symptomatic drug. It is evident how a
symptomatic strategy for daily headache exposed the patient to drug
overuse and to an unsuccessful therapy causing social and working
problems. It should be mentioned that the lack/absence of correct infor-
mation regarding early prophylaxis also contributed to the unsuccess-
ful resolution of headache pain.
HEMIPLEGIC MIGRAINE WITH PROLONGED SYMPTOMS
IN ATYPICAL STURGE-WEBER SYNDROME
M.A. Tavoni, N. Zamponi, E. Cesaroni, L. Porfiri, C. Cardinali
Riuniti University Hospitals, Paediatric Neurology Department,
Children’s Hospital “G. Salesi”, Ancona, Italy; e-mail: npisalesi@
ao-salesi.marche.it
Introduction The Sturge-Weber Syndrome (SWS) is a rare disease
characterized by an encephalotrigeminal or leptomeningeal
angiomatosis and facial vascular nevus (port-wine stain). It is part of a
phenotypic spectrum, which includes other syndromes with capillary
angiomatosis malformations in various sites, such as Klippel
Trenaunay Weber Syndrome with malformations not only of the capil-
laries, veins, arteries, and lymphatic vessels, but also of soft tissues and
bone hypertrophy [1].
Case report We report a patient with a mixed phenotype, of a facial
nevus on the right forehead, right arm and left leg soft tissues and
bone hypertrophy, obesity, high blood pressure, and epileptic seizures,
who presented at 14-years of age with pulsating unilateral headache
with visual disorders and acute - prolonged left hemiparesis. None of
the episodes were preceded or accompanied by loss of consciousness
or ictal clonic jerks. The EEG was normal during the headache
episode, MRI showed the typical Sturge-Weber angiomatosis without
ischemic lesions.
Results and discussion Our case report suggests a Sturge-Weber atyp-
ical syndrome that could be responsible for symptomatic migraine-like
headache. According to criteria of the ICHD-II classification 2004, this
syndrome could be clinically diagnosed with probable migraine with
aura (subtype 1.6.2) with atypical features.
Vasomotor modifications in venous flow in relation with pial angiomato-
sis are probably at the origin of these migraine-like episodes. Chronic
oligoemia and the pre-existent metabolic cortex damage caused by
hypoperfusion would worsen the clinical symptomatology [2].
Epileptic seizures between the prodromic and pain phase of migraine
attack are rarely reported in paediatric age and in patients affected by
SWS. Probably, the migraine attacks, like the seizures, are to be con-
sidered another expression of brain damage as a result of microvascu-
lar disturbances.
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A CASE OF POSTERIOR SCLERITIS: HEADACHE ATTRIB-
UTED TO OCULAR INFLAMMATORY DISORDER
1S. Ruffatti, 1L. Santelli, 1F. Maggioni, 1E. Mampreso, 2F. Dainese, 
1G. Zanchin
1Headache Centre, Department of Neuroscience, University of Padua,
Padua, Italy; 2Headache Centre, Neurological Unit, SS Giovanni and
Paolo Hospital Venice, Italy; e-mail: silvia.ruffatti@unipd.it
Introduction A case of posterior scleritis is described. Posterior scleritis
is an uncommon form of scleral inflammation, which can be confused
with several inflammatory and non-inflammatory ocular diseases or ocu-
lar tumors. Anterior scleritis can be associated with this condition. It may
be idiopathic or associated with systemic disease, particularly connective
tissue disorders [1]. In the International Headache Society Classification
[2] it is included in the chapter “Headache attributed to ocular inflamma-
tory disorder” (11.3.4). Periocular pain, pain on movement and decreased
vision are the most frequent symptoms [1]. Pain can also be referred to
the forehead, maxilla, or sinuses and is described as penetrating in char-
acter. Redness of the affected eye can be observed. Ultrasonography is the
key investigation necessary to make the diagnosis of posterior scleritis
[1]. CT scan and fundus fluorescein angiography can also be used.
Case history We report a case of a 26-year-old woman who began to
complain of right-sided ocular and periocular pain, exacerbated by
ocular movements, irradiating to the ipsilateral temple and zygoma, not
associated with visual disturbances. Admitted to our Emergency
Department, she underwent an ophthalmological consultation, which
showed a normal fundus oculi and visual acuity. Trigeminal neuralgia
was suspected and she was then treated unsuccessfully with analgesics.
Seven days later, she underwent a second ophthalmological and a neu-
rological consultation, which were both normal. After one week, she
experienced a worsening of facial pain associated with conjunctival
injection, eyelid edema, and developed a central scotoma. She was then
admitted to our clinic. Fundus oculi showed in the right eye a hyper-
emic optic disc with blurred margins. Blurred vision in the right eye
with a central scotoma was referred. The remaining neurological exam-
ination was normal. A third ophthalmological consultation showed a
visual acuity of 1/10 in the right eye (10/10 in the left) with conjuncti-
295
val injection. Fundus oculi confirmed the above reported findings and
some retinal folds; ultrasonography revealed scleral thickening and
exudative retinal detachment, suggesting a posterior scleritis. Chest X-
ray, routine blood tests, brain MRI with gadolinium and cerebrospinal
fluid examination were normal.
The patient was treated with methylprednisolone i.v. 1 gr/day for 10
days with complete regression of pain and clear improvement of visu-
al disturbances. Ultrasonography performed 10 days after the end of
treatment showed a reduction of scleral thickening, fluid in the Tenon
capsule, and regression of retinal detachment. Visual acuity was 6/10
in the right eye. A month after discharge the patient began to complain
of left periocular pain, without visual loss. Ultrasonography showed
posterior scleritis in the left eye; she fully recovered after a further
course of steroid treatment.
Discussion Posterior scleritis is a common form of scleritis and
should be suspected in patients who present with ocular pain and
visual loss. It is one of the most commonly misdiagnosed condi-
tions in ophthalmology, especially when, as in our case, pain is not
associated with visual disturbances or ocular signs at the onset of
symptoms.
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HEADACHE AND ISOLATED PARALYSIS OF THE 12TH
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Case description A 60-year-old man came to our attention for the
onset of symptomatology characterized by continuous, left-sided, fron-
to-orbital headache of moderate intensity, associated with photophobia,
which did not regress after taking common analgesics. After about
three days, the patient presented with a worsening of the headache,
which was of stronger intensity and with the appearance of dysphagia
and dysarthria.
The neurological examination revealed a deficit of the left XIIth cra-
nial nerve. Brain CT, brain MRI, Echo-colordoppler of the supra-aor-
tic vessels, and ultrasound of the neck were normal. Angio-CT and sub-
sequent angio-MRI of the vessels of the neck showed findings com-
patible with dissection of the intrapetrosal segment of the left internal
carotid artery.
Discussion Carotid artery dissection is an important cause of stroke
in the young. Headache and facial pain, often associated with
Horner’s syndrome, constitute a common onset symptom and may
precede stroke by a few days [1]. Headache associated with deficit of
the hypoglossal nerve is not a common onset symptom, and only a
few cases are described in the literature [2]. More frequently, this
symptomatology may be secondary to diseases of the jugular fora-
men, and in this case, is associated with paralysis of other cranial
nerves (IXth and Xth).
In the case described, brain MRI excluded intracranial diseases. Echo-
colorDoppler of the supra-aortic vessels could not visualise the dissec-
tion, in that this involved the intraosseous segment of the internal
carotid artery, thus warranting a specific study of the complete intracra-
nial course of this artery.
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PAINFUL RECURRENT BILATERAL OPHTHALMOPLEGIA
SECONDARY TO BILATERAL CAROTID CAVERNOUS
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Case description A 68-year-old woman presented to us one week
after onset of symptoms characterized by a stabbing headache of
strong intensity, in the retro-orbital and left fronto-temporal regions,
with nausea, photophobia and phonophobia associated with diplop-
ia. The neurological examination revealed paresis of the left VIth
cranial nerve, tactile hypoesthesia, and left-sided pain of the first
division of the trigeminal nerve.
Brain CT revealed slight enhancement with gadolinium in the left
cavernous sinus. Blood tests, Echo-colorDoppler ultrasound of the
supra-aortic vessels and the superficial temporal arteries were normal.
The patient was treated with prednisone 50 mg/day for one week and
subsequently 25 mg/day. After 48 hours the headache regressed, but
the diplopia persisted.
After two months, the patient also presented diplopia on right gaze,
eyelid edema, conjunctival injection in the right eye, associated with
unilateral retro-orbital pain. The neurological examination revealed:
proptosis, eyelid edema, conjunctival chemosis, partial deficit of the
right IIIrd cranial nerve, and deficit of the left VIth cranial nerve.
Brain MRI was repeated and in the norm. Subsequently, brain angio-
MRI was performed, which revealed a bilateral dural fistula of the
cavernous sinuses and the occiptal foramen. 
The lesion was treated with embolization via the left transjugular
approach.
Discussion Dural arteriovenous fistulas (AVFs) are a rare condition,
with a rate of incidence of 0.16 per 100 000 inhabitants/year; with respect
to other intracranial vascular malformations they can be acquired,
often as a consequence of cerebral venous thrombosis, previous head
traumas, aneurysmal rupture, and local and systemic infections [1].
Cavernous carotid fistulas constitute 20%–40% of all dural AVFs
[2], and are formed by an abnormal communication between the
carotid artery and cavernous sinus.
Venous hypertension subsequent to shunt formation results in retro-
grade venous drainage into the ophthalmic venous system, which is
responsible for the ocular symptoms, cortical venous reflux, and ten-
dency to haemorrhage.
Headache is rarely a presenting symptom, but when present, it is
associated with ophthalmoplegia. The differential diagnosis is with
other forms of painful ophthalmoplegia.
Neuroimaging studies are normal or furnish indirect signs (often
non-specific) of fistula presence; the only certain diagnostic investi-
gation is brain angio-MRI [1].
In the case of carotid-cavernous fistulas, among the various thera-
peutic options endovascular embolization is the least invasive
method, and when possibile, the transvenous access can lead to com-
plete obliteration of the fistula [1].
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PAINFUL OPHTHALMOPLEGIA WITH CSF ALTERATIONS: A
CASE REPORT
A. Mercurio, G. Caranci, M. Altieri, V. Di Piero
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Rome “La Sapienza”, Rome, Italy; e-mail: vittorio.dipiero@uniroma1.it
Introduction Painful ophthalmoplegia (PO) is a syndrome character-
ized by the occurrence of periorbital pain and ophthalmoparesis, with
or without the involvement of other cranial nerves, caused by several
different etiologies.
Case historty A 46-year-old man was admitted to our ward, with a
severe dull and steady pain in the right orbit and in the surrounding
area of the forehead, associated a few days later with the appearance of
diplopia and right eyelid ptosis. The neurological examinations showed
a paresis of both the right third and fourth cranial nerves. Physical and
laboratory examinations, trigeminal reflexes, cerebral MRI, arterial
and venous MR angiography were all normal.
A CSF sample showed an elevated protein content (93 mg/dL), with a
positive Pandy reaction and alteration of blood-brain barrier indices,
and was negative for the presence of common infectious agents. Two
days after the clinical admission, the headache disappeared, and the
third and fourth nerve palsy improved significantly, with full recovery
from diplopia a few days later. The increase in CSF proteins persisted
at 2 weeks (73 mg/dL) and 1 month (64 mg/dL).
There are several causes of PO: vascular, inflammatory, infections,
dismetabolisms, neoplasia, trauma, recurrent demyelinating neu-
ropathy and ophthalmoplegic migraine (OM). OM may be suspect-
ed when a severe headache is associated with ophthalmoparesis, nor-
mal MRI investigations and a benign course [1]. In our case this
diagnosis could be hypothesized. In this regard, it is noteworthy that
the IHS criteria (1988) required a single episode (probably because
of its rarity), while ICHD-II criteria require its recurrence [1]. In our
patient, the CSF abnormalities, the single episode and the “non-
migrainous” features of the headache, except for the severity, are
consistent with an uncommon viral infection. Because OM is more
a syndrome than a specific disease, this case suggests that if a diag-
nosis of OM is suspected, the possibility of a benign inflammatory
disease should be considered, in particular, when ICHD-II criteria
are not fully satisfied [1].
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HEADACHE IN A PATIENT WITH CEREBRAL SINUS
THROMBOSIS AND SPONTANEOUS INTRACRANIAL
HYPOTENSION
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Cerebral venous sinus thrombosis (CVST) is an uncommon, life-
threatening condition that mostly affects middle-aged women. The
principal, and also earliest symptom is headache (80%–90%), followed
by other neurological symptoms. The headache has no specific charac-
teristics, is most often diffuse, progressive, severe and associated with
other signs of intracranial hypertension. It can also be unilateral and
sudden, and sometimes mimick migraine, primary thunderclap
headache, cerebrospinal fluid (CSF) hypotension or subarachnoid
haemorrhage (ICHD-II, 2004). CVST recognizes a wide variety of risk
factors and causes. In 20%–35% of cases, where aetiology remains
unknown, CVST is classified as idiopathic.
Intracranial hypotension (ICH) syndrome is a very infrequent clinical
condition. Its most common symptoms are orthostatic headache asso-
ciated with nausea and/or vomiting, diplopia, hearing disturbances
(hypoacusia, tinnitus), neck pain, visual deficit and vertigo.
We report the case of a 43-year-old female who presented with
headache, which began three days before, characterised initially by
pressing/tightening, and later on, pulsating quality localised at the ver-
tex, of mild intensity, without accompanying symptoms, associated with
mild nausea and tinnitus and occurring only on standing. Brain CT scan
showed less evident cortical sulci, small basal cisterns, small ventricular
cavities, without parenchymal alterations. Neurological examination
showed brisk reflexes and bilateral Babinski sign; fundus oculi was nor-
mal. Brain MRI with contrast and angio-MRI showed thrombosis of the
transverse and sigmoid sinuses and of the internal jugular vein on the left
side, along with alterations suggestive of ICH (pachymeningeal contrast
enhancement and Arnold-Chiari-like descent of cerebellar tonsils). The
clinical history was unremarkable, in particular for thromboembolic risk
factors. Complete blood count, thrombophilia tests, and neoplastic
markers were normal, as were ECG, chest X-rays, somatosensory
evoked potentials, and epiaortic vessels and transcranial EchoDoppler.
Spinal MRI with contrast showed signs of CSF leak (deliquoration) in
the dorsal spine. Then, the clinical history was specifically reassessed
and no possible causes of CSF leak were identified. The patient was
treated with anticoagulant therapy: an angio-MRI performed 18 days
later showed a partial recanalization. At discharge and at two months
follow-up the patient was asymptomatic.
Cases of CVST in patients with ICH secondary to CSF leak are found in
the literature, but only 4 cases of CVST have been associated with spon-
taneous ICH. Based on these observations, and on our case, it could be
possible that compensatory venous sinus dilation and consequent hemat-
ic stasis conditions associated with ICH may predispose to CVST.
MIGRAINE WITH VISUAL AURA ASSOCIATED WITH ARTE-
RIOVENOUS MALFORMATION
1G. Alberti, 2A. Giorgetti, 1G.M. Patruno, 1A. Romorini
1Neurology Service, Magenta Hospital, Milan, Italy; 2Neurology Unit,
Neurology Department, Legnano Hospital, Legnano, Milan, Italy; 
e-mail: alessandro.romorini@ao-legnano.it
Objective To describe two cases of migraine with aura associated with
cerebral arteriovenous malformation (AVM).
Case 1: A 57-year-old woman complained of headache of unusual
severity. She had a history of migraine since age 17, characterized by
an aura of scintillating scotoma for 20–30 minutes on the right side.
Thereafter, a strictly unilateral (left-sided in all cases) throbbing
headache with nausea, vomiting and photophobia occurred. Pain was
mild and responsive to simple analgesics. MRI showed an arteriove-
nous malformation in the left occipital lobe.
Case 2: A 22-year-old woman had a history of migraine since age 15
with visual aura of scotoma and fortification (zig-zag patterns) on the
left side, occasionally accompanied by numbness in the left hand and
face. Her mother had a history of migraine. Three times she had tongue
biting; EEG showed epileptiform discharges. She started valproate
therapy and the visual aura terminated. The aura always occurred on
the left suggesting a possible right-sided structural lesion. MRI showed
a right parietal AVM.
Discussion Arteriovenous malformation is a congenital anomaly that
consists of abnormal arteries and veins without the presence of a cap-
illary bed. The majority of patients initially show intracranial haemor-
rhage, while others may present symptoms of seizures, headaches and
progressive neurological deficits. In the general population, AVMs are
an extremely infrequent cause of headache. Headache occurs in
10%–50% of patients with AVM. The headache may be typical of
migraine. Migraine headaches have a complex pathophysiology, and
(both vascular and neuronal mechanisms) have been proposed. One
possible scenario begins with brain initiated events evolving to cortical
spreading depression (CSD). Susceptibility to CSD appears to be
genetically determined. Structural lesions may cause the initial event.
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When a patient with migraine manifests symptoms always on the same
side, neuroimaging workup is warranted. This should aid in the early
diagnosis of cerebral AVM in order to start treatment before the occur-
rence of cerebral haemorrhage.
TRIGEMINAL NEURALGIA AS PRESENTING SYMPTOM OF
ARNOLD CHIARI TYPE 1 MALFORMATION: A CASE
REPORT
G. Caranci, A. Mercurio, M. Altieri, V. Di Piero
Headache Centre, Department of Neurological Sciences, University of
Rome “La Sapienza”, Rome, Italy; e-mail: vittorio.dipiero@uniroma1.it
Introduction Clinical presentation of Arnold Chiari type 1 malforma-
tion is highly variable. About 13% of patients are asymptomatic;
headache may be the sole clinical manifestation of the malformation;
however, it is one of the most frequent. No headache type seems to be
particular to the malformation; both short- and long-lasting headaches
are described [1].
Case history A 36-year-old woman presented with throbbing-stabbing
pain in the left supraorbital region, which started 3 years earlier. Pain
occurred three or four times a day; the paroxystic pain was severe, and
lasted 7–10 seconds. There were no warning symptoms; trigger factors
were coughing, sneezing, defecation, and nodding movement. There
were no accompanying symptoms but mild nausea. Between attacks,
she was completely pain-free. She was treated with NSAIDs and car-
bamazepine without any improvement. Neurological examination and
laboratory blood tests were normal. MRI showed an Arnold Chiari type
1 malformation with downward herniation of the cerebellar tonsils
through the foramen magnum into the upper cervical spinal canal. A
CT scan of the maxillary and frontal sinuses was normal.
Neurosurgical intervention was suggested.
Discussion Our patient satisfied all the criteria for a symptomatic neu-
ralgia probably caused by the Arnold Chiari type 1 malformation. In
this view, we excluded other types of headaches, such as rhinosinusi-
tis, short-lasting unilateral neuralgiform headache attacks with con-
junctival injection and tearing (SUNCT), supraorbital neuralgia and
idiopathic trigeminal neuralgia. The otolaryngologic examination and
CT scan excluded the possibility of rhinosinusitis.
Due to the location, duration and frequency of the pain described, it
could be compatible with a SUNCT, however, the neurovegetative dis-
turbances, such as conjunctival injection and lacrimation, were absent.
Regarding the supraorbital neuralgia, it lacked tenderness over the
nerve in the supraorbital notch, and there was no pain in the medial
aspect of the forehead in the area supplied by the supraorbital nerve.
Unlike trigeminal neuralgia, there were no trigger points, a very rare
location only in the first branch, and the lack of any response to high
carbamazepine dosage [1].
Conclusions To our knowledge, this is the first case with Arnold Chiari
Type 1 malformation and symptomatic trigeminal neuralgia exclusive-
ly in the first branch. It is probable that the pain is caused by an
anatomical compression on the trigeminal nucleus, and that the differ-
ence in pressure found in the intracranial and intraspinal compart-
ments, evoked by the Valsalva maneuvre, emphasises this compres-
sion, setting off the short-lasting sharp pains [2].
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HEADACHE ATTRIBUTED TO BRAIN ABSCESS: A CASE
REPORT
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Brain abscess is a focal suppurative process in the brain parenchyma
that still contributes to high mortality rates. Outcome is closely related
to correct and early management. In order to evaluate early manage-
ment, we have reviewed the brain abscesses treated in our Department
of Neurosurgery during the last five years, choosing to describe one
case among these. We present a 38-year-old male who was admitted to
the Emergency Department (ED) complaining of a frontal headache
and fever (37.5C°), unresponsive to treatment with NSAIDs. The
patient described weakness and numbness of the right limb, which
resolved in 20–30 minutes. After CT scan resulted normal, the patient
was discharged. The day after, the patient returned to the ED com-
plaining of two new episodes, characterized by weakness and numb-
ness involving the right limb with spontaneous resolution in ten min-
utes, while an intense, diffuse bilateral headache persisted. The patient
was admitted to our department. The neurological examination was
unremarkable. However, within five days the patient showed right
hemiparesis; the inflammatory index was elevated and MRI revealed a
productive, expanding lesion with marked edema in the left parietal
region. The modality of treatment was surgical excision with catheter
drainage-aspiration of the left parietal abscess. Outcome was excellent:
the patient recovered promptly from the hemiparesis, and there was
progressive attenuation of headache until it disappeared. Brain
abscesses are severe infections with lethal outcome in the case of delay
in diagnosis and treatment. Predisposing factors are sepsis of adjacent
organs and bacteraemia. The most frequent clinical manifestations are
fever and headache. Headache is usually the most frequently encoun-
tered symptom. When under observation our patient continuously com-
plained of bilateral, constant headache with increasing intensity to
severe grade, aggravated by straining and accompanied by nausea. A
new type of headache associated with general feeling of illness and/or
fever should direct attention toward an intracranial infection.
IS THE TREATMENT OF HEADACHE BY SPONTANEOUS
CERVICAL CSF LEAK WITH LUMBAR EPIDURAL BLOOD
PATCH A RATIONAL CHOICE?
1E. Ferrante, 2I. Arpino, 1A. Citterio, 2A. Savino
1Neurosciences and 2Emergency Departments, Niguarda Cà Granda
Hospital, Milan, Italy; e-mail: enricoferrante@libero.it
Background Spontaneous intracranial hypotension (SIH) generally
results from spinal spontaneous CSF leakage [1]. Treatment is usually
conservative. Sometimes an autologous EBP at the site of CSF leakage
may be necessary [2].
Objective To evaluate the spread of blood injected into the epidural
space during lumbar epidural blood patch (LEBP) for treatment of
spontaneous cervical CSF leakage (SCCSFL) by MRI.
Materials and methods We report one case of SCCSFL [among the 32
with this condition evaluated between 1992 and the present].
Results A 45-year-old man presented sudden, intense, gravative fron-
to-occipital orthostatic headache. Neurological examination, routine
blood tests, and brain CT scan were normal. Brain MRI showed diffuse
pachymeningeal enhancement. Gadolinium spinal MRI showed CSF
epidural collection from C2 to D3. After one month of bed rest, ortho-
static headache was still present. The patient was treated with autolo-
gous lumbar EBP (25 mL) at the L2-L3 level. The blood was mixed
with 0.05 mL of gadolinium. During and after injection, he remained
in the Trendelenburg position (TP) approximately 30° for 1 hour.
Spinal post-patch MRI showed gadolinium mixed with blood in the
epidural space from the lumbar to cervical level (C2-C3). He subse-
quently remained in the TP for 22 hours. He was asymptomatic within
24 hours after LEBP. At 6-month follow-up he was asymptomatic.
Discussion and conclusions We demonstrate that EBP, even though
injected at the level of the lumbar spine (i.e., far from the site of CSF
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leak), may move upward reaching the cervical segments. This is possi-
bly favoured by the TP. A rapid coagulation response at the level of the
dural hole stops CSF leakage. Thus, EBP at the level of the cervical
spine, where the procedure is difficult to attempt, may not be neces-
sary. To our knowledge, this is the first report that shows the spread of
blood from lumbar to cervical epidural space with LEBP and demon-
strates that the treatment of spontaneous cervical CSF leak with autol-
ogous lumbar epidural blood patch is a rational choice.
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REFERRED FACIAL PAIN AS A SYMPTOM OF NON-
METASTATIC LUNG CANCER: A CASE REPORT AND
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Introduction Facial pain is a common clinical symptom caused by a
wide variety of underlying conditions, including neurological, odonto-
logical, and otolaryngological pathologies. A patient who developed an
intractable facial pain as an unusual first manifestation of a remote
lung carcinoma is described.
Case Report A 39-year-old woman presented with a 2-month history
of pain localized in the left jaw, with extension into the ipsilateral orbit
and temple. The pain was continuous, moderate to severe in intensity,
and possibly associated with tearing, eye redness, and mild nausea. She
had been smoking 1 pack of cigarettes a day, for at least 20 years. An
odontological visit, a brain MRI and a carotid Doppler ultrasound were
normal. The pain was unresponsive to a number of analgesics as well
as carbamazepine, gabapentin, and prednisone. About 2 weeks before
presentation the patient developed cough and poor appetite. The neu-
rological examination was unremarkable. The physical examination
revealed diminished breath sounds in the left-upper lobe and right
supraclavicular lymphadenopathy. A CT scan of the chest showed a
large solid mass in the superior aspect of the left mediastinum sur-
rounding the supra-aortic vessels and hilus. A fine-needle biopsy of the
supraclavicular node confirmed the presence of a large cell carcinoma.
The ESR was markedly elevated at 83 mm/h. A few days later, the
patient became dysphonic, with laryngoscopic evidence of paresis in
adduction of the left vocal cord. The facial pain gradually improved
and then spontaneously ceased before starting chemotherapy. The
patient was still pain-free after a 6 months follow-up.
Discussion Referred facial pain is a rare symptom of nonmetastatic
malignant lung lesions, and was first described by Des Prez and
Freemon in 1983. Since then, 36 patients (17 M, 19 F) have been
described, including the present patient. The presumed mechanism by
which a thoracic mass can provoke a pain referred to the face is com-
pression of the vagus nerve, which drives pain signals originating from
thoracic and abdominal viscera. Convergence of the visceral and somat-
ic afferents at the level of the descending nucleus of the trigeminal sys-
tem may explain the ipsilateral referred facial pain. The most frequent
locations are the ear (about 90% of cases), jaw and temple. The diagno-
sis can be delayed from 1 month to 4 years after the onset of the pain.
All patients described were smokers. ESR is increased in most patients.
Unlike the previous cases, in the present case the pain spontaneously
disappeared after the patient became dysphonic, indicating the putative
importance of the integrity, at least in part, of the laryngeal nerve.
Conclusions Lung cancer should be included in the differential diag-
nosis of facial pain with atypical signs and/or refractory to treatment.
A CASE OF ATYPICAL INTRACTABLE FACIAL PAIN SEC-
ONDARY TO METASTATIC LUNG CANCER
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Introduction Persistent idiopathic facial pain is defined by the
International Headache Society Classification (ICHD-II) (chapter
13.18.4) as a pain in the face, present daily and persisting for all or
most of the day, confined at onset to a limited area on one side of the
face, deep and poorly localised. According to the classification, pain
around the ear or temple may precede the detection of an ipsilateral
lung carcinoma [1]. Nearly 30 cases of intractable facial pain sec-
ondary to lung neoplasm are described in the literature [2]. We report
a case of intractable facial pain associated with metastatic lung cancer.
Case history A 70-year-old woman presented to the clinic with a 15-
month history of constant, right-sided facial pain, with paroxysms of the
upper teeth, irradiating to the auricular and temporal areas. Six months
after the onset of pain she underwent CT scan and EEG, which were
both normal. She was unsuccessfully treated with amitriptyline (40 mg
per day) and gabapentin (up to 2000 mg per day). She had additional
complaints of poor appetite with weight loss of 4 kg in the last 6 months
and a 9-month history of persistent cough with recent onset of chest
pain on the right side. Auscultation of the lungs revealed abnormal
breath sounds on the right hemithorax; neurological examination
revealed a sensory loss on the right side of the face. Routine blood tests
were normal. Chest X-ray revealed a mass in the right hylar region, con-
firmed by chest CT. She underwent bronchoscopy with lung biopsy; the
histological examination revealed pulmonary adenocarcinoma. Brain
MRI with gadolinium revealed small multiple supratentorial and
infratentorial brain lesions, none of them localized near the right trigem-
inal nucleus and pathways. The patient was treated with chemotherapy
with slight improvement of facial pain. She died shortly thereafter. 
Discussion Facial pain secondary to lung cancer is usually described as
a unilateral constant ache, ipsilateral to the lung mass, frequently
involving the auricular area, and often associated with signs suggesting
a lung cancer (weight loss, digital clubbing, cough, etc.). The pain
seems to be due to invasion of the vagus nerve [2]. Our case referred
to a metastatic lung cancer, but none of the lesions seen on brain MRI
could possibly explain the pain referred by the patient and probably
occurred at a distance from the onset of pain. It is important to consid-
er lung neoplasm as a possible cause of facial pain, especially if it pre-
sents with the characteristics seen above and in smokers.
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Introduction In recent years the quality of medical research in the
field of headaches has reached levels of excellence that have amazing-
ly broadened our panorama of knowledge and justified the develop-
ment in the international publishing field of specialized journals.
Discussion Confinia Cephalalgica was born at the Neurological Institute
C. Mondino in Pavia, at the end of the 1980s. At the beginning, it was the
official journal of the Italian Society for the Study of Headaches, and then
it became the official journal of the University Centres for Adaptive
Disorders and Headache. The journal is published 3 times a year and con-
tains original articles, clinical cases of interest, impossible cases, reviews,
editorials, therapeutic and historical notes, book reviews and congress
reports. The goal of the journal is to constitute a forum for integrating dif-
ferent ideas and expertise through an open dialogue among experts from
different disciplines in order to contribute to the advancement and devel-
opment of knowledge in the field of headaches. The editorial board has
always supported the role of the journal as a tool for communication and
cultural exchange on headache themes, among Italian-English communi-
ties in the world and between Italy and others countries with neolatin lan-
guage and culture. Not less important is its role as the expression of the
patient associations (AL.CE. Group – CIRNA Foundation) that financially
supported the journal. During the last ten years (1997–2006), the journal
published upon invitation or by direct submission more than 120 papers,
furnished by 354 authors. The journal publishes integrated scientific infor-
mation, promoting a multidisciplinary environment that involves first of all
neurologists, but also philosophers and psychiatrists, physiologists and
men of literature. After the restyling of the journal cover in 2004, beginning
this year, Confinia Cephalalgica is editing, except for special events, only
in an online version (free download at the website www.cefalea.it).
Conclusions Although the paper version will be missed, the new elec-
tronic online version is looked at as a challenge, with the desire to be
of valuable assistance for physicians and researchers. Thus, the future
challenge will be the confrontation and exchange of headache infor-
mation on the Web.
HEADACHES: THERAPEUTIC ASPECTS
TOPIRAMATE IN MIGRAINE PROPHYLAXIS: AN OPEN
STUDY
R. Iannacchero, F. Peltrone, U. Cannistrà, E. De Caro
Regional Headache Centre, “Pugliese-Ciaccio” Hospital, Catanzaro,
Italy; e-mail: rosarioiann@tiscali.it
Introduction Patients who suffer frequent severe migraine or chronic
daily headaches are often prescribed prophylactic drugs. A number of
beta-blockers, calcium-channel blockers, serotonin agonists, and anti-
depressants have been tested as prophylactic agents. Topiramate is a
new antiepileptic agent that has GABA agonist properties and has few
side effects when used in low doses.
Objective and methods The aim of this study was to examine the
effects of topiramate on the frequency and intensity of migraine attacks
during prolonged use. Patients who demonstrated 3 to 10 migraine
attacks per month; in addition to migraine, also had chronic daily
headaches from a variety of causes, and all patients had failed treat-
ment with a number of prophylactic agents.
Results We present 35 patients, who kept a daily diary that recorded
the frequency, severity of headaches, and the amount and type of res-
cue medication used. Over a 3–9 months follow-up, 11 patients (30%)
had a very significant improvement in headache frequency (headaches
decreased by over 60%), and 11 patients had a moderate improvement
in headaches (decrease of 40%–60%). Three patients discontinued
therapy due to side effects (lightheadedness, tinnitus, and numbness in
hand) and eight patients did not report any improvement despite hav-
ing been on therapy for over 12 weeks. The remainder of patients had
only 8 weeks of therapy.
Conclusions Our open uncontrolled study in patients with resistant
headaches suggests that topiramate may be a useful prophylactic med-
ication with limited side effects. A large placebo-controlled study is
needed, however, before the results are generalized.
PROPHYLAXIS OF HEMICRANIA CONTINUA WITH TOPI-
RAMATE: REPORT OF 2 CASES
1A. Palermo, 1G. Giglia, 2A. Sandullo, 1G. Cosentino, 1F. Brighina, 
1B. Fierro
1Department of Neurology, Ophthalmology, Otorhinolaryngology and
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Introduction Hemicrania Continua (HC) is an uncommon and under-
recognized primary headache disorder. It is characterized by a strictly
unilateral continuous headache of moderate intensity with possible
exacerbations, and it is associated with ipsilateral autonomic features,
such as ptosis, miosis, conjunctival injection, lacrimation or rhinor-
rhoea, that tend to be less pronounced than those seen with cluster
headache [1]. The pathophysiology of HC is poorly understood.
HC has generally a prompt and enduring response to indomethacin
25–300 mg daily, although 25%–50% of treated patients develop gas-
trointestinal side effects and unresponsive forms have been described.
Patients who cannot tolerate indomethacin pose a difficult manage-
ment challenge as no other drug is consistently effective in HC.
Recently, Matharu et al. [2] reported 2 patients affected by atypical
forms of HC that showed good response to topiramate.
Case reports Here we describe two patients who fulfil both the IHS
diagnostic criteria for HC. The physical and neurological examinations
and brain magnetic resonance imaging with gadolinium were normal in
both patients.
The patients demonstrated a very good response to indomethacin but
both developed the most common side effect, gastritis, that led us to
stop this treatment. Thus, these patients were started on topiramate
with slow titration to 100 mg b.d, and they had a complete benefit with
the prophylatic treatment with topiramate after 30 days. The dose of
topiramate required to give complete relief of pain was somewhat less
than that usually needed for the antiepileptic effect of the drug. There
were no side effects during the treatment with topiramate.
Discussion and conclusions Topiramate has multiple mechanisms of
action, which include: blockade of the voltage-mediated sodium chan-
nels, enhancement of GABA-mediated chloride influx to GABA antag-
onism of the glutamate kainate/AMPA receptor and carbonic anhy-
drase inhibition. The mechanism(s) of action responsible for the bene-
ficial effect in various headache syndromes is currently unknown.
Whatever the mechanism, if the favourable response observed in our
patients can be confirmed in other cases, it would broaden the thera-
peutic armamentarium available for the treatment of this severe and
sometimes incapacitating condition.
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EFFICACY AND TOLERABILITY OF LEVETIRACETAM IN
EPISODIC AND CHRONIC MIGRAINE
1G. Dalla Volta, 1S. Griffini, 1P. Zavarise, 2A. Pezzini
1Neurology Unit, Clinical Intitute, Brescia, Italy; 2Stroke Unit, Vascular
Neurology, Civilian Hospital, Brescia, Italy; e-mail: dalla@numerica.it
Background Because of its effect in stabilizing neuronal hyperex-
citability, the antiepileptic drug levetiracetam is a promising molecule
for the prophylaxis of migraine.
300
Methods Twenty-five patients with episodic migraine without aura (at
least 4 attacks per month of moderate-severe intensity; Group 1) and
18 patients with chronic migraine (no drug abuse; Group 2) were treat-
ed with levetiracetam 500 mg/day for 5 days, increased to 1000 mg/day
in two administrations, after 5 days. Number of days with
headache/month, accompanying symptoms (mild-moderate vs severe),
use of symptomatic drugs for migraine attacks (number of drugs), and
side effects of levetiracetam were recorded at baseline and at the end
of the 3-month treatment period in both groups.
Results One patient in Group 1 did not complete the study because of
intolerable side effects (somnolence and asthenia). Patients in Group 1
reported a mean reduction in the number of days/month with headache
from 8.4 at baseline to 4.1. In Group 2, 12 patients were nolonger clas-
sified as chronic (from 23.8 to 10.3 days/month, mean values), four
patients had an improvement of their chronic headache (from 23.8 to
16.2 days/month, mean values) and two had no improvement at the end
of the treatment period. Severe accompanying symptoms became mild-
moderate in 83% of patients in Group 1 and in 62% of patients in
Group 2. Drug intake for acute attacks per month changed from 12.3 at
baseline to 5.2 drugs in Group 1 and from 32 to 13 drugs in Group 2.
Side effects were somnolence (6 patients - 5 patients), asthenia (4 and
3), postural instability (2 and 0) in Groups 1 and 2, respectively.
Conclusions This study confirms the role of levetiracetam as a poten-
tial preventive treatment for migraine.
COMBINED NEUROMUSCULAR RELAXING AND SHIATSU
TREATMENT INTEGRATED WITH MELATONIN IN TEN-
SION-TYPE HEADACHE
A. Lera, M. Bernardini
Headache Centre DSM Giulianova, ASL Teramo, Teramo, Italy; 
e-mail: antonio.lera@aslteramo.it
Objective The aim of this study was to evaluate a combined neuro-
muscular relaxing and Shiatsu programme integrated with melatonin in
the treatment of tension-type headache. We tried to consider a possible
positive role of physical activity in reducing the frequency and intensi-
ty of headache attacks and, in particular, in decreasing activity limita-
tions at a working, social and family level, and therefore, to evaluate
the overall improvement in the patients’ quality of life.
Patients and methods Before enrolment in the study, 20 middle-aged
female subjects underwent psychodiagnostic evaluation with the fol-
lowing scales: MIDAS, MSQOL, MQoLQ, HIT, and MSQ. We utilised
the MIDAS scale in this study because it is an objective measure of the
severity of a headache attack; it specifies the level of inability and is
suitable for identifying the appropriate therapy on the basis of the sever-
ity level of each patient. MIDAS scores for our patients were between
6 and 10, which indicated no need for pharmacological therapy, exclud-
ing headaches with mild (level 1) and severe inability (levels 3–4). 
The study group, consisting of 10 females aged 35 – 60 years, under-
went combined neuromuscular, relaxing and shiatsu treatment every
week, integrated with melatonin retard formulation, 1 tablet per day,
for the entire length of the study. For the combined treatment there was
a successive prolongation phase: at first, every 15 days for an addi-
tional three months, then every month for a further three months. A
control group of the same number of subjects did not carry out any
treatment programme. At the end of nine months, both the study and
control groups underwent another psychodiagnostic evaluation.
Results Comparison of the MIDAS scores between the first and last
evaluations showed a decrease of six points in 10% of cases, five points
in 20%, four points in 15%, two points in 25%, with no change in 30%
of cases in the study group. No statistical difference was observed in the
comparison of the same group of MIDAS scores in the control group,
indicating a positive result only for the combined neuromuscular relax-
ing and Shiatsu programme integrated with melatonin. 
Conclusions On the basis of our results, we can assert that in the study
group, which underwent combined neuromuscular relaxing and Shiatsu
treatment integrated with Melatonin retard formulation, the quality of
life as evaluated by the MIDAS scale was improved significantly. This
combination programme seems to have a positive role in reducing the
frequency of headache attacks and in alleviating their severity.
EFFECTS OF DENTAL MALOCCLUSION CORRECTION ON
PAIN FROM CHRONIC TENSION-TYPE HEADACHE
L. Di Ianni, E. Tafuri, A. Fabrizio, A. Savini, G. Sidonio, G. Affaitati,
R. Lerza, P. de Bigontina, A. Mezzetti, M.A. Giamberardino
Headache Centre, “G. D’Annunzio” University of Chieti, Chieti, Italy;
e-mail: ldiianni@interfree.it
Introduction Dental malocclusion is a very frequent finding in
patients with chronic tension-type headache. The aim of this study was
to investigate how malocclusion contributes to both the subjective
(number and intensity of attacks) and objective (pain thresholds in
muscles of the cervical and upper shoulder regions) painful sympto-
matology of this type of headache.
Methods Twenty-five patients (18 women and 7 men, aged 18–36 years)
were studied. They had been suffering from chronic tension-type
headache for at least 1 year prior to examination (diagnosis performed
according to IHS criteria) and also presented dental malocclusion. Their
headache pain was located in the occipital, parietotemporal and, in 11
cases, also fronto-orbital regions, bilaterally. In all of them pain thresh-
olds to electrical stimulation were measured bilaterally in the trapezius,
sternocleidomastoid and splenius muscles before and 30 days after appli-
cation of the bite to correct dental malocclusion. Measurements were
performed in the pain-free interval. Number and maximal intensity (VAS
scale) of headache attacks were also recorded in the month of treatment
and compared with those relative to the 30 days preceding treatment.
Results Before treatment, pain thresholds in all muscles were signifi-
cantly lower when compared to thresholds recorded in corresponding
sites of 20 non-headache sufferers (p<0.001) (hyperalgesia). In the
month of application of the bite there was a significant reduction in the
number of headache attacks (p<0.003) but not of their peak intensity;
pain thresholds on day 30 were still lower than normal (p<0.05) but
significantly increased with respect to pre-treatment values (p<0.008
for trapezius, p<0.004 for sternocleidomastoid, p<0.007 for splenius).
A significant linear correlation was found between the decrease in
headache pain and the increase in threshold (p<0.01).
Conclusions In patients with chronic tension-type headache, dental
malocclusion contributes directly to the triggering of the painful
attacks, probably through sensitization of muscles of the cervical/upper
shoulder regions.
EFFICACY OF A WORKPLACE COGNITIVE AND PHYSICAL
PROGRAMME ON PSYCHOSOMATIC SYMPTOMS IN A
WORKING COMMUNITY WITH HEADACHE, NECK AND
SHOULDER PAIN: A LONGITUDINAL CONTROLLED STUDY
1F. Mongini, 1E. Rota, 2G. Ciccone, 2C. Galassi, 1L. Ferrero, 1A. Ugolini
1Headache-Facial Pain Section, Department of Clinical
Pathophysiology, University of Turin, Turin, Italy; 2Unit of Cancer
Epidemiology, San Giovanni Battista Hospital, Turin, Italy; e-mail:
franco.mongini@unito.it
Objective Our purpose was to examine the effect of a workplace cogni-
tive programme on psychosomatic symptoms in a working community.
Materials and methods Three hundred and eighty-four employees of
the city of Turin, whose working activities involved public contact (reg-
istry and tax office), were divided into two groups: study group (n=192)
and controls (n=192). In all subjects data regarding headache, neck and
shoulder pain, if present, were collected in a standardized fashion. Each
subject underwent a physical examination and muscle palpation of per-
icranial and cervical muscles. The presence of 28 symptoms, mainly
psychosomatic in nature, (such as colitis, gastritis, swallowing difficul-
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ties, digestive difficulties, phobias, sleep disorders, palpitations, dizzi-
ness, cramps, etc.) were also assessed. These items that belong to those
generally investigated when taking a medical history showed in previ-
ous studies a significantly higher prevalence in pain patients in respect
to a normal population. An instruction programme was then adminis-
tered to the study group: it consisted of brief shoulder and neck exer-
cises, a relaxation exercise and instructions on how to reduce hyper-
function of the craniofacial and cervical muscles during the day. After
six months, all subjects were re-examined in the same way as at base-
line and the presence of psychosomatic symptoms was assessed again.
In the two groups, the difference between the data at baseline and those
at the end was calculated and the data compared (Student’s test).
Results In the study group, the mean amount of psychosomatic symp-
toms decreased significantly (p=0.002) from baseline (7.27±5.19 SD) to
the end (5.73±4.77 SD). In the control group no significant difference
was observed (baseline: 6.65±5.07 SD; end: 6.55±4.93 SD; p=0.78).
Discussion The data demonstrate that the administration of a simple
cognitive instruction programme can significantly decrease psychoso-
matic symptoms in a working community. This finding, in contrast,
may be the direct consequence of the cognitive programme, or may be
partially due to the beneficial effects of such programme on the
headache, neck and shoulder pain in the study population.
Conclusions A cognitive instruction programme can significantly
reduce the presence of psychosomatic symptoms in extensive popula-
tion samples.
EFFECTIVENESS OF AN INTEGRATED APPROACH IN THE
PROPHYLACTIC TREATMENT OF CHRONIC TENSION-
TYPE HEADACHE
1,2,3B. Ciccone, 1,2,3G. Griso, 1,2,3S. Lenzuolo
1Headache Clinic, Medicine of the Future, Acerra, Naples, Italy;
2Medical Diagnostics Clinic, Mercogliano, Avellino, Italy; 3Athena
Clinic, Saviano, Naples, Italy; e-mail: b.ciccone@libero.it
Introduction Retrospective study of patients from our clinics, suffering
from chronic tension-type headache (CTTH), diagnosed in accordance
with the criteria of the ICHD-II classification, code 2.3 (OMS G44.2).
Objective The purpose of this study was to demonstrate the effectiveness
of an integrated pharmacological and non pharmacological approach
compared with an approach that was exclusively pharmacological.
Materials and methods We selected 14 patients suffering from CTTH,
14 F, mean age 33 years (range 15–59)±14.1 years, who used an inte-
grated prophylactic therapy, compared with 14 patients suffering from
CTTC, 1 M and 13 F, mean age 33 years (range 13–50)±11.7 years,
treated solely with medication. The study was carried out over a period
lasting from 60 to 180 days. The patients using the integrated approach
received daily medication in addition to a weekly session of relational
systemic psychotherapy consisting of individual and familial meetings
(7 patients) or osteopathic treatment consisting of craniosacral therapy
and visceral manipulation (7 patients). The patients in the control group
(14) underwent only daily pharmacological prophylactic treatment.
The clinical diary regarding the headache of each patient was reviewed
to determine the number of crises per month and to monitor the per-
centage decrease of the crises.
Results The patient group following the pharmacological prophy-
laxis had only an average decrease of 64% in the number of
headaches per month.
The patient group using the integrated approach with weekly psy-
chotherapy had an average decrease of 88%, while the patients who
underwent craniosacral/visceral manipulation treatment had an average
decrease of 92%. Comparison of the two treatments indicated a statis-
tically significant decrease (p<0.005).
Discussion and conclusions The integrated approach in patients with
CTTH is more effective than the pharmacological approach alone, as it
affects treatment motivation, therapeutic reliability, compliance and
the consequent improvement of quality of life.
RATIONAL EMOTIVE BEHAVIOUR THERAPHY (REBT) IN
TENSION HEADACHE
1A. Mascaro, 1I. Salvaggio, 1E. Adducci, 1S. Barbi, 1L. Zappia, 
2G. Di Trapani
1Department of Anaesthesiology and Intensive Care and 2Department
of Neurology, Catholic University Medical School, Rome, Italy; 
e-mail: iclar@rm.unicatt.it
Introduction During the last few years, many studies have demonstrat-
ed how an emotional condition can influence pain. This aspect is espe-
cially evident for headache, in which the connection between emotion-
ality, pain, intensity and frequency is very important. In the Centre for
Pathophysiology and Pain Therapy of the Catholic University Medical
School of Rome, we studied a Rational Emotive Behaviour Therapy
(REBT) that underscores the importance of patients’ cognitive process-
es in the genesis and feeding of emotive and behavioural disturbances.
Materials and methods From September 2004 to April 2006, after
informed consent, we studied 60 patients (35 females and 25 males,
mean age 35 years). Their tension headaches (ICHD-II criteria, 2004)
were bilateral with occipital localization, without aura, vomiting, pho-
tophobia and phonophobia; they had eight crises per month and visual
analogue scale (VAS) score=7.
Their clinical history, objective and neurological examinations exclud-
ed a secondary headache. We had an indepth conversation with each
patient, and we noticed that everyone was depressed or anxious or hos-
tile; we gave them some forms to fill out and a headache diary to com-
plete before and after the start of therapy. They were divided into two
randomised groups of 30 patients. The first group was treated with cog-
nitive, emotional and behavioural techniques; the second group was
treated with pharmacological therapy with amitriptyline 30 mg/day,
alprazolam 0.25 mg/day and celecoxib 200 mg, if needed. They were
treated for 6 months.
Results In the first group, treated with cognitive psychotherapy, VAS
decreased from 7 to 3, the crises decreased from 8 to 2, and the emo-
tional condition improved with a reduction of depression, anxiety and
hostility. In the second group, treated with pharmacological therapy,
VAS decreased from 7 to 2, and the crises decreased from 8 to 3.
Conclusions From our results we observed that patients treated with
cognitive psychotherapy showed improvement in VAS scores and their
emotional condition, and reduction in the number of montly crises,
while patients treated with pharmacological therapy also had improved
VAS scores and reduction in the number of crises, but with no modifi-
cations of their emotional condition.
GYMNASTIC-PHYSICAL ACTIVITY: PERFECT SHAPE
FUNCTION IN MIGRAINE AND CLUSTER HEADACHE
1A. Lera, 1M. Bernardini, 2C. Germani
1Headache Centre DSM Giulianova, ASL Teramo, Teramo, Italy;
2Institute of Experimental Research for Motor Sciences Life Quality
Project, S. Benedetto del Tronto, Ascoli Piceno, Italy; e-mail:
antonio.lera@aslteramo.it
Objective The aim of this study was to evaluate the effects of a pro-
gramme of gymnastic-physical activity (Perfect Shape System) on the
quality of life in a group of subjects suffering from migraine and clus-
ter headache. We tried to consider a possible positive role of physical
activity in reducing the frequency and intensity of headache attacks
and, in particular, in decreasing inability at a working, social and fam-
ily level, and therefore, improving overall the patients’ quality of life.
Patients and methods Before enrolment in the study, forty subjects
suffering from primary headaches (30 with migraine and 10 with clus-
ter headache) underwent clinical evaluation with the following scales:
MIDAS, MSQOL, MQoLQ, HIT, and MSQ. We utilised the MIDAS
scale in this study since it is an instrument which objectively measures
the severity of a headache attack; it specifies the inability level and is
suitable for identifying the appropriate therapy on the basis of the
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severity level of each patient. MIDAS scores for our patient group
were between 6 and 10, which indicated no need for pharmacological
antimigraine therapy, excluding headaches causing mild (level 1) and
severe inability (levels 3–4). 
The study group consisted of 20 females aged 35–60 years, who under-
went gymnastic-physical activity through the methodical Perfect Shape
System, which lasted two months, followed by further activities for an
additional six months. A control group of equal number of subjects did
not carry out any gymnastic-physical programme at all. At the end of
eight months, all 40 patients of both the study and control groups,
underwent another clinical evaluation.
Results Comparison of the MIDAS scores between the first and last
evaluations showed a decrease of seven points in 5% of cases, six
points in 5%, five points in 15%, three points in 10%, one point in
20%, with no change in 45% of cases for the subjects who practised
Perfect Shape. No statistical difference was observed in the compari-
son of the same group of MIDAS scores in the control group, indicat-
ing a positive result only for the patients who followed the Perfect
Shape programme. 
Conclusions On the basis of our results, we can assert that in the study
group, which followed the Perfect Shape System, the quality of life as
evaluated by the MIDAS scale improved, although in a different way,
with reduction in negative social, working and family effects. This is
in marked contrast to the control group, who showed no improvement
in quality of life parameters. Gymnastic-physical activity and, in par-
ticular, the Perfect Shape programme, seem to contribute in a positive
way to reducing the frequency of headache attacks and to alleviating
their severity. However, there were no relevant changes in terms of
quality of life parameters between the different forms of primary
headaches.
USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE
BY PATIENTS WITH CLUSTER HEADACHE: RESULTS OF A
MULTI-CENTRE HEADACHE CLINIC SURVEY
1,2P. Rossi, 3P. Torelli, 1C. Di Lorenzo, 2G. Sances, 3G.C. Manzoni, 
2C. Tassorelli, 2,4G. Nappi
1Headache Clinic, INI Grottaferrata, Grottaferrata, Rome, Italy;
2UCADH Pavia, Italy; 3UCADH Parma, Italy; 4University of Rome
“La Sapienza”, Rome, Italy; e-mail: paolo.rossi90@alice.it
The use of complementary and alternative medicine (CAM) in cluster
headache (CH) is a phenomenon about which little is known. This
study was undertaken to evaluate the rates, pattern, satisfaction and
presence of predictors of CAM use in a clinical population of patients
with CH. One hundred CH patients attending three headache clinics
were asked to undergo a physician-administered structured interview
designed to gather information on CAM use.
Past use of CAM therapies was reported by 29% of the patients sur-
veyed, with 10% having used CAM in the previous year. Only 8% of
the therapies used were perceived as effective, while a partial effec-
tiveness was reported in 28% of CAM treatments. The most common
source of recommendation of CAM was a friend or relative (54%).
Approximately 62% of CAM users had not informed their medical
doctors of their CAM use. The most common reason for deciding to try
a CAM therapy was that it offered a “potential improvement of
headache” (44.8%). Univariate analysis showed that CAM users had a
higher income, had a higher lifetime number of conventional medical
doctor visits, had consulted more headache specialists, had a higher
number of CH attacks per year with disease and had a significantly
higher proportion of chronic CH vs episodic CH. A binary logistic
regression analysis was performed and two variables remained as sig-
nificant predictors of CAM use, the income level (OR=5.7, 95%
CI=1.6–9.1, p=0.01), and the number of attacks per year with disease
(OR=3.08, 95% CI=1.64–6.7, p<0.0001).
Our findings suggest that CH patients, in their need of and quest for
care, seek and explore both conventional and CAM approaches, even
if only a very small minority finds them satisfactory. Conventional
MDs and CAM practitioners should be made aware of this redefinition
of the role of modern biomedicine, given that they are in a unique posi-
tion to provide patients with help and guidance.
STANDARDIZED APPROACH TO PATIENTS WITH MIGRAINE
IN A HEART-BRAIN CENTRE: 6-MONTH EXPERIENCE
1G. Dalla Volta, 1B. Troianiello, 1S. Griffini, 1P. Zavarise, 2A. Pezzini,
3A.M. Lanzone, 3R. Albero, 4M. Guindani
1Neurology Unit, Clinical Intitute, Brescia, Italy; 2Stroke Unit,
Vascular Neurology, Civilian Hospital, Brescia, Italy; 3St. Rocco
Cardiology Clinic, Brescia, Italy; 4Clinical Institute S. Anna, Brescia,
Italy; e-mail: dalla@numerica.it
Background Because a pathogenic relationship between patent fora-
men ovale (PFO) and migraine with aura is assumed, percutaneous clo-
sure of PFO has been recently proposed as an effective treatment.
However, definitive criteria to identify a priori migraine patients who
will benefit from PFO closure and those whose migraine will not be
influenced by this treatment are lacking. We propose the standardized
approach to these patients in use at the Heart-Brain Centre of the
Clinica St Rocco of Ome, Brescia.
Methods During a 6-month period, 120 patients with migraine with
aura, 48 patients with migraine without aura, and 18 patients with clus-
ter headache were evaluated. All subjects underwent a contrast-
enhanced transcranial Doppler (TCD) investigation to detect the pres-
ence/absence of PFO. This was diagnosed in 62.5% of cases with aura,
37.5% of those without aura, and 38.8% of cluster headache. In the case
of a positive finding, a standardized work-up including brain MRI,
thrombophilic tests (proteins C and S, antithrombin III, APCR, anti-
phospholipid antibodies, total plasma homocysteine, vitamin B12 and
folate levels, G1691A polymorphism of factor V, G20210A polymor-
phism of factor II, C677T polymorphism of MTHFR), ultrasound eval-
uation of the deep veins of the legs and the carotid-vertebral arteries was
carried out. Transesophageal echocardiography was performed in cases
of PFO-positivity with curtain effect, MRI evidence of ischemic lesions
(MRI+), or evidence of a prothrombotic state (T+). This allowed the
identification of co-existent atrial septal aneurysm (ASA).
Discussion and conlusions Based on these findings, PFO closure can
be considered in cases with co-existent ASA when at least one of the
following conditions is present: curtain pattern on TCD, MRI+, or T+.
It can also be considered in those cases without co-existent ASA in
which MRI+ or T+ are present.
Although the management of PFO in patients with migraine is still a
matter of debate, the proposed standardized approach can be of help in
selecting patients who will benefit from percutaneous closure in clini-
cal practice.
EPIDURAL BLOOD PATCH IN THE TRENDELENBURG POSI-
TION TO TREAT HEADACHE BY SPONTANEOUS CSF LEAK
1E. Ferrante, 2I. Arpino, 1A. Citterio, 2R. Wetzl, 2A. Savino, 1R. Sterzi
1Neurosciences and 2Emergency Departments, Niguarda Cà Granda
Hospital, Milan, Italy; e-mail: enricoferrante@libero.it
Background Spontaneous intracranial hypotension (SIH) generally
results from spontaneous spinal CSF leakage [1]. Treatment is usually
conservative but epidural blood patch (EBP) has emerged as the most
important nonsurgical treatment for SCSFL [2].
Objective To evaluate the efficacy of epidural blood patch (EBP) in
the Trendelenburg position in the treatment of headache by sponta-
neous CSF leakage (SCSFL).
Materials and methods We observed 30 patients with SCSFL
between 1992 and 2005. Eleven patients (6 women and 5 men; age
range 31–66 years, mean age 40) received EBP. All patches were per-
formed in the lumbar region, using 15 to 30 mL (mean 23 mL) of autol-
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ogous blood. All patients mantained a 30° Trendelenburg position dur-
ing the procedure and for 24 hours after the procedure. Follow-up
ranged from 6 months to 2 years.
Results All patients had orthostatic headaches. Other manifestations
were nausea, vomiting, mild neck stiffness, tinnitus, blurred vision,
diplopia and bilateral upper limb numbness. CT myelography, spinal
MRI or brain MRI or radionuclide cisternography showed CSF leak-
age sites in 6 out of 11 patients; 2 sites were at the cervical level, the
others at the lumbar level. In 10 out of 11 patients, brain MRI
showed diffuse pachymeningeal gadolinium enhancement (neu-
roimaging of intracranial hypotension). All patients failed an initial
conservative treatment, which consisted of bed rest and hydration,
over a period of 1 to 13 months. All treated patients became asymp-
tomatic, 1 responded only after 3 EBP, and 1 had a residual mild
headache during the Valsalva manoeuvre for 2 months. Until now,
none has had a relapse.
Discussion and conclusions Our data confirm the efficacy of EBP in
the SCSFL headache and suggest also the importance of a prolonged
Trendelenburg position especially when the leak site is at the cervical
level and the autologous blood patch in the lumbar region is performed.
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HEADACHE IN CHILDHOOD AND ADOLESCENCE I
CLIMATIC VARIATIONS AND MIGRAINE IN CHILDHOOD
D. Moscato, M.I. Peracchi
Headache Centre, Saint Charles Hospital, Rome, Italy; e-mail:
dmoscat@tin.it
The incidence of migraine in childhood has increased in recent years.
Up to now that increase has been attributed to the worsening of
childern’s conditions: the job of both parents, the long distance to
school, the high number of separations, divorces etc. [1, 2].
Regardless, the environmental situation, unexpected climatic varia-
tions, and elevated levels of pollutants, may also have had a specific
influence on migraine.
We tried to estimate the influence of these factors in a group of 120 chil-
dren (72 F, 48 M, age range 5–17 years) affected by migraine without
aura (n=112) and migraine with aura (n=8), assessed from 1995 to 2005.
For these patients the headache triggers were evaluated (Table 1).
No significant variations were found in the percentage of stress as a
trigger factor, whereas the number and percentages of patients refer-
ring atmospheric variations and solar exposure as a triggering factor
increased over time.
These preliminary data need to be confirmed by further studies.
Among triggers examined, solar exposure as a controllable trigger
should be avoided or limited to reduce its influence in inducing
migraine attacks.
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TENSION-TYPE HEADACHE IN CHILDREN
A. Forabosco, T. Grandi, M. Malavasi
University of Modena and Reggio Emilia, School of Dentistry,
Modena, Italy; e-mail: forabosco.andrea@unimo.it
Introduction Tension-type headache is a common problem among
children in primary school. Dental malocclusion can often be the cause
of this form of primary headache [1].
Materials and methods Twenty schoolchildren who had already
received a diagnosis of primary headache treated with analgesic sub-
stances came to our clinic. An orthodontic evaluation and
orthopanoramic X-ray film were performed. All patients were found
suffering from malocclusion. Limitation of the functional mandible’s
movements, teeth abrasions, and hypertrophy of the mandibular eleva-
tor muscles were present. To treat muscular problems originating from
the stomatognathic system, an occlusal splint was performed. Intensity
[using a graphic rating scale (GRS)] and frequency (daily, weekly,
monthly) of headache before treatment (T0), after one month (T1),
after three months (T2) and after six months (T3) were recorded.
Wilcoxon test was applied for statistical evaluation.
Results All patients showed a considerable reduction of their symp-
toms. A significant improvement of the intensity and the frequency of
headache attacks was registered after treatment (p<0.0001).
Discussion and conclusions The high occurrence of malocclusion in
the subjects with tension-type headache seems to play an important
role in the genesis of headache. At present, the treatment for patients
who suffer from these disorders has increasingly required the need for
a collaborative team approach. An orthodontic treatment should be
suggested, both for an improvement of the headache and the function-
al aspects, but the results may not be significant before 2 years [2]. An
application of a plate bite, without any drug therapy, can be the treat-
ment of choice to reduce the symptomatology in children suffering
from tension-type headaches.
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HEADACHE AND QUALITY OF LIFE IN A CHILD AND ADO-
LESCENT COHORT
1D. Brovia, 2S. Cesi, 3M.M. Cainazzo, 3L.A. Pini
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Introduction Up to 10% of children between the ages of 5 and 15 have
migraines [1], while an even higher number of adolescents have
migraines [2].
The primary aim of this study was to evaluate the quality of life in
young patients, using the PED-MIDAS, the QLH-Y Questionnaire and
Table 1 Trigger Factors
1995 1997 1999 2001 2003 2005 Total
Emotional stress, % 90 90 80 90 100 70 83
Physical stress, % 50 30 30 40 60 30 40
Environment stress, % 70 80 90 50 90 60 73
Lights, % 50 40 60 30 70 40 48
Smell, % 40 20 40 60 30 40 33
Smoke, % 20 40 20 40 10 20 25
Food, % 20 20 20 10 00 10 15
Climatic Variations, % 40 50 60 60 70 80 60
Solar exposure, % 10 20 40 60 90 70 48
304
Children’s Depression Inventory (CDI) scales. A secondary end-point
was to examine the changes in clinical picture and diagnoses related to
headache treatment.
Methods and patients The study included 70 patients (32 F, 38M; age
range: 8–15 years, mean age 12.34±1.91 years) visited in the Modena
Headache Centre between January 2002 and June 2004. At the initial
visit, each patient underwent complete history-taking and general and
neurological examinations in the presence of a parent. A second fol-
low-up visit was performed in the period January-June 2005;
headaches were diagnosed according to the International Headache
Society criteria (ICHD-II).
Questionnaire At the follow-up visit, the patients were asked to check
MIDAS, QLH-Y and CDI Questionnaires in the presence of a trained
doctor. They were urged to express their own judgements, but they
could ask a parent for advice.
Results All 70 patients completed the study. Mean illness duration was
44.31 months. Forty-two patients had migraine without aura, 10 had
migraine with aura, 18 had tension-type headache (16 with episodic
tension-type headache (ETTH) and 2 with chronic tension-type
headache (CTTH)). Sixty-eight out of 70 patients confirmed the first
diagnosis. The frequency of headache was related to the degree of dis-
ability, while the intensity was moderate-severe in almost all patients
in spite of disability scores.
Pathological values found in Children’s Depression Inventory (CDI) at
the follow-up visit showed that almost 50% of patients had a bad percep-
tion of themselves with devaluation and often with feelings of despera-
tion, and thus referred disobedience, asthenia and a negative body image.
According to the QLH-Y data, our patients seemed to experience
stress, fatigue and somatic symptoms. The most used drug for
headache attack was acetaminophen.
Discussion The results of this study suggest that the prevalence of
migraine without aura and ETTH decreases with increasing age.
Optimal care for children and adolescents with headache can be realized
with collaboration among primary care practitioners and headache spe-
cialists; behavioural treatment is a foundation for provision of such care.
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HEADACHE AND EPILEPSY IN CHILDREN
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Introduction The association between headaches and epileptic
seizures is a well-known phenomenon. The headache could be peri-
ictal and interictal, in 50% of epileptic patients [1]. The incidence of
interictal headache is not clear, but many authors have shown that the
incidence of interictal migraine headache was significantly higher in
patients with migraine-like postictal headache [2].
Materials and methods Forty-three children aged 4–18 years, 22
males and 21 females, affected by epilepsy and suffering from
headache, were studied in order to verify the correlation between peri-
ictal and interictal headache. Headache was diagnosed according to
ICHD-II criteria, and epilepsy according to ILAE 1989 criteria.
Epilepsy was diagnosed as: Benign focal epilepsy with vertex spikes
and waves (BVSWE) in 9 children; reflex photosensitive epilepsy in 11
children, occipital epilepsy in 5 children, juvenile myoclonic epilepsy
in 4 children, and generalized epilepsy in 12 children.
The headache diagnosis was: migraine without aura (MO) in 18 chil-
dren, migraine with aura (MA) in 4 children, tension-type headache
(TTH) in 4 children, migraine-like and tension-type like headache in 6
children, and stabbing headache in 5 children.
Results In 20 children, the headache started before epilepsy began and
in 5 children after epilepsy began. In 26 children, the diseases were
contemporary. There was no correlation between the region of EEG
anomalies and the side of pain. Only 3 children, suffering from
BVSWE, and 5, suffering from generalized epilepsy, showed headache
in the vertex region.
In 11 children (25%), there was a temporal relationship between
headache and epilepsy. In 4 patients with seizures while sleeping, the
headache occurred upon awakening, in 3 children with occipital epilep-
sy the headache was postictal, and in 4 children with photosensitive
epilepsy the headache was preictal and was triggered by photic stimuli
(TV, play station).
The preictal headache was defined by children as stabbing, the postic-
tal headache as migraine-like.
Conclusions Migrainous-like headache is prevalent among epileptic
children during the peri-ictal and interictal periods. In fact, migraine-
like headache was found in 50% of patients with photosensitive epilep-
sy and migraine in 100% of children with rolandic epilepsy.
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PREVALENCE OF MIGRAINE IN FAMILIES OF CHILDREN
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Introduction Early-onset benign occipital seizure susceptibility syn-
drome or the “Panayiotopoulos type” of childhood epilepsy with occip-
ital paroxysms (PS) is a partial form of epilepsy that occurs in 13% of
children aged 3–6 years with one or more non-febrile seizures [1].
Although many authors have studied the relationship between
headache and PS, there do not seem to be any clear results [1].
Aim The aim of our study was to determine the relationship between
migraine and PS in childhood and the prevalence of family history of
migraine and epilepsy in patients with PS.
Patients and methods This was a retrospective study conducted at the
Child and Adolescent Neuropsychiatry Unit of our University
Hospital, in patients recruited between 1999 and 2006, diagnosed as PS
on the basis of the ILAE Task Force on Classification and Terminology
criteria. Anamnestic, clinical, and instrumental data were collected to
clear the semiology and the frequency of the seizures. All patients
underwent a video-EEG during wake and sleep cycles with HP and
ILS, and a brain MRI. All patients were given the specific record for
headache in children and adolescent patients of the Italian Child and
Adolescent Neuropsychiatry Society Group. The diagnosis of migraine
was based on the criteria of The International Classification of
Headache Disorders, 2nd edition (ICHD-II).
Migraine prevalence in children with PS and in their families was com-
pared with a member of the general population of the same age group.
Results We evaluated 20 patients with PS, 11 males and 9 females,
mean age at the end of follow-up=8.5 years, range 4 to 14 years.
Among these, 7/20 (35%) had migraine (six migraine without aura and
one with visual aura). Regarding family history: 13/20 cases (65%)
were positive for migraine, 5/20 (25%) for epilepsy, 4/20 (20%) for
both, and 4/20 for febrile seizures.
All children with migraine also had a family history of migraine. The
headache usually started in the same year in 2/7 cases (29%) or after
the diagnosis of epilepsy in 5/7 (71%).
Conclusions So far, no study has showed a clear relationship between
a family history of migraine and PS. In particular, Panayiotopoulos says
“there is no family history of similar disorders of benign childhood
seizure susceptibility, epilepsies or migraine” in children with PS [2].
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To our knowledge, this is the first retrospective study to report a preva-
lence of 65% for migraine, 25% for epilepsy, and 20% for both in fam-
ily members of affected children. PS and migraine are probably genet-
ically determined. Our study supports the hypothesis of a clinical con-
tinuum between migraine and epilepsy, particularly PS that share sim-
ilar characteristics and a familial spectrum.
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HEADACHE AND CARDIO-EMBOLIC STROKE: THE IMPOR-
TANCE OF CLINICAL SUSPICION. REPORT OF A PAEDI-
ATRIC CASE
1G. Indolfi, 1S. Trapani, 1C. Massai, 2L. Calistri, 2C. Scalas, 1M. Resti
1Department of Paediatrics, University of Florence, Anna Meyer
Paediatric Hospital, Florence, Italy; 2Children’s Headache Centre,
Paediatric Neurology Clinic, Anna Meyer Paediatric Hospital,
Florence, Italy; e-mail: g.indolfi@meyer.it
A 14-year-old boy, with an underlying history of asymptomatic
ostium secundum atrial septal defect and a family history negative
for vascular diseases or coagulation disorders, was admitted to the
emergency department of a general hospital because of a severe
headache and visual disturbance that began during a school exami-
nation. As brain CT scan and fundoscopic examination were normal,
he was dismissed with the diagnosis of migraine with aura and
symptomatic therapy. Twelve hours later for the persistence of the
same complaints, he was newly admitted: physical examination
showed right homonymous hemianopsia and a systolic ejection
murmur, but no other abnormalities. EEG showed bioelectric abnor-
malities on the left temporal and occipital regions and magnetic res-
onance imaging revealed acute left occipital infarction and normal
head and neck vessels. He was then transferred to our tertiary care
paediatric hospital; in the following days his clinical conditions
were stable. An expanded investigation for an underlying prothrom-
botic tendency showed increased plasma homocysteine (29 micro-
mol/L) and homozygosity for the methylenetetrahydrofolate reduc-
tase gene C677C>T polymorphism. Anticoagulant therapy, folic
acid and vitamin B12 supplementation was given and the 6-month
follow-up was uneventful: right temporal hemianopsia persisted.
Atrial septal defect was subsequently closed via percutaneous
approach.
Arterial ischemic stroke is being increasingly diagnosed and recog-
nized in childhood. Recognition of clinical stroke may be difficult, par-
ticularly in infants and young children. Ischemic events are usually
suspected when a child presents with abrupt onset of a hemiparesis but
the initial symptom can be a common complaint, such as isolated
headache and/or subtle and difficult to recognize focal sensory deficits
or visual disturbances.
A detailed history focused on the most frequent risk factors, such as
congenital thrombophilic states, cardiac diseases, infections, trauma
and sickle cell anemia, represents the initial screening for the diagno-
sis of paediatric stroke since multiple risk factors commonly coexist in
individual patients [1]. As demonstrated by our case report, magnetic
resonance is the imaging modality of choice to confirm that an acute
ischemic event has occurred and to determine the extent and location
of acute cerebral injury, the patency of major neck and intracranial
arteries and relative cerebral perfusion.
It is crucial to increase clinician awareness of stroke also in children as
clinical suspicion can reduce the time lag to diagnosis and to appropri-
ate treatment of this disease [2].
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HEADACHE IN ADOLESCENTS: SYMBOLIC MEANING
BETWEEN CLINICAL DATA AND INNER PSYCHIC LIFE
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Division of Child Neurology and Psychiatry, “G.F. Ingrassia”
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Introduction Primary headaches can present occasional and nonspe-
cific anatomical and/or functional anomalies, but although they do not
have an aetiological and pathophysiological role in producing painful
attacks, they can influence the symptomatic course through the sym-
bolic meaning that they have for the patients and their family. We pre-
sent and analyse three cases of adolescents with these characteristics.
Case 1: A twelve-year-old boy with a story of migraine-type attacks
occurring every weekend for the last three months; brain MRI showed
a pineal cyst and for this reason he underwent neurosurgical consulta-
tion and another MRI with gadolinium; during the clinical evaluation,
migraine appeared the day before every examination and afterward, he
was migraine-free for long periods.
Case 2: An eleven-year-old boy suffering from tension-type headache
and depressive symptoms: his father was operated on for cerebral
aneurysm, the boy’s EEG showed positive occipital sharp waves,
evoked by all IPS frequencies; undergoing MRI, which was normal,
and clinical interviews regarding the family’s fears, in the last two
years, the boy nolonger suffered from headache.
Case 3: A fourteen-year-old girl presented with very frequent and severe
migraine-type attacks for about two months; she had been wearing an
orthodontic appliance for over two years. The decision to remove the
orthodontic appliance resulted in the disappearance of the headache.
Discussion The nonspecific anomalies, considered as symbols,
found in these three clinical cases are “dumb elements” [1], but they
represent an important meaning in the patients’ inner psychic life
and may induce the manifestation of some developmental emotion-
al problems. In the first case, pineal cyst may represent a need of
dependence in the relationship between the patient and his busy fam-
ily and help him to receive attention and be listened to. In the sec-
ond case, the abnormal EEG and the father’s history of cerebral
aneurysm produced in the boy an identity problem with a father who
was always absent. The clinical and psychological therapy and nor-
mal brain MRI examination disintegrated the “symbol” with the dis-
appearance of the headache. In the third case, the relationship with
a very perfectionist mother resulted in the onset of migraine-type
attacks. The removal of the orthodontic appliance allowed the
patient to become independent without being forced to accept a self-
image that the mother imposed.
Conclusions The three cases, with their different data and life events,
confirm that nonspecific signs need attention, because their symbolic
meaning may be significant and influence the course of pain.
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PRESENT AND PAST PSYCHOPATHOLOGY IN CHILDHOOD
MIGRAINE: A STUDY WITH THE CHILD BEHAVIOUR
CHECKLIST
F. Salvadori, V. Gelmi, F. Muratori
Division of Child Neuropsychiatry, Scientific Institute Stella Maris,
Department of Neurosciences, University of Pisa, Pisa, Italy; e-mail:
francesco.salvadori@inpe.unipi.it
306
Introduction A strong association has been observed between
migraine and psychiatric problems such as depression and anxiety.
Objective The aim of this study was to describe the premorbid state of
migraine in children by using a structured questionnaire, designed to
obtain standardized reports of children’s behavioural problems and
capabilities, as observed by parents.
Subjects and methods Thirty subjects with migraine and 30 healthy
subjects were enrolled in a case-control study. Using the Child
Behaviour CheckList (CBCL), ratings were obtained for maternal
memories of the past for two age periods (0–3 years and 4–6 years) and
for the present state (7–16 years). The CBCL scores of the migraine
group (MG) were compared to those of the control group (CG) for the
three periods. A longitudinal analysis was performed to evaluate the
evolution of psychopathology, by comparing the CBCL scores of the
MG in the three age periods.
Results In the 7–16 year group, children of the MG had significantly
higher mean CBCL scores – i.e., nearer to the clinical threshold – than
those of the CG in several scales: total problems (p<0.01), internaliz-
ing (p<0.001), somatic (p<0.001), anxious/depressive (p<0.01),
thoughts (p<0.05) and attention problems (p<0.01). At 4–6 years, sig-
nificantly higher scores between the MG and the CG were found in the
total problems scale (p<0.001), internalizing (p<0.001), somatic
(p<0.001), anxious/depressive (p<0.001), attention (p<0.01), social
problems (p<0.01) and withdrawn (p<0.05). At 0–3 years, significant-
ly higher scores between the MG and the CG were found in the total
problems scale (p<0.01), internalizing (p<0.05), somatic (p<0.001),
and anxious/depressive (p<0.01). In a longitudinal perspective we did
not demonstrate statistically significant differences between 7–16 and
4–6 year age periods. Comparing the age periods of 4–6 years and 0–3
years, significant differences were found in total problems (p<0.01),
internalizing (p<0.001), somatic (p<0.01) and also in externalizing
(p<0.01) and aggressive syndrome scale (p<0.01), but not in the anx-
ious/depressive scale.
Discussion Our study suggests the association between migraine,
depression and anxiety during childhood and adolescence. The inter-
nalizing component (depression and anxiety) may represent a persis-
tent factor that feeds the migraine. The demonstration of an internaliz-
ing score in a headache patient, by means of the CBCL, could be of the
utmost importance to prevent migraine from becoming chronic.
Conclusions Migraine may begin during childhood/adolescence with a
symptomatology, which may have its roots in previous behavioural
problems. Even if they rarely reach the clinical threshold with the
CBCL questionnaire, children who develop migraine are different from
healthy children for the higher rate of behavioural problems..Migraine
could be considered the expression of a previous vulnerability.
HEADACHE: WHAT DO CHILD AND MOTHER WANT FROM
THEIR PHYSICIAN?
V. Raieli, G. La Franca, M. La Vecchia, E. Pandolfi, D. Puma, 
D. Ragusa, R. Ceraulo, M. Eliseo
Division of Child Neuropsychiatry “L. Biondo”, Ingrassia Hospital,
A.U.S.L. 6, Palermo, Italy; e-mail: vinzi.raielk@inwind.it
Introduction To establish a good “strategic compliance” between the
doctor, and the young headache patient and the patient’s family, it is
important to know what the mothers or the children want from paedia-
tricians and neurologists.
Objective The aim of this study was focused on child’s and mother’s
expectations regarding the diagnostic and therapeutic approaches from
the paediatrician and neuropsychiatrist. Moreover, we wanted to know
the doctors’ opinions.
Methods We selected 100 consecutive children older than 10 years
with primary headaches, admitted for the first time to our department.
A questionnaire was administered individually to the children and to all
100 mothers before the visit. It had several multiple choice questions
about the child’s and mother’s fears, their expectations and opinions
regarding medical visits, and symptomatic and prophylactic therapy. A
short questionnaire was also administered to 50 paediatricians, having
common characteristics previously selected with a questionnaire.
Results The principal reasons for seeking consultation were because
the pain was more frequent and severe (72% and 24%, respectively).
The mothers’ main questions concerned the reasons for headache
and reassurance about their fears (respectively 61% and 46%). Fifty-
six percent of the mothers thought that the use of symptomatic drugs
was necessary, while only 33% thought that preventive drugs were
useful and 34% of mothers feared that they cause dependency or
serious side effects. The children wanted to be mainly reassured
(60%), know the reasons for the headache (45%), and if they would
suffer from headaches in adulthood (36%) (mothers and doctors only
4%). The children thought that the use of symptomatic drugs was
necessary (68%) and that preventive therapy was useful (61%).
Fifty-eight percent of doctors believed that the principal reasons for
the consultation were the frequency (58%) and intensity (26%) of
headache, and the fear of tumour (24%). In the opinion of the doc-
tors, the more important mothers’ questions concerned reassurance
about their fears and the prescription of medical diagnostic tests
(60% and 50%, respectively). They believed that the children want-
ed to be mainly reassured, cured and to have explanations about the
headache (62%, 38% and 44%, respectively). The paediatricians
(90%) believed that symptomatic drugs were necessary and that pre-
ventive therapies were useful (74%).
Discussion These data suggest that the child’s and mother’s main con-
cerns pertain to explanation of headache and reassurance about it, while
the prescriptions of drugs or medical tests are not believed necessary.
The doctors’ opinions seem in part similar. The main differences regard-
ed the use of diagnostic tests and pharmacological therapies and the
question about headache progression into adulthood made by children.
HEADACHE IN CHILDHOOD AND ADOLESCENCE II
DEPRESSION AND CHRONIC HEADACHE IN CHILDHOOD
AND ADOLESCENCE 
M.A. Tavoni, O. Papa, E. Cesaroni, C. Cardinali
Riuniti University Hospitals, Paediatric Neurology Department,
Children’s Hospital “G. Salesi”, Ancona, Italy; e-mail: npisalesi@
ao-salesi.marche.it
Introduction The role and importance of the psychiatric and psycho-
logical aspects in determining and influencing the insurgence and evo-
lution of chronic headache in childhood and adolescence have been the
object of numerous studies. Many authors have tried to analyse the
possible correlations between depression, anxiety disorders and
headache.
Objective The aim of our study was to analyse the possible correla-
tions between chronic headache and depressive disorder with or with-
out anxiety disorder.
Materials and methods Sixty-two children (38 males, 24 female;
mean age 9 years, 5 months; range: 6–13 years) were enrolled from
493 subjects seen from 2003 to 2005 among the outpatients from the
Departments of Headache and Psychology of the “Ospedali Riuniti “G.
Salesi” Children’s Hospital. Fifty-two patients affected with chronic
headache were subdivided into 3 subgroups: chronic tension-type
headache (CTTH), chronic daily headache (CDH) and mixed headache
(CTTH and headache); 10 patients affected from episodic tension-type
headache (ETTH) were identified according to IHCD-II 2004 criteria.
The patients under investigation were evaluated by the juvenile
headache flow-chart (haematological, clinicians, neurophysiologic and
neuroimaging exams) and by a psychodiagnostic protocol that we use
in our centre.
Results Following the DSM IV criteria the subjects of the two groups
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were subdivided in:
- Depressive Disorder Mood (DDM);
- Depressive Disorder Mood + generalized anxiety disorder
(DDM+GAD);
- Depressive Disorder Mood + Learning Disorder Not Otherwise
Specified (DDM+LDNOS);
- Depressive Disorder Mood + Oppositional Defiant Disorder
(DDM+ODD);
- Generalized Anxiety Disorder (GAD);
- Others.
The clinical history of the 62 subjects was negative for psychiatric
pathologies or history of acute traumatic events. Depressive disorders
were comorbid in 37/52 of the subjects with chronic headache, primar-
ily represented by DDM + GAD (30/52). The GAD subgroup was pre-
sent in 13/52 chronic headache patients and in 3/10 ETTH patients.
Male gender was more represented, but female gender prevailed in the
group of chronic headache with DDM + GAD. Chronic headache was
not associated with DDM + ODD but was present in 2 patients affect-
ed by ETTH. The prevalence of depressive disorders was greater in
chronic headache (71.1%) than in ETTH (40%). DDM was more fre-
quently associated with GAD (57.6%).
Conclusions Chronic headache is frequently associated with depressive
and anxiety disorders both in adult and paediatric patients. Headache can
be the first symptom silently expressed by the depressed child.
Therefore, headache that evolves to acquire chronic characteristics
must be carefully evaluated because it could mask important psychi-
atric disorders that should be considered for the diagnosis and therapy.
PSYCHOLOGICAL ASSESSMENT OF MIGRAINOUS CHIL-
DREN AND ADOLESCENTS
1P. Mariotti, 1R. Chiera, 1F. Perrino, 1S. Staccioli, 1P. De Rose, 
2C. Vollono, 2G. Della Marca, 3G.M. Vecchio, 4C. Pastorelli
1Unit of Child Neuropsychiatry, and 2Unit of Neurology, Policlinic “A.
Gemelli”, Catholic University, Rome, Italy; 3Faculty of Psychology 2,
and 4Department of Psychology, University of Rome, “La Sapienza”,
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Introduction General population studies suggest a non-casual asso-
ciation between headache, major depression and anxiety disorders
[1]. The consensus is that migraine sufferers are at higher risk of
depression, bipolar disorders and certain forms of anxiety – this is
particularly true for migraine with aura. Co-morbidity with psychi-
atric disorders has also been described for chronic tension-type
headache and for chronic daily headache [2]. The data available in
the literature are still relatively scarce and contradictory, especially
for young people.
Objective The aim of our study was to evaluate the association
between headache and different psychological characteristics, includ-
ing tendencies toward depression, perfectionism and repressed aggres-
sion, in children and adolescents.
Methods Clinically referred children and adolescents (n=45) 8–18
years of age, subdivided into two age groups: 8–10 years (n=19) and
11–18 years (n=26), suffering from primary headache according to the
diagnostic criteria of the International Headache Society, 16 with
migraine with aura (MA), 29 with migraine without aura (MO), and
1 021 normal controls without headache (NC), were assessed using the
Parent Child Behaviour Checklist (CBCL), the Youth Self Report
(YSR), Children’s Depression Inventory (CDI), and the Centre for
Epidemiological Studies Depression Scales (CESD).
Results According to the literature, our data confirm that children with
migraine have significantly higher levels of total internalizing, partic-
ularly for somatic complaints with respect to those without headache.
Attention has been focused on the YSR interview, a self-report assess-
ment, never used until now in this field, that was administered to ado-
lescents aged 11–18 years. Both thought problems and internalizing
symptoms in migraineurs have been demonstrated by YSR. We wish to
emphasize that thought problems are not significantly different
between the general paediatric population and migraineurs in some
studies in parental reports (CBCL). Moreover, CDI (self rating of
depression) results show statistically significant differences between
migraine and non-headache paediatric subjects, in comparison with
other studies published in the literature.
Conclusions We stress the importance of the use of YSR for the assess-
ment of psychological traits in migrainous children and adolescents,
because generally parents have been found to be poorer at internaliz-
ing symptoms than the child, and parents’ reports of CBCL may under-
estimate anxiety symptoms. This holds not only for the diagnostic and
therapeutic implications but also for the prognostic aspects.
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EFFICACY OF TOPIRAMATE IN PAEDIATRIC MIGRAINE
PROPHYLAXIS
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Introduction Migraine is the most common type of primary headache
in childhood and often hampers common daily routines.
Objective The aim of our study was to investigate the efficacy and
safety of topiramate in the prevention of paediatric migraine.
Materials and methods Twenty-five children (mean age 11 years,
range 5–16 years; 10 females, 15 males) were recruited. In 23 children,
migraine without aura was diagnosed according to the International
Headache Society classification (ICHD-II, 2004), while the remaining
2 children had migraine with aura. 
Results Before treatment, our patients showed 8±5.7 (mean±stan-
dard deviation) pain attacks per month. The children received a
mean topiramate dose of 1.3 mg/kg/day, ranging from 0.5 to 1.8
mg/kg/day, for a period of 3.2±1.2 months. Treatment was effective
(reduction in attack number ≥ 50%) in 19 out of 25 children (76%).
In particular, 3 patients (12%) became free from migraine episodes.
One patient (4%) interrupted the treatment for adverse side effects
(excessive drowsiness). Seven patients in which the initial treatment
was effective underwent a worsening in migraine frequency after
topiramate interruption and needed a further treatment after 4.3±2.8
months. Six patients had a reduction in the frequency of pain
episodes greater than 75%, while in one child the therapy was inef-
fective. Two patients had a third treatment at 3 and 4 months, respec-
tively, after interrupting the second topiramate cycle. The therapy
was ineffective in both patients. Adverse events were observed in 6
out of 25 children (24%). They consisted of drowsiness (3 patients),
anxiety (1 patient), weight loss (2 patients), and behavioural distur-
bances (3 patients).
Discussion and conclusions Our results suggest that topiramate is a
useful and safe tool in paediatric migraine prophylaxis. Even low doses
allowed us to control migraine in most of our paediatric patients, thus
improving their quality of life.
MELATONIN, 3 MG, IS EFFECTIVE FOR MIGRAINE PRE-
VENTION ALSO IN SCHOOL-AGED PATIENTS
M. Carotenuto, F. Tagliente, F. Ruju, A. Pascotto
Department of Developmental Neurology and Psychiatry, Second
University of Naples, Naples, Italy; e-mail: marco.carotenuto@unina2.it
Background Hypothalamic dysfunction may be present in migraine
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and in circadian periodicity of headache attacks, more specifically, the
suprachiasmatic nucleus and melatonin have been suggested to play a
role in the pathogenesis [1]. Altered melatonin levels have been found
in cluster headache, migraine with and without aura, menstrual
migraine, and chronic migraine. Melatonin may have many metabolic
effects, such as anti-inflammatory effects (melatonin and indomethacin
share similar chemical structure), reducing the up-regulation of proin-
flammatory cytokines, and inhibiting nitric oxide synthase activity and
dopamine release. Melatonin administration is thus a possible candi-
date for migraine prevention [2].
Objective The aim of this open trial was to test the hypothesis of the
potential effectiveness of melatonin for migraine prophylaxis also in
school-aged children.
Patients and methods We performed an open-label trial of mela-
tonin, 3 mg, for migraine prevention. Twenty-three patients (11 M, 12
F) aged 6–15 years (mean 12.8 years, SD±1.38) with episodic
migraine with or without aura according to ICHD-II 2004 criteria,
were screened for the baseline period. All patients started prophylac-
tic treatment with melatonin, 3 mg, 10 minutes before bedtime for 3
months. A complete clinical interview and examination as well neu-
rophysiological recordings (wake and sleep EEG) were performed
for each patient. Study participants experienced between two and six
attacks per month. Exclusion criteria included the presence of sleep
disorders, as confirmed by the mothers of all subjects who filled out
the Sleep Disturbances Scale for Children [SDSC]. The SDSC is a
sleep questionnaire that consists of 26 items subdivided into 6 sleep
disorder subscales according to American Sleep Disorders
Association criteria: DIMS (disorders in initiating and maintaining
sleep), SDB (sleep disordered breathing), DA (disorders of arousal),
SWTD (sleep-wake transition disorders), DES (disorders of exces-
sive somnolence), SHY (sleep hyperhydrosis).
Results Twenty out of 23 patients completed the study (86.95%). That
patients (85%, 17/20) who completed the study had at least a 50%
reduction in intensity and frequency of headache attacks. Nobody
reported an increase in headache frequency. Complete (100%)
response was achieved in 12 patients (60%) and no adverse effects
were recorded.
Conclusions There is increasing evidence to indicate that the hypo-
thalamus plays a major role in the pathophysiology of several of the
primary headache disorders, such as migraine, and hypnic headache
[1, 2]. Melatonin, an indole compound derived from serotonin, was
reported safe and effective in adult patients [2], but no data were
available for school-aged children. This is an original study to assess
melatonin, 3 mg, for prophylactic treatment of headache also in
childhood.
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EMERGENCY IN CHILDREN. BRAIN TUMOUR: CLINICAL
CASES
D. Moscato, M.I. Peracchi
Headache Centre, Saint Charles Hospital, IDI Rome, Rome, Italy; 
e-mail: dmoscat@tin.it
Brain tumours in children, due to their characteristic of slow invasive-
ness and easy infiltration in the nervous tissue, tend to give specific
symptoms only when they are of a large size.
We present a few cases which came to our attention last year.
Martina is an eight-year-old girl, who came to us due to widespread
headache that started three years before. She was a child presenting a
conflicting separation since the age of 3, which she responded to ini-
tially with hyporexia; she was anxious, agitated, very attached to her
mother. The symptoms seemed linked more to the psychological
aspects. Neurological testing was negative. During Day Hospital she
presented an intense headache crisis, which receded without treatment
with NSAIDs. A MRI identified a new formation in the posterior cra-
nial fossa. Surgical intervention revealed an adenoma, 2 months later,
the headache had fully disappeared.
Giorgia is 13-years old, suffering from migraine for two years. Her
parents are separated, and she is very attached to her mother, who still
sleeps with her. In the past 3 months, she has suffered from sleep dis-
turbances, sleep talking and frequent accentuated awakenings, with
intense headache almost daily during the same period. Vomiting with
coughing was present, but the girl had been following a diet for one
month. The neurological examination was negative. Emotional ten-
sion was evident in the family. During hospitalisation she experi-
enced slight difficulty in climbing the stairs. TAC shows a 6 cm
hypodense formation in the temporal occipital area. Surgical resec-
tion of a grade 1 medulloblastoma was followed by one cycle of
chemotherapy.
Gianluca is 5-years old, and had been complaining of intense cluster
headache for a few months after occipital cranial trauma without
loss of consciousness. The headache worsened overtime with an
increase in severity. During Day Hospital, 10 days after the trauma,
he complained of diffuse violent headache, with crying.
Neurological examination was negative except for slight fluctua-
tions on Romberg. CT showed a voluminous new formation in the
posterior cranial fossa. He was transferred to the Neurosurgery Unit,
where neurological signs began with vomiting, drowsiness, dysme-
tria, and dysarthria. Surgical resection of a Grade 4 medulloblastoma
was followed by chemotherapy and radiotherapy. The following year
he relapsed, and was operated on again, followed by another cycle
of chemotherapy, but his condition worsened. Sixteen months after
being diagnosed, he died.
Conclusions In the cases presented above the specific symptoms of
intracranial pressure, vomiting and papilledema stasis without
headache, as well as those linked to focality, are absent. Also, the neu-
rological examination yielded no precise indications. The same psy-
chological characteristics could have led to the wrong diagnosis.
Observation overtime of the reactions of children to headache during
Day Hospital had led us to select neuroimaging testing, which led to
the diagnosis. Therefore, we believe that a child with an important
headache must always be visited during a crisis.
HEADACHE IN A PAEDIATRIC EMERGENCY DEPARTMENT
1,2L. Calistri, 2M. Guasti, 1,2C. Scalas, 2M. de Luca, 3F. Festini, 
2S. Masi, 2F. Mannelli
1Headache Centre for Childhood and Adolescence, Paediatric
Neurological Clinic, 2Emergency Department, 3Department of
Paediatrics, University Hospital “A. Meyer”, Florence, Italy; e-mail:
l.calistri@meyer.it
Objective The aim of this study was to determine the prevalence of
headache as the chief complaint in patients presenting to a paediatric
Emergency Department (ED), to assess its characteristics, to study the
spectrum of primary and secondary headache diagnoses and to analyze
the diagnostic tests and the treatment applied. 
Methods We retrospectively analysed the clinical records of patients
presenting to the ED of the Paediatric Hospital A. Meyer of Florence,
Italy with the chief complaint of headache from January 1, 2005, to
June 30, 2005. All the patients underwent a clinical evaluation/case
history, and if necessary also had laboratory or imaging tests per-
formed. The ED records were searched for triage color code, age, gen-
der, location of pain, associated symptoms, case history, physical
examination (particularly neurological examination), assessments and
specialists’ visits, therapy at the ED, time spent at the ED, and outcome
(discharge – hospitalization – further assessments at the Centre for
Headache in Childhood and Adolescence).
Nosology was established using the International Classification for
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Headache Disorders ICDH-II.
Results Two hundred and twenty-three clinical records (2.2% of the
total number of visits) concerning 203 patients (121 male and 82
female) were analyzed; the average age was 8.9 years (range
2.1–17.1 years). Primary headaches (migraine and tension-type
headache) were recorded in 33 subjects (16.2%): 10 patients with
migraine without aura, 10 subjects with probable migraine, 2 cases
of migraine with aura, 2 subjects with benign paroxysmal vertigo of
childhood; from all the tension-type headaches, 7 were frequent, 4
infrequent, and 1 chronic. Three subjects were found to have both
migraine and tension headache (mixed headache). Secondary
headaches were mainly attributed to infections in 80 subjects
(39.4%) and to sinusitis in 16 patients (7.9%). Five cases (2.5%)
were found to be attributed to serious neurological conditions: 1
cerebral empyema, 1 cerebral ischemia, 1 intracranial haemorrhage
attributed to arteriovenous malformation, and 2 patients with
intracranial hypertension already treated at the Oncohematology
Centre for cerebral expansive lesion. After the clinical assess-
ment/case history, 144 patients (64.6%) were discharged from the
ED without further tests. Radiological and laboratory assessments
and/or specialists’ examinations were performed in 35.4% of the
patients. Neuroimaging tests were performed in 27 patients of whom
44.4% presented pathological results. Eighteen subjects (8.8%) were
hospitalized.
Conclusions This study confirms that headaches in the paediatric ED
have different etiology. In 57 subjects (28.1%) headache could not be
classified. Future prospective studies may be useful to assess the fol-
low-up in this group of patients.
HEMORRHAGIC PROLACTINOMA IN THE PAEDIATRIC AGE
GROUP: TWO CASES WITH DIFFERENT CLINICAL PRE-
SENTATION
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3R. Faggin
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Introduction Pituitary juvenile adenomas are rare (2% to 6% of all
supratentorial neoplasms) and prolactinoma is the prevalent tumour [1].
Subjects and methods We present two paediatric cases of hemor-
rhagic prolactinoma. The first case was a 7-year-old boy, with an
acute left-sided visual loss (acuity 1/10 and fundus oculi was nor-
mal). Visual evoked potentials (VEPs) showed increased latencies
after left eye stimulation. MRI showed a suprasellar lesion hyperin-
tense on T1- and T2-weighted images without enhancement and bor-
dering on the optic chiasm. The serum prolactin was 439 µg/L (nor-
mal <15), with decreased cortisol (88 nmol/L, normal >198) and
ACTH (3 ng/L, normal >10). After steroidal therapy, visual acuity
improved (8–9/10). He then underwent a transphenoidal complete
resection of the prolactinoma and subsequently presented panhypopi-
tuitarism. The second case was a 17-year-old girl with a three-month
last recurrent, moderate, biparietal headache associated with photo-
phobia, especially in the afternoon. In the previous year an oligomen-
orrhea was treated with hormonal therapy. This treatment was
stopped because of headache, which was unresponsive to pill with-
drawal. Neurological examination was normal. MRI showed a T1-
and T2-weighted hyperintense suprasellar lesion without enhance-
ment. As in the first case, these findings indicated a hemorrhagic
pituitary macroadenoma. The serum prolactin was 203 µg/L (normal
<25). Visual acuity and visual field were normal. After the surgical
resection, she needed substitutive hormonal therapy and, since then,
she has never suffered from headache.
Discussion and conclusions Hemorrhagic prolactinomas are rare in
children [2]. Patients usually present headache and visual field deficits.
Other findings are gynecomastia and puberal delay in males and amen-
orrhea in females. The cases reported are characterized by peculiar
clinical features. The first one presented a pituitary apoplexy, rare in
paediatric age group, and a monolateral visual loss with VEPs abnor-
malities consistent with an optic neuritis. In the second one, instead,
the oligomenorrhea although of a mild pattern was the key-sign for the
correct diagnosis of a secondary headache.
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SPHENOID MUCOCELE IN CHILDREN: DESCRIPTION OF
TWO CASES
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Introduction Sphenoid mucoceles are very rare, benign cystic lesions
(1% of all localizations) [1, 2]. Due to connection with several struc-
tures (cavernous sinuses, pituitary, orbits and choanas), clinical mani-
festations can be extremely variable.
Subjects and methods Case 1: An 8-year-old male presented with a
subcontinuous mild-moderate, bifrontal, pressing headache on awak-
ening for seven days, without any associated symptoms. On the eighth
day, an acute left III cranial nerve palsy with exotropia, ptosis and
mydriasis appeared. CT scan showed an erosion of the parasellar struc-
tures and MRI revealed a lesion of the sphenoid body, hyperintense on
both T1-T2 sequences without enhancement. The maxillofacial CT
scan confirmed the sphenoid body lesion. Hormone levels, visual fields
and acuity were normal. After ten days the headache spontaneously
disappeared, but nerve deficit persisted. Endoscopic trans-sphenoidal
permitted total removal of the lesion, followed by histological confir-
mation and complete resolution of the third cranial nerve palsy. He was
asymptomatic at the 5-year follow-up.
Case 2: A 12-year-old male since last year suffered from recurrent, pul-
sating, weekly headache, localized to the right frontal-ocular region,
with photophobia and phonophobia, sometimes nausea, rarely vomit-
ing and responsive to NSAIDs. His father suffered from migraine with-
out aura. During the recent admission to our hospital the neurological
examination was negative. Brain MRI showed hypointense signal on
T1 and hyperintense signal on T2 in the left part of the sphenoid sinus,
with partial involvement of the ipsilateral ethmoid and maxillary sinus-
es. Sinus CT confirmed a left-sphenoidal mucocele, with indication for
an endoscopic sphenoidotomy.
Discussion and conclusions The first case presented a painful oph-
thalmoplegia which, considering only the clinical picture, could be
diagnosed as ophthalmoplegic migraine (ICHD-II, 2004 classification,
point 13.17), a very rare condition in young patients, or as Tolosa–Hunt
syndrome (ICHD-II, 2004, point 13.16), which also presents with sim-
ilar features, although with unilateral pain. Neuroimaging, however,
documented a rare benign pathology.
In the second case, the patient may be affected by migraine without
aura, considering the family history, the type and stability of attacks
over time, the resolution with vomiting after the attacks, and the later-
alization of the sphenoid lesion, contralateral to the pain. Thus the dis-
covery of a sphenoid mucocele at an early stage can be considered
accidental, even if this diagnosis is confirmed after surgery.
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TWO CLINICAL CASES OF RED EAR SYNDROME (RES)
CONNECTED WITH HEADHACHE
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Introduction The Red Ear Syndrome (RES) is characterized by sud-
den events when the patient feels a kind of uneasiness (sometimes a
real painful sensation) mainly localized in one ear, which becomes
red and warm. Sometimes it happens in a spontaneus way, some-
times it is caused by triggers, like touching the ears, feeling warm or
cold, moving the neck, chewing, drinking, coughing or sneezing,
The first description of RES dates back to 1996 thanks to Lance [1]
who studied its characteristics in 12 patients, some of them having a
past of headache. More recently, Raieli et al. 2002) [2] discovered a
closer connection between RES and migraine in eight patients. Here,
we present two clinical cases that might confirm what is reported in
the recent literature. The first one concerns a little boy of 11 years
affected by an almost daily headache bilaterally localized to the
forehead, causing heaviness of variable intensity lasting about 30
minutes together with nausea, vertigo, phosphenes, pallor, perspira-
tion and hyporexia. The second case concerns a little boy of 7 years
who was observed because of a symptomatology of weekly
headaches, localized on the parietotemporal side, characterized by
pulsating, variable intensity, and lasting no more than 30 minutes. In
both cases, the headaches were accompanied by the reddening of a
single ear.
Materials and methods Before admittance a careful clinical history
was taken according to our protocol for headache diagnosis, and
through an accurate clinical and instrumental neurological examina-
tion, following the guidelines of the Italian Headache Society for the
Study of Headache (SISC).
Results This diagnostic approach allowed us to place the patients’
symptomatology in a context of headache connected with RES,
bypassing the difficulty in classifying the kind of headache they were
affected by, as often happens in patients of that age.
Conclusions Our experience is further proof of the observation made
by other authors regarding the connection between RES and headache
symptomatology. This suggests the possibility that RES, when present
in patients suffering from headache, is epidemiologically understated
at present, and the debate is still open on the possibility of including
RES in an unclassified category of headache disorders according to the
IHS classification.
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